WO2000005345A1 - Human thyrotropin receptor compositions and use thereof - Google Patents

Human thyrotropin receptor compositions and use thereof Download PDF

Info

Publication number
WO2000005345A1
WO2000005345A1 PCT/US1999/016636 US9916636W WO0005345A1 WO 2000005345 A1 WO2000005345 A1 WO 2000005345A1 US 9916636 W US9916636 W US 9916636W WO 0005345 A1 WO0005345 A1 WO 0005345A1
Authority
WO
WIPO (PCT)
Prior art keywords
tshr
cells
tsh
autoantibodies
ectodomain
Prior art date
Application number
PCT/US1999/016636
Other languages
French (fr)
Inventor
Basil Rapoport
Sandra M. Mclachlan
Original Assignee
Basil Rapoport
Mclachlan Sandra M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basil Rapoport, Mclachlan Sandra M filed Critical Basil Rapoport
Priority to AU51245/99A priority Critical patent/AU5124599A/en
Publication of WO2000005345A1 publication Critical patent/WO2000005345A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates generally to the fields of cell physiology, endocrinology and immunology. More particularly, the present invention relates to human thyrotropin receptor compositions and to diagnostic and therapeutic
  • TSHR thyrotropin receptor
  • TBI TSHR stimulatory immunoglobulin assay
  • TSHR expressed in mammalian cells are well-recognized by autoantibodies in TBI assays involving intact cells (Harfst, et al, Molec. Cell. Endocrinol,
  • TSHR is of pivotal importance in the regulation of thyroid gland physiological function and is also the direct cause of hyperthyroidism when targeted by autoantibodies in Graves' disease (Rees Smith, et al, Endocr. Rev.,
  • Graves' disease is a very common ( ⁇ 1% prevalence)(Vanderpump, et al, Clin. Endocrinol, 43:55-68 (1995)), organ-specific autoimmune disease, affecting
  • TSHR thyrotropin receptor
  • TSHR autoantibodies like TSH, predominantly recognize discontinuous, highly conformational epitopes (Nagayama, et al, Proc. Natl. Acad. Sci. USA, 88:902-905 (1991); Nagayama, et al, /. Clin. Invest., 88:336-340 (1990); Tahara, et al, Biochem. Biophys. Res. Comm., 179:70-77 (1991)).
  • TSHR expressed on the surface of mammalian cells are conformationally intact and are unquestionably recognized by autoantibodies in patients' sera (Wadsworth, et al, Science, 249:1423-1425 (1990); Ludgate, et al, Molec. Cell Endocrinol, 73:R13-R18 (1990); Filetti, et al, /.
  • TSHR-expressing mammalian cells can be produced in fermentors (Matsuba, et al, /. Biochem., 118:265-270 (1995)) and TSHR overexpression in Chinese hamster ovary (CHO cells) has been achieved by transgenome amplification (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)).
  • CHO cells Chinese hamster ovary
  • the seven membrane-spanning segments of the TSHR do not facilitate purification. Contrary to expectations, when the 418 amino acid residue, autoantibody-binding TSHR ectodomain is expressed in CHO cells without its serpentine region, it is not secreted but is
  • a number of factors may contribute to the difficulty in detecting TSHR autoantibody binding by direct means, including: i) low TSHR concentration, ii) requirement for conformational integrity of the antigen, iii) the high background observed with polyclonal antibodies in human sera and, iv) low autoantibody titer.
  • Autoantibodies to thyroid peroxidase may be present at very high concentrations (Beever, et al, Clin. Chem., 35:1949-1954 (1989)).
  • An early study suggested that TSHR autoantibodies are present at very high concentrations in
  • TSHR A two subunit form of TSHR has been recognized for many years.
  • covalent crosslinking of radiolabeled TSH to thyrocyte membranes revealed a ligand-binding glycoprotein A subunit linked by disulfide bonds to a membrane- spanning B subunit (Buckland, et al, FEBS Letters, 145:245-249 (1982)).
  • the TSHR is encoded by a single mRNA species (Parmentier, et al, Science, 246:1620-1622 (1989); Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989); Libert, et al, Biochem. Biophys. Res.
  • TSH can activate chimeric TSH-LH/CG receptors that do not cleave into two subunits (Chazenbalk, et al, Biochem. Biophys. Res. Comm., 225:479-484 (1996)).
  • subtilisin-related proprotein convertases Chozenbalk, et al, /. Biol. Chem.,
  • TSHR and lutropin/chorionic gonadotropin receptor are closely related members of the G protein-coupled receptor family with glycoprotein hormone ligands. Both the TSHR and LH/CGR have large, heavily glycosylated ectodomains with leucine-rich repeats and are encoded by numerous exons (Gross, et al, Biochem. Biophys. Res. Comm., 177:679 (1991); Tsai-Morris, et al, /. Biol Chem., 266:11355 (1991); Koo, et al, Endocrinology, 128:2297 (1991)). Despite their common evolutionary background, these receptors have several remarkable
  • LH/CGR are extremely rare. Thus, engagement of the TSHR by autoantibodies is the direct cause of thyrotoxicosis in Graves' disease. Another striking difference exists at the structural level. As detected by TSH crosslinking to the surface of intact cells, the functional TSHR exists in two forms; a single chain receptor and a receptor with two subunits (Furmaniak, et al, FEBS Letters, 215:316 (1987); Russo, et al, Mol Endocrinol, 5:1607 (1991)). In contrast, the LH/CGR exists only in a single chain form (Segaloff, et al, Endocr. Rev., 14:324 (1993)).
  • the two subunit TSHR involves a ligand binding, glycosylated A subunit and a membrane-associated B subunit linked by disulfide bonds (Buckland, et al, FEBS Letters, 145:245 (1982)). Because the TSHR
  • a and B subunits must be formed by intramolecular cleavage, a process believed to involve a matrix mellatoprotease (Couet, et al, /. Biol Chem., 271:4545 (1996)).
  • Fi g ure 1 Panel A: Specific 125 I-TSH binding to CHO cell monolayers expressing the human TSHR on their surface. In order to obtain similar numbers of TSHR per well, 4 kb TSHR cells and TSHR-0 cells were cultured in 24 well and
  • Panel B TBI assay using 4 kb TSHR and TSHR-0 cells cultured in 24 well and 96 well plates, respectively. The assay was performed with the same Graves' patient serum at a saturating concentration of 125 I-bTSH (10 6 cpm/ml), as described in Example 1. Data shown in both panels are the mean of closely agreeing values from duplicate dishes of cells.
  • FIG. 2 Comparison of radiolabeled human and bovine TSH in a TBI assay. Data are shown for 12 sera assayed using TSHR-0 cells (-150,000 TSHR per cell) cultured in a 96 well microtiter plate. TBI assay was as described in Example 1. Fifty ml of either 125 I-bTSH or 125 I-hTSH (5 x 10 4 cpm; 10 6 cpm/ml) was added to each well. Values shown are the mean of closely agreeing triplicate wells for each tracer.
  • Tracer TSH binding in the presence of normal serum was: ,25 I-bTSH, 12,396 cpm (mean of 12,044, 12,323, 12821 cpm); hTSH, 2442 cpm (mean of 2509, 2362, 2454 cpm).
  • FIG. 4 Comparison of solubilized porcine and human TSHR in a TSH binding inhibition assay.
  • TBI activity was determined in 30 sera sent to a clinical laboratory for known or suspected Graves' disease. Sera were tested with a commercial kit using porcine TSHR. In addition, the same sera were assayed with the same reagents with the exception that solubilized human TSHR was substituted for porcine TSHR (Example 1). The cut-off point for positivity, as defined in the kit (TBI >15%), is indicated. The arrow indicated two sera that have detectable TBI activity with the human TSHR, but not with the porcine TSHR.
  • FIG. 5 Correlation between thyroid stimulating immunoglobulin (TSI) activity and TSH binding inhibitory (TBI) activity determined with solubilized human (panel A) or porcine (panel B) TSHR.
  • TAI activity was determined on 28 of the sera depicted in Fig. 4 using a bioassay involving Chinese hamster ovary
  • Figure 7 Immunoblots of the TSHR overexpressed in TSHR-10,000 cells.
  • crude membrane preparations of these cells, or of untransfected CHO cells (“CHO") were left untreated (Con) or were treated with N-glycosidase F (Endo F) or with endoglycosidase H (Endo H)(Example 2).
  • the material was then subjected to polyacrylamide gel electrophoresis (10%) under reducing conditions, transferred to PVDF membranes and probed with the indicated mAb.
  • Panel A Immunoblots using mAb T3-495 and T3-365, both to the TSHR B subunit (epitope within residues 604-764)(Example 2).
  • Panel B Specificity of the T3-495 and T3-365 mAb, as determined by their lack of interaction with untransfected cells.
  • Panel C Confirmation of the size of the deglycosylated A subunit on immunoblotting with mAb AlO (epitope including TSHR amino acid residues 22-35). Similar data were obtained with another mAb to the TSHR A subunit, mAb All (data not shown).
  • Panel D Specificity of mAb AlO for the TSHR as determined by its lack of recognition of untransfected CHO cells, as well as by the lack of detection of the TSHR by a mAb to a non-relevant antigen (TPO).
  • TPO non-relevant antigen
  • FIG. 8 Schematic representation of the TSH receptor subunits. The diagram is not drawn to scale and is a modification of our previous version (Chazenbalk et al, /. Biol. Chem., 269:32209-32213 (1994)) based on the new information in the present study. The amino terminal two-thirds of the TSHR
  • ectodomain contains 9 leucine rich repeats, each with an ⁇ -helix and ⁇ -sheet, and is based on the three-dimensional structure of ribonuclease A inhibitor (Kobe et al, Nature, 366:751-756 (1993)). A more detailed model of this region has been
  • the primary non-glycosylated B subunit is -42 kDa, thereby placing the second cleavage site at about residue 380. Cleavage at these two sites would release a putative C peptide of -50 amino acid residues.
  • the thick line between residues 317-366 represents a 50 amino acid "insertion" that is unique to the TSHR relative to the other glycoprotein hormone receptors
  • cysteines shown to be involved in disulfide bonding are hypothetical, but convey the fact that they maintain A and B subunit linkage after
  • TSHRmyc contains a c-myc epitope substituted for residues 338-
  • Panel A Cell proteins were labeled with 35 S- methionine and 35 S-cysteine (one hr pulse; overnight chase) followed by
  • Panel C Specificity of the deglycosylated, 35 kDa A subunit band recognized by mAb AlO, as determined by immunoprecipitation of untransfected HEK cells, as well as of TSHRmyc cells with a non-relevant mAb
  • glycosylated may represent precursor or degradation products of the TSHR within the cell.
  • mAb 9E10 of the c-myc epitope in the TSHRmyc cells see Tanaka et al, Biochem. Biophys. Res. Comm.,
  • Figure 10 Comparison of 125 I-TSH cross-linking to TSHR on the surface of intact TSHRmyc and TSHR-0 cells. Both cell types express similar number of
  • TSHR ( - 10 5 and - 1.5 x 10 5 per cell, respectively).
  • Radiolabeled TSH crosslinking, PAGE (10%) under reducing conditions and autoradiography (18 hr) were as described in Example 2.
  • the ligand, 12S I-TSH itself contains two subunits linked by disulfide bonds. Under reducing conditions, only one of these subunits ( ⁇ 14 kDa) remains covalently linked to the TSHR. Therefore, the size of the TSHR can be deduced by subtracting this mass from the complex.
  • Figure 11 Additional evidence for the existence of two cleavage sites in the TSHR.
  • the ectodomain of the TSHR is shown divided into 5 arbitrary domains (A through E) that were used in creating chimeric TSH-LH/CG receptor molecules (Nagayama et al, Proc. Natl Acad. Sci. USA, 88:902-905 (1991)). Three chimeric receptors that are relevant to the present study are indicated, as well as a TSHR mutant in which amino acid residues 317-366 are deleted (Wads worth et al, Science, 249:1423-1425 (1990)). These 50 amino acids are not present in the LH/CG receptor. Therefore, when domain D of the TSHR is replaced with the
  • Figure 12 Immunoprecipitation of TSHR protein in whole CHO cells.
  • CHO cell lines were used:- CHO - untransfected cells; TSHR-WT - cell transfected with the 4 kb TSHR cDNA containing both 5'- and 3'-untranslated regions
  • the arrow indicates the 100 kDa TSHR holoreceptor form previously observed by Misrahi et al, Eur. /. Biochem., 222:711- 719 (1994)) that was quantitated by densitometry.
  • Figure 13 Crosslinking of ,25 I-TSH to TSHR on the surface of intact cells. The cells used are described in the legend to Fig. 12. Radiolabeled TSH crosslinking, PAGE (7.5%) under reducing conditions and autoradiography (20
  • Figure 14 Cyclic cAMP levels in stably-transfected CHO cell lines expressing different numbers of TSHR. Cells were incubated in hypotonic medium (Fig. 14A) or in isotonic medium (Fig. 14B), as described in Example 3.
  • Figure 15 Binding of ,25 I-TSH to CHO cells expressing the TSHR in the presence of increasing concentrations of unlabeled TSH.
  • FIG. 17 Schematic representation of three TSHR ectodomain variants truncated at their carboxyl-termini.
  • FIG 18 Relative secretion into the culture medium of TSHR ectodomain variants.
  • CHO cells stably expressing TSHR ectodomain variants truncated at amino acid residues 261, 289 and 309 were precursor labeled for 1 hr followed by a chase of 16 hr (Example 4).
  • TSHR in medium (M) and cells (C) was then
  • TSHR in medium was also recovered using Ni-NTA resin that binds to the 6 histidine residues inserted at the C-termini of the ectodomain variants.
  • Ni-NTA is not an effective method for identifying precursor-labeled TSHR in cells because of its interaction with a large number of CHO cell proteins. Autoradiography in the experiment shown was for 12 hr.
  • Figure 19 Recognition of TSHR ectodomain variants by TSHR autoantibodies in Graves' disease serum.
  • the assay involves the ability of
  • conditioned medium from CHO cells serum from a Graves' patient, unlike serum from a normal individual, reduces 125 I-TSH binding by ⁇ 60%.
  • Conditioned medium from a non-relevant cell culture secreting thyroid peroxidase (TPO) has no effect on TSH binding inhibitory (TBI) activity.
  • TPI TSH binding inhibitory
  • conditioned medium from TSHR-261 and TSHR-289 cell cultures nearly completely reverses the TBI activity. Bars indicate the mean + range of duplicate determinations. See Fig. 25 for data on 18 Graves' sera using TSHR-261 after partial purification from conditioned medium.
  • FIG. 20 Lectin specificity for TSHR-261 ectodomain variant.
  • Conditioned medium from CHO cell cultures expressing TSHR-261 was adsorbed with Sepharose linked to the indicated lectins (Example 4). Both unadsorbed
  • Figure 21 Immunoblots of TSHR-261 enriched from conditioned medium using lectins. Material obtained from equivalent volumes of the same medium using Bandeiraea simplificifolia, Concanavalin A or Wheat germ agglutinin was either left untreated (-) or was subjected to endoglycosidase H (Endo H) or endoglycosidase F (Endo F) digestion (Example 4). The samples were electrophoresed on a 10% polyacrylamide gel. Proteins were transferred to PVDF membrane and probed with murine mAb AlO (Example 4).
  • FIG. 22 Immunoblot of TSHR ectodomain variants.
  • TSHR-261, TSHR- 289 and TSHR-309 were affinity-enriched from conditioned medium using
  • Concanavalin A (Example 4). Material was either left untreated (-) or was subjected to endoglycosidase H (Endo H) or endoglycosidase F (Endo F) digestion (Example 4). The samples were electrophoresed on a 10% polyacrylamide gel. Proteins were transferred to PVDF membrane and probed with murine mAb AlO to amino acid residues 22-35 (Nicholson, et al, /. Mol
  • Serum from a Graves' patient with moderate TSH binding inhibitory (TBI) activity was assayed using the commercial autoantibody kit (Example 4) in the presence of increasing concentrations of partially purified TSHR-261. Serum from a normal individual does not inhibit 125 I-TSH binding to solubilized porcine thyroid TSHR (hatched bar). In the absence of TSHR-261, TSH binding is
  • FIG. 25 Neutralization of TSHR autoantibodies by TSHR-261 partially purified from conditioned medium.
  • FIG. 26 Flow cytometric analysis of IgG-class TSHR autoantibody binding to CHO cells expressing different numbers of TSHR on their surface.
  • TSHR-WT cells are stably transfected with the 4 kb TSH cDNA (Nagayama et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)).
  • TSHR-0 cells contain the 2.3 kb translated region of the TSHR cDNA (Kakinuma, et al, Endocrinology, 137:2664- 2669 (1996)).
  • TSHR-800 and TSHR-10,000 cells the transgenome has been amplified and TSHR expression has been increased to ⁇ 10 6 and ⁇ 1.9 x 10 6 per cell, respectively, as shown in Example 3.
  • Cells were incubated with serum (1:10) from a normal individual (open histogram) and from a patient with Graves' disease (BB1) containing high levels of TSHR autoantibodies as measured by the
  • TSH binding inhibition assay (shaded histogram). Fluorescence was developed as described in Example 5.
  • Controls sera (open histograms) were a mouse monoclonal antibody to thyroid peroxidase and normal rabbit serum, all at the same the dilutions used for the specific sera. Fluorescence was developed as described in Example 5.
  • Figure 28 Effect of adsorption of sera with untransfected CHO cells on the specificity of the autoantibody fluorescence signal on flow cytometry with TSHR-expressing cells. Representative examples are shown of sera from two individuals, 7H and BB1 (shaded histograms), each with very high TBI values
  • Sera (1:10 dilution) were either not preadsorbed (upper panels) or preadsorbed on untransfected CHO cells (lower panels) prior to incubation with TSHR-10,000 cells (Example 5). Included as a negative control is serum from a normal individual without TSHR autoantibodies detectable by the TBI assay (open histogram).
  • Figure 29 Adsorption of TSHR autoantibodies using cells expressing the recombinant TSHR on their surface.
  • Sera BB1, 10H, 3H and 10M that generated a fluorescent signal on FACS analysis with TSHR-10,000 cells (Table 1) were preadsorbed (0.5 hours at room temperature, three times) on TSHR-10,000 cells prior to analysis using the same cells (open histograms). Fluorescence generated
  • Figure 30 Relative titers of TPO and TSHR autoantibodies in the BB1 serum, as determined by flow cytometry on CHO cells expressing either the
  • TSHR or TPO on their surface.
  • Serum BB1 serum from a normal individual without TSHR or TPO autoantibodies detectable by clinical assay (open histograms) were tested at dilutions between 1:10 and 1:1000.
  • FIG. 31 The ectodomain of the TSHR is shown divided into 5 arbitrary domains (A through E) that were used in creating chimeric TSH-LH/CG receptor
  • FIG 32 A Amino acid substitutions introduced in the region of putative cleavage site 1 in the TSHR. Mutations were made in the D domain of chimeric receptor TSH-LHR-5 (Fig. 31). The dashed line for the LH/CG receptor indicates that this region is unique to the TSHR and is absent in the LH/CG receptor.
  • B Radiolabeled TSH crosslinking to CHO cells stably expressing the receptors described in A. Cross-linked products were subjected to PAGE (7.5%) under reducing conditions followed by autoradiography. Note that the ligand,
  • the mass of the hormone ligand complex includes one subunit of the ligand, which itself contains two subunits linked by disulfide bonds. Under reducing conditions, only one ligand subunit ( ⁇ 14 kDa) remains covalently linked to the TSHR.
  • Figure 33 A. Amino acid substitutions introduced in the region of putative cleavage site 2 in the TSHR. Mutations were made in the E domain of chimeric receptor TSH-LHR-4 (Fig. 31). The mutations shown in bold prevent cleavage, as determined by TSH cross-linking. In the El, E2 and E3 mutations,
  • Figure 34 The presence of the GQE 267 . 269 NET mutation does not prevent cleavage of the wild-type TSHR.
  • Cross-linked 125 I-TSH-TSHR products were reduced and subjected to PAGE (10%) and autoradiography.
  • the present invention is directed to novel human thyrotropin compositions which are useful in diagnostic and therapeutic methods for the diagnosis and treatment of autoimmune diseases, particularly Graves' disease.
  • radiolabeled TSH (bovine vs. human) can influence the TBI value obtained.
  • cells expressing very large numbers of receptors are an excellent
  • the present invention is directed broadly to methods for the therapeutic treatment of autoimmune disease, and particularly, Graves' disease, involving administration of the therapeutic compositions described herein and such variants thereof as will be appreciated by those of skill. Accordingly, in one aspect, the invention is directed to a method for the treatment of Graves' disease comprising administering to a patient suffering from Graves' disease an effective amount of
  • compositions useful according to the methods of the invention are preferably selected for use according to the invention by means of one or more assay methods disclosed herein or known to those of skill.
  • compositions useful in the methods of the invention are preferably substantially isolated human thyrotropin receptor, which may be recombinantiy produced according to the invention, or variants or mutants thereof, capable of modulating Graves' disease in a patient, and may be selected, as described herein,
  • TSH compositions so selected may be administered by methods known to those of skill in order to achieve the desired therapeutic result.
  • compositions of the invention may be desirable, for example, to increase or decrease the half life of the resulting peptide in the bloodstream or tissue.
  • compositions useful according to the methods of the invention by introducing therein alterations, such as are known in the art, which may include the use of synthetic or non-traditional arriino acid residues, side chains, non-amide bonds as in peptides, and the like, which may act as blocking groups to protect the peptide against degradation.
  • compositions useful according to the invention may be isolated from natural sources and purified. However, it is preferred to synthesize the
  • compositions by means well known in the art. Preferred is solid phase synthesis, although any suitable method of synthesis may be employed.
  • TSHR ectodomain material Trace amounts of "functional" TSHR ectodomain material are present in insect cells infected with recombinant baculovirus containing the TSHR cDNA (Chazenbalk, et al, /. Biol Chem., 270:1543-1549 (1995)), as well as in stably transfected CHO cells (Rapoport, et al, /. Clin. Endocrinol Metab., 81:2525-2533 (1996); Harfst, et al, Lancet, 339:193-194 (1992)).
  • TSHR ectodomain Unlike the non-secreted, high mannose-containing ectodomain (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)), secreted, C-terminal truncated TSHR ectodomain variants are recognized by autoantibodies. Whether the complex carbohydrate comprises part of the
  • the LH/CG receptor truncated at residue 329 or further downstream is secreted to a limited extent (VuHai-LuuThi, et al, Biochem., 31:8377-8383 (1992); Tsai-Morris, et al, /. Biol. Chem., 265:19385-19388 (1990)).
  • Alternately-spliced truncated forms of TSHR mRNA have been detected in thyroid tissue (Graves, et al, Biochem. Biop hys. Res. Comm., 187:1135-1143 (1992); Takeshita, et al, Biochem. Biophys. Res. Comm., 188:1214-1219 (1992)), however whether these transcripts are actually expressed and, if so, secreted by thyrocytes is unknown.
  • TSHR-261 The lectin specificity of TSHR-261 is consistent, in part, with previous data on the extraction of TSH holoreceptor activity from detergent-solubilized thyroid membranes.
  • B. simplificifolia was effective for bovine, but not for human, TSHR (Kress, et al, Endocrinology, 118:974-979 (1986)).
  • TSHR TSHR
  • the bovine TSH holoreceptor was also bound well by Wheat germ agglutinin and was irreversibly bound by Concanavalin A (Kress, et al, Endocrinology, 118:974-979 (1986)).
  • Lectin chromatography Lectin chromatography by itself
  • TSHR-261 may be more stable than TSHR-261, which loses activity over
  • TSHR-289 may be preferred according to the present invention although TSHR-261 is somewhat more effectively secreted. Also within the scope of the present invention are other truncations between 261 and 309, which may be utilized by those of skill without undue
  • the present invention is directed to methods of selecting truncated forms of TSHR, preferably mammalian TSHR, and more preferably human TSHR, useful according to the invention in that they exhibit one or more of the qualities or characteristics described herein for representative truncated forms TSHR-261, TSHR-289 and TSHR-309.
  • TSHR preferably mammalian TSHR
  • human TSHR useful according to the invention in that they exhibit one or more of the qualities or characteristics described herein for representative truncated forms TSHR-261, TSHR-289 and TSHR-309.
  • those of skill will be able to select, express and screen suitable candidates based upon the desired degree (or presence or absence) of stability, solubility secretion and other characteristics as will be appreciated when the teachings of the present invention are understood, without undue experimentation.
  • truncated TSHR variants shorter than TSHR- 261 and longer than TSHR-309 may be evaluated according to the methods of invention, and may be identified and screened for suitability in accordance with the teachings of the invention, and that such suitable variants are within the contemplated teachings and scoped of the invention.
  • suitable variants are within the contemplated teachings and scoped of the invention.
  • several different screening approaches may be employed as described herein.
  • TSHR cDNA-transfected mammalian cells withradiolabled amino acids, such as 35 S-methionine/cysteine, followed by immunoprecipitation with a monoclonal antibody to the TSHR.
  • radiolabled amino acids such as 35 S-methionine/cysteine
  • medium is precleared with mouse IgG and Protein A, prior to the addition of mouse monoclonal antibody to the TSHR.
  • TSHR-antibody complexes are precipitated with Protein A, electrophoresed on polyacrylaminide gels and visualized by autoradiography.
  • An alternative exemplary screening approach according to the invention is to use an agent, such as Nickel-chelate resin, to bind to a 6 histidine tag engineered into the TSHR ectodomain, or fragment thereof.
  • an agent such as Nickel-chelate resin
  • Another screening approach which will be readily understood and appreciated by those of skill is immunoblotting of proteins transferred electrophoretically to a membrane, such as by western blotting.
  • TSH receptors employ flow cytometry to detect these proteins on the surface of transfected cells.
  • An example of such a direct detection procedure for TSH receptors is described in detail herein.
  • TSHR antibodies which may be, for example, mouse monoclonal antibodies or Graves' patient serum
  • the cells are rinsed three times and fluorescent-tagged anti-mouse or antihuman IgC added for 45 minutes at 4°C.
  • the cells are analyzed using the Becton Dickinson FACScan-CELLQuest system or other suitable device.
  • Yet another exemplary screening method according to the invention utilizes neutralization of TSHR autoantibodies in the serum of Graves' patients.
  • the principle of this assay is the ability of autoantibodies to compete for 125 I-TSH binding to solubilized TSHR ("TSH binding inhibition," or TBI assay).
  • solubilized TSHR 50 ⁇ l are preincubated (15 min) with patient's serum (50 ⁇ l). Buffer containing 125 I-TSH is then added (2 hours at room temperature). Solubilized TSHR complexed with TSH is precipitated by, for example, polyethylene glycol.
  • Antibody activity is measured as % inhibition of 125 I-TSH binding relative to a standard serum from a normal individual without autoantibodies.
  • the assay may be conveniently
  • SUBSTITUTE SHEET flttJLE 26 modified by preincubating (30 min at room temperature) serum from Graves' patients (25 ⁇ l) with conditioned medium from cells expressing TSHR ectodomain variants (25 ⁇ l). Solubilized TSHR (50 ⁇ l) is then added to the serum /medium mixture (50 ⁇ l).
  • serum from normal individuals and conditioned medium from CHO cells secreting a truncated form of thyroid peroxidase may be used.
  • transfected cells e.g., in monolayer or suspension culture
  • binding buffer Hank's buffer with 280 mM sucrose instead of NaCl and supplemented with 0.25% bonvine serum albumin
  • the cells are solubilized in 1 N NaOH and radioactivity counted in a gamma counter. Non-specific binding to untransfected cells is subtracted to obtain values for specific binding. From these screening results, suitable truncated TSHR variants may be identified.
  • TSHR-261 Autoantibody-reactivity of TSHR-261 is reminiscent of the observation nearly three decades ago that freezing and thawing thyroid tissue releases a water soluble factor (LATS absorbing activity; LAA) that neutralizes TSHR
  • TSHR-261 required for autoantibody neutralization is orders of magnitude lower than those used in studies with synthetic peptides (Morris, et al, Autoimmunity, 17:287-299 (1994)). This quantitative information will be useful as a future benchmark by which to judge
  • the invention is directed to TSH receptor assays for the detection and/ or quantitation of autoantibodies against TSHR in a biological fluid, employing secreted, soluble, complex carbohydrate-containing forms of the TSHR ectodomain as taught herein.
  • the secreted, soluble, complex carbohydrate-containing form of the TSHR ectodomain will be truncated at its C- terminal end.
  • Secreted, soluble, complex carbohydrate-containing forms of the TSHR ectodomain useful in TSH receptor assays may preferably be selected by those of skill employing screening methods as taught herein, or variants of such methods, without undue experimentation.
  • Secreted, soluble, complex carbohydrate-containing TSHR ectodomain variants useful in TSH receptor assays according to the invention and which may be selected using the screening methods taught herein include, but are not limited to, truncations between 261 and 309, preferably, truncations between 261 and 289.
  • TSHR ectodomain variants for use in accordance with the diagnostic and therapeutic aspects of the invention, the skilled person may employ screening methods such as those described herein, mindful of selection criteria including the capability of being secreted, of solubility, and of the presence of complex carbohydrate, that will result in TSHR ectodomain variants and composition containing them which are suitable for the intended use or purpose.
  • Assays according to the invention may include indirect assays or direct assays, with direct assays presently preferred.
  • Methods and reagents for assays according to the invention which employ the secreted, soluble, complex carbohydrate-containing form of the TSHR ectodomain taught herein may be conventional, and will admit of design and selection by skilled person who understands the present disclosure, mindful of well accepted principles of diagnostic and immunodiagnostic methodology and interpretation. Such principles are set forth, for example, in Rose, Noel R., et al., eds., Manual of Clinical Laboratory Immunology. Fifth Edition, ASM Press, Washington D.C. (1997), and prior editions; Rich, R. et al., eds., Clinical Immunology. Mosby, Publisher, St.
  • Direct assay formats include, but are not limited to, flow cytometric assays and direct TSHR receptor assays, with the latter being presently preferred.
  • TSHR-289 (or other TSHR ectodomain variant selected for use) preferably includes a 6 histidine tail as described hererin (TSHR-289-6His).
  • TSHR-289-6His antigen is preferably produced in tissue culture medium harvested from CHO cells secreting TSHR-289-6His, as described herein.
  • histidine tail is presently preferred because it allows use of labeled anti-histidine antibody, available from commercial sources, to detect and/ or quantitate the secreted, soluble, complex carbohydrate- containing TSHR ectodomain variant which, in the preferred direct assay format, binds to TSHR autoantibodies in the sample, thereby affording the investigator means of directly detecting and/or quantitating TSHR autoantibodies.
  • labeled anti-histidine antibody available from commercial sources, to detect and/ or quantitate the secreted, soluble, complex carbohydrate- containing TSHR ectodomain variant which, in the preferred direct assay format, binds to TSHR autoantibodies in the sample, thereby affording the investigator means of directly detecting and/or quantitating TSHR autoantibodies.
  • any suitable epitope capable of being recognized by a specific antibody or other ligand in a manner similar to that of ⁇ His may be used.
  • Non-limiting examples of such epitopes include the Flag, c-myc and bir (Altman, J.D., et al, Science 274:94-96 (1996)) epitopes, available from commercial sources or from known depositories such as the American Type Culture collection.
  • Labeled anti-histidine antibody may be monocloncal or polyclonal, preferably monoclonal, more preferably, mouse monoclonal, and most preferably, anti-histidine mouse monoclonal antibody labeled with Na 125 I obtained from QIAGEN, Inc., Chatsworth, California.
  • Na 125 I is presently preferred for use as a label in a direct assay according to the invention
  • any suitable label may be employed which allows detection and/ or quantitation.
  • labels and methods of labeling known in the art. Examples of the types of labels which can be used in the present invention include, but are not limited to, enzymes, radioisotopes, fluorescent compounds, chemiluminescent compounds, bioluminescent compounds and metal chelates. Those of ordinary skill in the art will know of other suitable labels, or will be able to ascertain the same be the use of routine experimentation. Furthermore, the binding of these labels to antigens and antibodies can be accomplished using standard techniques commonly known to those of ordinary skill in the art.
  • TSHR ectodomain variant antigens and antibodies according to the present invention can be detectably labeled is by linking them to an enzyme.
  • This enzyme when later exposed to its substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected as, for example, by spectrophotometric or fluorometric means.
  • enzymes which can be used to detectably label antibodies include malate dehydrogenase, staphylococcal nuclease, delta- V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, biotin-avidin peroxidase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, betagalactosidase, ribonuclease, urease, catalase, glucose- Vl-phosphate dehydrogenase, glucoamylase and acetylcholine esterase.
  • detectably labeled TSHR ectodomain variant antigens and antibodies also can be detected by labeling the TSHR ectodomain variant antigens and antibodies and a radioactive isotope which then can be determined by such means as the use of a gamma counter or scintillation counter.
  • Isotopes in addition to 125 I which are particularly useful for the purpose of the present invention are 3 H, 32 P, 35 P, 14 C, 5I Cr, 36 C1, 57 Co, 58 Co, 59 Fe and 75 Se.
  • labels such as radiolabels may be bound to antigens and antibodies according to the present invention either directly or by using and intermediary functional group.
  • DTP A diethylenetriaminepentaacetic acid
  • Typical examples of metallic cations which are bound in this manner are: 99n Tc, 123 I, IN, 13 '1, 97 Ru, 67 Cu, 67 Ga and 68 Ga.
  • the antigens and antibodies of the invention can also be labeled with non-radioactive isotopes for purposes of diagnosis. Elements which are particularly useful in this manner are 157 Gd, 55 Mn, 162 Dy, 52 Cr and 56 Fe.
  • TSHR ectodomain variant antigens and antibodies it is also possible to detect the binding of detectably labeled TSHR ectodomain variant antigens and antibodies by labeling the antigens and antibodies with a fluorescent compound.
  • a fluorescently labeled antibody When a fluorescently labeled antibody is exposed to light of the proper wave length, its presence then can be detected due to the fluorescence of the dye.
  • fluorescent labeling compounds are fluoroscein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
  • the TSHR ectodomain variant antigens and antibodies of the invention also can be detectably labeled using fluorescent emitting metals such as 152 Eu, or others of the anthanide series. These metals can be attached to the antibody molecule using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).
  • DTPA diethylenetriaminepentaacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • TSHR ectodomain variant antigens and antibodies also can be detectably labeled by coupling them to a chemiluminescent compound. The presence of the chemiluminescent-tagged antigen or antibody is then determined by detecting the presence of luminescence that arises during the course of the chemical reaction.
  • chemiluminescent labeling compounds are luminal, isoluminol, aromatic acridinium ester, imidazole, acridinium salts, oxalate ester, and dioxetane.
  • a bioluminescent compound may be used to label the TSHR ectodomain variant antigens and antibodies according to the present invention.
  • Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent antigen or antibody is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling include luciferase and aequorin.
  • kits may comprise a carrier means being compartmentalized to receive in close confinement therewith one or more container means such as vials, tubes and the like, each of said container means comprising the separate elements of the assay to be used.
  • kits form The types of assays which can be incorporated in kit form are many, and include, for example, competitive and non-competitive assays.
  • Typical examples of assays which can utilize the antibodies of the invention are radioimmunoassays
  • immunometric assay or "sandwich immunoassay,” it is meant to include simultaneous sandwich, forward sandwich and reverse sandwich immunoassays. These terms are well understood by those skilled in the art. Those of skill will also appreciate that TSHR ectodomain variant antigens and antibodies according to the present invention will be useful in other variations and forms of assays which are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention. Forward sandwich assays are described, for example, in United States Patent
  • blocking be present in the incubation medium (usually added with the labeled soluble antigen or antibody).
  • the “blockers” are added to assure that non-specific proteins, protease, or human antibodies to mouse (or other) immunoglobulins present in the experimental sample do not cross-link or destroy the antigens or antibodies on the solid phase support, or the radiolabeled indicator antigen or antibody, to yield false positive or false negative results.
  • the selection of “blockers” therefore can add substantially to the specificity of the assays described in the present invention, and will be carefully considered by those of skill designing such assays.
  • solid phase immunoadsorbents There are many solid phase immunoadsorbents which have been employed and which can be used in the present invention.
  • Well known materials which may be employed include glass, polystyrene, polypropylenes dextran, nylon, agarose, dextran, acrylamide and other materials, in the form of tubes, beads, and microtiter plates formed from or coated with such materials, and the like.
  • the immobilized TSHR ectodomain variant antigens or antibodies can be either covalently or physically bound to the solid phase immunoadsorbent, by techniques such as covalent bonding via an amide or ester linkage, or by adsorption.
  • suitable solid phase immunoadsorbents and methods for immobilizing antibodies thereon or will be able to ascertain such, using no more than routine experimentation.
  • SEPHAROSE beads obtained from commercial suppliers such as Sigma Chemical Co., St. Louis, Missouri.
  • the Sepharose beads are coated with Protein A, a polypeptide isolated from Staphylococcus aureus, that is known to bind to the F c region of immunoglobulin molecules without interacting at the antigen binding site, Surolia, A., et al., Trends Biochem. Sci. 7:14 (1981), allowing formation of tertiary complexes of Protein A, antibody and antigen.
  • Protein A-coated Sepharose beads bind human IgG present in the biological fluid sample, which is preferably a human serum sample in the preferred direct assay format of the invention. Following incubation of the serum sample and washing of the Sepharose Protein A beads, the beads will retain IgG, possibly including autoantibodies against TSHR. The beads are thereafter resuspended in medium which has been conditioned with a TSHR ectodomain variant according to the invention. The TSHR ectodomain variant is prepared so that it is capable of being visualized. As described herein, presently preferred is the addition of a 6 histidine "tail" to the TSHR ectodomain variant.
  • Labeled antibody against the 6His tail is then used to detect and/or quantitate the TSHR ectodomain variant antigen retained on the Sepharose Protein A bead, thereby detecting and/ or quantitating TSHR autoantibodies present in the sample.
  • a first antibody against the TSHR ectodomain variant antigen may be used instead of the 6His tail, against which a second, detectably labeled antibody is generated for visualization, as is conventional, and that the first antibody will be selected such that its binding does not interfere with autoantibody binding to the TSHR ectodomain variant selected for the assay.
  • TSHR ectodomain variant for use in a direct assay according to the invention is TSHR-289-6His.
  • antibody which may be polyclonal or, preferably, monoclonal
  • TSHR autoantibodies may be used for more specific solid phase capture than is presently accomplished with Protein A, and may offer reduced nonspecific binding and background, and that liquid-liquid phase assay formats may be employed which offer improved reaction kinetics as compared to solid-liquid phase assay formats.
  • Example 7 using the direct assay of the invention, human serum autoantibodies against human TSHR were shown to be markedly elevated in patients with confirmed clinical Graves' disease as compared to normal human serum (Table 3), with mean TSHR autoantibody levels in the two Graves' disease patients, as reflected in counts per minute (cpm) of 125 I activity, exceeding mean normal serum levels by over 600%.
  • Such elevated autoantibody levels as measured according to the direct assay methods of the present invention are consistent with TSHR activation, known to result in thyroid overactivity and thyrotoxicosis in Graves' patients ( Rees Smith, et al, Endocr. Rev., 9: 106-121 (1988)).
  • the present invention is the first description of a direct assay for TSHR autoantibodies, it will be appreciated that improvements in the assay method are to be expected, including streamlining of incubation and washing procedures and selection of reageants to simplify and shorten the time required for the assay, use of a standard curve for improved quantitation of test results and correlation of results to pathophysiological state, and the like, which will be accomplished employing known principles of clinical diagnostic practice.
  • the TSHR ectodomain variants of the invention may be used to detect or measure antibody to TSH receptor in a biological fluid sample, such as serum, lymph or urine, using an automated diagnostic system.
  • the automated diagnostic system is a microsystem platform suitable to manipulate the sample.
  • the TSH binding site on the TSHR is
  • TSHR autoantibody epitope(s) may, therefore, be more limited than the TSH binding site. Support for this notion is provided by
  • autoantibodies are also discontinuous and extend downstream of residue 261
  • TSHR-261 contains the dominant portion of a discontinuous epitope, sufficient to neutralize most TSHR reactivity in Graves' patients sera.
  • TSHR-261 is highly potent in interacting with TSHR autoantibodies.
  • Antigenically active TSHR will provide a major impetus for future studies on the diagnosis, pathogenesis and immunotherapy of Graves' disease.
  • thyroidal tissue sells a therapeutic effect may be observed by any number of known clinical endpoints.
  • the compounds of the present invention also have utility in combatting drug resistance, which may be a problem with current
  • the compounds of the invention may be used.
  • the quantities of active ingredient necessary for effective therapy will depend on many different factors, including means of administration, target site, physiological state of the patient, and other medicaments administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the active ingredients. Animal testing of effective doses for
  • a treatment regimen will be selected which will achieve a sufficient concentration of the composition(s) to achieve the desired therapeutic effect in the
  • compositions of the present invention One method for administering the compositions of the present invention
  • the powder In order to allow for absorption of the active components through the alveoli into the bloodstream, the powder must be very fine; on the order of 1-5 micron particles.
  • the highly disbursable powder is delivered via an inhaler which generates an aerosol cloud containing the bolus of drug at the top of the inhalation chamber.
  • compositions of the present invention will lend themselves to injection into the bloodstream of a patient.
  • the half life of the active compositions so administered may be manipulated for best therapeutic effect by employing known drug technologies.
  • One example of such technologies is known as DEPOFOAM phospholipid spheres (Depo Tech Corp., San Diego, CA), which gradually release the active component(s) over a period of days to weeks. This allows for a constant level of systemic concentration with lower initial drug levels and injection frequency.
  • compositions of the present invention may be employed to accommodate several different routes of drug delivery.
  • One example of such technologies is the TECHNOSPHERE
  • the pH-sensitive spheres when injected into the blood, dissolve and release the active component, which
  • Fine powders such as these are suitable for pulmonary, oral, intravenous and intraperitoneal administration.
  • the site of administration and cells will be selected by one of ordinary skill in the art based upon an understanding of the particular disorder being treated.
  • the dosage, dosage frequency, and length of course of treatment can be determined and optimized by one of ordinary skill in the art depending upon the particular disorder being treated.
  • the particular mode of administration can also be readily selected by one of ordinary skill in the art and can include, for example, oral, intravenous, subcutaneous, intramuscular, etc. Principles of pharmaceutical dosage and drug delivery are known and are described, for
  • liposomes for example, in Ansel, H. C. and Popovich, N. G., Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Ed, Lea & Febiger, Pub., Philadelphia, PA (1990). It is possible, for example, to utilize liposomes to specifically deliver the agents of the invention. Such liposomes can be produced so that they contain additional
  • bioactive compounds and the like such as drugs, radioisotopes, lectins and toxins, which would act at the target site.
  • Nucleic acid compositions encoding the compositions and variants thereof useful according to the invention will generally be in RNA or DNA forms, mixed polymeric forms, or any synthetic nucleotide structure capable of binding in a base-specific manner to a complementary strand of nucleic acid.
  • Such a nucleic acid embodiment is typically derived from genomic DNA or cDNA, prepared by synthesis, or derived from combinations thereof.
  • the DNA compositions are typically derived from genomic DNA or cDNA, prepared by synthesis, or derived from combinations thereof.
  • compositions, or fragments thereof generally include the complete coding region encoding the compositions, or fragments thereof.
  • composition of the invention and is intended to include “fragments,” “variants,” “analogs,” “homologs,” or “chemical derivatives” possessing such activity or characteristic.
  • Functional equivalents of a peptide according to the invention may not share an identical amino acid sequence, and conservative or non- conservative amino acid substitutions of conventional or unconventional amino acids are possible.
  • glycine, alanine, valine, leucine and isoleucine make up a group of amino acids having aliphatic side chains; serine and threonine are amino acids having aliphatic-hydroxyl side chains; asparagine and glutamine are amino acids having amide-containing side chains; phenylalanine, tyrosine and tryptophan are amino acids having aromatic side chains; lysine, arginine and histidine are amino
  • cysteine and methionine are amino acids having sulfur-containing side chains. Interchanging one amino acid from a given group with another amino acid from that same group would be considered a conservative substitution.
  • Preferred conservative substitution groups include asparagine-glutamine, alanine-valine, lysine-arginine, phenylalanine-tyrosine and valine-leucine-isoleucine.
  • mutant refers to a peptide having an amino acid sequence which differs from that of a known peptide or protein by at least one amino acid. Mutants may have the same biological and immunological activity as the known protein. However, the biological or immunological activity of
  • mutants may differ or be lacking.
  • a mutant may lack the biological activity which characterizes a TSHR of the invention, but may be useful as an eptitopic determinant for raising antibodies or for the detection or purification of antibodies thereagainst, or as an agonist (competitive or non-competitive),
  • Suitable labels for use in assays according to the invention include a detectable label such as an enzyme, radioactive isotope, fluorescent compound, chemiluminescent compound, or bioluminescent compound. Those of ordinary skill in the art will know of other suitable labels or will be able to ascertain such using routine experimentation. Furthermore, the binding of these labels to the peptides is accomplished using standard techniques known in the art.
  • TSHR further isolation, purification and sequencing of TSHR according to the invention may be accomplished by standard biochemical methods such as,
  • Peptidomimetic agents are of use in the therapeutic treatment of disease. Such peptidomimetics are also provided by the present invention, and can act as drugs for the modulation of autoimmune disease, such as Graves' disease. Peptidomimetics are commonly understood in the pharmaceutical industry to include non-peptide drugs having properties
  • therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect.
  • such peptidomimetics have one or more peptide linkages optionally replaced by a linkage which may convert desirable properties such as resistance to chemical breakdown in vivo.
  • Peptidomimetics may exhibit enhanced pharmacological properties (biological half life, absorption rates, etc.), different specificity, increased stability, production economies, lessened antigenicity and
  • compositions according to the invention may will vary depending upon a number of factors.
  • a given protein may be obtained as an acidic or basic salt, or in neutral form, since ionizable carboxyl and amino groups are
  • any form of peptide comprising human TSHR which retains the therapeutic or diagnostic activity of the compositions of the present invention is intended to be within the scope of the invention.
  • compositions of the present invention may be produced by
  • nucleotide sequences encoding human TSHR of the invention may be inserted into a suitable
  • DNA vector such as a plasmid
  • vector used to transform a suitable host The recombinant human TSHR is produced in the host by expression.
  • transformed host may be a prokaryotic or eukaryotic cell.
  • Preferred nucleotide sequences for this purpose encoding a human TSHR are disclosed herein.
  • Synthetic polynucleotide sequences may be constructed by known chemical synthetic methods for the synthesis of oligonucleotides. Such synthetic methods are described, for example, in Blackburn, G.M. and Gait, M.J., Eds., Nucleic Acids in Chemistry and Biology, IRL Press, Oxford, England (1990), and it will be evident that commercially available oligonucleotide synthesizers also may be used according to the manufacturer's instructions. One such manufacturer is Applied Bio Systems.
  • PCR Polymerase chain reaction
  • primers based on the nucleotide sequence data disclosed herein may be used to amplify DNA fragments from mRNA pools, cDNA clone libraries or genomic DNA.
  • PCR nucleotide amplification methods are known in the art and are described, for example, in Erlich, H.A., Ed., PCR Technology: Principles and Applications for DNA Amplification, Stockton Press, New York, New York (1989); U.S. Patent No. 4,683,202; U.S. Patent No. 4,800,159; and U.S. Patent No. 4,683,195.
  • nucleotide deletions, additions and substitutions may be incorporated into the polynucleotides of the invention as will be recognized by those of skill, who will also recognize that variation in the nucleotide sequence encoding human TSHR may occur as a result of, for example, allelic polymorphisms, minor sequencing errors, and the like.
  • the polynucleotides encoding the peptides of the invention may be incorporated into the polynucleotides of the invention as will be recognized by those of skill, who will also recognize that variation in the nucleotide sequence encoding human TSHR may occur as a result of, for example, allelic polymorphisms, minor sequencing errors, and the like.
  • polynucleotide sequences of the invention may include short oligonucleotides which are useful, for example, as hybridization probes and PCR primers.
  • the polynucleotide sequences of the invention also may comprise a portion of a larger polynucleotide and, through
  • polynucleotide linkage they may be fused, in frame, with one or more polynucleotide sequences encoding different proteins.
  • the expressed protein may comprise a fusion protein.
  • the polynucleotide sequences of the invention may be used in the PCR method to detect the presence of mRNA encoding autoantibodies in the diagnosis of disease or in forensic analysis.
  • sequence of amino acid residues in a protein or peptide is designated herein either through the use of their commonly employed three-letter designations or by their single-letter designations. A listing of these three-letter and one-letter designations may be found in textbooks such as Lehninger, A., Biochemistry, 2d Ed, Worth Publishers, New York, New York (1975). When the amino acid sequence is listed horizontally, the amino terminus is intended to be
  • residues of amino acids in a peptide may be separated by hyphens. Such hyphens are intended solely to facilitate the presentation of a sequence.
  • Suitable agents for use according to the invention include human TSHR and mimetics, fragments, functional equivalents and/or hybrids or mutants thereof, as well as mutants, and vectors containing cDNA encoding any of the foregoing. Agents can be administered alone or in combination with and/or
  • the agents of the present invention are suitable for the treatment of autoimmune diseases which are characterized by inappropriate cell death.
  • Autoimmune diseases are disorders caused by an immune response directed against self antigens. Such diseases are characterized by the presence of
  • Such diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis, and Graves' disease.
  • Standard reference works setting forth the general principles of immunology include Sell, S., Immunology, Immunopathology & Immunity, 5th Ed., Appleton & Lange, Publ., Stamford, CT (1996); Male, D., et al, Advanced Immunology, 3d Ed., Times Mirror Int'l Publishers Ltd., Publ., London (1996); Stites, D. P., and Terr, A. I., Basic and Clinical Immunology, 7th Ed., Appleton & Lange, Publ., Norwalk, CT (1991); and Abbas, A. K., et al, Cellular and
  • the human TSHR peptides, mimetics, agents and the like disclosed herein, as well as vectors comprising nucleotide sequences encoding them or their corresponding antisense sequences, and hosts comprising such vectors, may be used in the manufacture of medicaments for the treatment of diseases including autoimmune diseases.
  • the present invention describes improved assays for the detection of TSHR autoantibodies. Surprisingly and unexpectedly, it has been found that mammalian cells expressing more TSHR on their surface provide a less sensitive TBI assay when this assay is performed with intact cells in monolayer culture. Although not intending to be bound by any particular theory, one likely reason for this phenomenon is the very low absolute
  • TBI autoantibodies are generally present at much lower concentrations than thyroid peroxidase (TPO) autoantibodies in the same serum (Example 5).
  • TPO thyroid peroxidase
  • the efficacy of an occupancy assay such as the TBI assay depends on an excess of antibody over antigen.
  • TSHR large amount of antigen
  • a low concentration of antibody leads to low occupancy of the antigen. This, in turn, will reduce the sensitivity of the TBI assay, because many TSHR unoccupied
  • TBI assay should utilize a small amount of receptor and a very effective ligand, as is the case with the affinity-purified bovine 12S I-TSH in the procedure developed by Rees-Smith (Shewring, et al, Clin. Endocrinol, 17:409-417 (1982); Rees Smith, et al, Methods in Enzymology, 74:405-420 (1981)).
  • TSHR can readily be obtained from mammalian cells in large amounts and in a form suitable for an effective TBI assay. Soon after a stably-transfected CHO cell
  • TSHR from resuspended cells and indicates that the direct extraction of TSHR from cell monolayers can overcome the evident fragility of this very difficult receptor.
  • a cell line such as TSHR-10,000, that expresses very high, levels of TSHR, can provide TSHR suitable for direct use in a TBI assay according to the invention without further purification or concentration, and is preferred on that basis.
  • TSHR species may be important in bioassays for stimulatory autoantibodies (Murakami, et al, Eur. J. Endocrinol, 133:80-86 (1995); Vitti, et al, /. Clin. Endo. Metab., 76:499-503 (1993); Endo, et al, Biochem. Biophys. Res. Comm., 186:1391-1396 (1992)). Whether or not the use of human, rather than
  • TSHR would be advantageous in a TBI assay has not heretofore been established. This factor was considered during the original development of the
  • porcine TSHR became the standard in TBI assays. It is worth noting that most sera in this study had relatively high TBI values, making discrimination at the very important low end of the assay difficult to discern.
  • TSH ligand
  • the present invention also provides evidence for two cleavage sites in the TSHR ectodomain. This evidence must be viewed in the context of previous data
  • the smaller than expected sum of the sizes of the deglycosylated TSHR A subunit and the non-glycosylated B subunit support the concept of two cleavage sites in the TSHR, with the loss of an intervening portion of the polypeptide chain. While we recognize that size estimations cannot be absolutely precise, they are sufficiently reproducible among different laboratories, using different methodologies for TSHR detection, to suggest that a piece of the TSHR has been lost during intramolecular cleavage. We observed the deglycosylated A subunit and the B subunit to be -35 kDa and -42 kDa, respectively. Others have reported A and B subunits of similar sizes (Loosfelt, et al, Proc. Natl. Acad.
  • the c-myc epitope lies within a 50 amino acid segment (residues 317-366) that we observed to be unique to the TSHR when compared to other glycoprotein hormone receptors (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)). Although the precise boundaries of this 50 amino acid "insertion" are uncertain (because of low homology among the receptors in adjacent regions), this TSHR segment has been the subject of intense study.
  • residues 317-366 led us to speculate that it was a projection on the exterior of the TSHR molecule, perhaps important in ligand specificity (Wadsworth, et al, Science, 249:1423-1425 (1990)). Surprisingly, however, its deletion had no effect on TSH binding or on TSH-mediated signal
  • peptides corresponding to portions of this region for generating antisera to the TSHR are highly immunogenic and is reported to be recognized by TSHR autoantibodies in the majority of Graves' sera (Kosugi, et al, Thyroid, 1:321-330 (1991); Kosugi, et al, " /. Biol. Chem., 266:19413-19418 (1991)).
  • an antiserum to a closely related synthetic peptide recognizes the A subunit in FRTL-5 rat thyroid cells, but very poorly in transfected COS cells (Ban, et al, Endocrinology, 131:815-829
  • the present invention achieves high level of expression of the human TSHR in mammalian cells.
  • the extent of TSHR overexpression on the surface of TSHR-10,000 cells, -1.9 x 10 6 receptors per cell, is quite remarkable considering the estimate of only ⁇ 5 x 10 3 TSHR on thyrocytes (Rees Smith, et al, Endocr. Rev., 9:106-121 (1988)).
  • This level of expression 10-12-fold higher than previously attained in stably-transfected mammalian cells (Costagliola, et al, /. Clin. Endocrinol. Metab., 75:1540-1544 (1992); Matsuba, et al, /.
  • TSHR generated in bacteria or insect cells is typically insoluble and requires solubilization in chaotropic agents followed by renaturation (Graves, et al, Endocrinology, 136:521-527 (1995); Huang, et al, /. Mol. Endocrinol, 10:127-142
  • the TSHR-10,000 cells are also of potential value in providing antigen for the study of TSHR autoantibodies.
  • these uses are the development of new assays for TSHR autoantibodies, flow cytometric analysis of TSHR autoantibodies in patients' sera and the isolation of human monoclonal autoantibodies from immunoglobulin gene combinatorial libraries derived from patients' B cells.
  • the high basal cAMP levels in these cells reduces their
  • TSHR-10,000 cells provides insight into the function of the TSHR, at least as expressed in CHO cells.
  • the data on stably-transfected cell lines strongly support transient transfection data (Van Sande, et al, Eur. ⁇ . Biochem., 229:338-343 (1995)) that the TSHR maintains a moderate level of activity in the absence of ligand.
  • Such spontaneous activity was first observed with the ⁇ lB- adrenergic receptor (Kjelsberg, et al, /. Biol. Chem., 267:1430-1433 (1992)).
  • thyroid overactivity could result from an increased number of TSHR expressed on the thyrocytes of a particular individual consequent to mutations in the mRNA untranslated region in the same way as mutations in the mRNA coding region can increase the increased constitutive activity of an unchanged number of receptors (Duprez, et al, Nature Genet., 7:396-401 (1994); Parma, et al, Mol. Endocrinol, 9:725-733 (1995)).
  • a second interesting feature of the TSHR overexpressed in the TSHR- 10,000 cells is the ability of TSH to bind to single chain TSHR expressed on the cell surface.
  • the proportion of single chain and two-subunit TSHR on the surface of CHO cells is independent of the number of receptors expressed.
  • the stronger signal with the TSHR-10,000 cells makes the phenomenon much more clear and supports our previous evidence using chimeric TSH-LH/CG receptors that cleavage into A and B subunits is not a requirement for TSH binding (Russo, et al, Endocrinology, 130:2135-2138 (1992)). This evidence raises the possibility that
  • the single chain TSHR is, at least in part, a physiological receptor, a concept disputed by other investigators (Loosfelt, et al, Proc. Natl. A ⁇ d. Sci. USA, 895:3765-3769 (1992)).
  • the most surprising feature of the CHO cells overexpressing the TSHR was the progressive reduction in affinity for TSH observed with increasing numbers of TSHR.
  • TSH affinity in studies examining the role of the 5'- 3'-untranslated regions of the TSHR (Kakinuma, et al, Endocrinology, (In Press) (1995)).
  • the affinity of the wild-type TSHR cDNA appeared to decrease from 2 x 10 "10 M to 5 x 10 "10 M Kd when TSHR expression increased after
  • the present invention facilitated by the availability of CHO cells overexpressing the human TSHR (Example 3), also describes and demonstrates that IgG class autoantibodies to the TSHR can be detected directly by flow cytometry. However, an unequivocal signal by flow cytometry was obtained
  • TPO autoantibodies are known to be of
  • TSHR autoantibodies recognize epitopes outside of this region.
  • TSHR-specific B lymphocytes and plasma cells This low frequency of TSHR-specific B lymphocytes and plasma cells is also likely to contribute to the great difficulty in obtaining IgG-class human monoclonal autoantibodies to the TSHR (McLachlan, et al, /. Clin. Endocrinol. Metab., 81:3152- 3154 (1996)).
  • flow cytometry cannot be used as an alternative to currently used clinical assays to detect TSHR autoantibodies.
  • the present invention also demonstrates and describes that the evolutionary divergence of the TSHR into a receptor that cleaves into two subunits is unique and enigmatic. Unlike thrombin (Vu, et al, Cell, 64:1057 (1991)), TSH does not cleave its receptor; two subunit TSHR are present in transfected cells cultured in the absence of TSH (Misrahi, et al, Eur. J. Biochem., 222:711 (1994); Koo, et al, Endocrinology, 128:2297 (1991)). TSH binds to both cleaved and uncleaved forms of the TSHR. Moreover, TSH action does not require a cleaved receptor (Russo, et al, Endocrinology, 130:2135 (1992);
  • TSHR receptor cleavage including the release of a small polypeptide between cleavage sites 1 and 2, may be related to the very common occurrence of disease-causing autoantibodies, a phenomenon rarely, if ever, encountered with other members of the G protein-coupled receptor family.
  • Example 1 describes TSH binding inhibition assays employing recombinant human TSHR compositions.
  • Example 2 presents the surprising and novel finding for G protein- coupled receptors that contrary to the prevailing concept of one cleavage site in the TSHR, there are, in fact, two such sites.
  • the TSHR like insulin, may
  • Example 3 describes high level expression of TSHR in CHO cells, as well as high constitutive activity of the TSHR in the absence of ligand, and the binding of TSH to the single subunit, uncleaved TSHR. Moreover, high level expression is associated with apparent negative co-operativity among the TSHR in terms of their affinity for ligand.
  • Example 4 demonstrates that carboxyl-terminal truncation of the human
  • TSHR ectodomain generates a secreted protein with complex carbohydrate
  • Antigenically active TSHR is useful for the diagnosis, pathogenesis and immunotherapy of Graves'
  • Example 5 presents data providing the strongest support for the notion
  • TSHR autoantibodies in the sera of patients with autoimmune thryoid disease are present at much lower levels than are TPO autoantibodies. This finding has important implications for the diagnostic detection of TSHR
  • Example 6 identifies the amino acid residues related to the putative cleavage sites of TSHR.
  • Example 7 presents data from a direct assay for TSHR autoantibodies in normal and Graves' patient serum, using truncated TSHR antigen according to the invention.
  • TBI Thyrotropin Receptor
  • CHO cell lines were used, each expressing different numbers of human TSHR on their cell surface (Table 1).
  • the transgenome in the "4 kb" TSHR cells contains the full-length cDNA with both the 5' and 3' untranslated ends
  • TSHR-0 cells expressing only the coding region of the TSHR cDNA, were renamed from the previously cumbersome pTSHR-5'3TR-NEO-ECE (Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)). The zero implies that the TSHR cDNA transgenome in these cells has not been amplified.
  • TSHR-10,000 cells was amplified by adaptation of these cells to 10,000 nM methotrexate (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)).
  • methotrexate Chozenbalk, et al, Endocrinology, 137:4586-4591 (1996).
  • all cell lines (cloned by limiting dilution in selection medium) were grown in Ham's F-12 medium supplemented with 10% fetal calf serum and standard antibiotics. Cells were cultured to confluence in either 10 cm
  • Table 1 Characteristics of cell lines expressing the human TSH receptor
  • TSHR and TSHR-0 cells were grown to confluence in 24 well and 96 cells culture dishes, respectively.
  • TBI activity was determined in a "two-step" assay as described previously (Filetti, et al, /. Clin. Endocrinol Metab., 72:1096-1101 (1991)) using polyethylene glycol (PEG)-precipitated IgG (Filetti, et al, /. Clin. Endocrinol. Metab., 72:1096-1101 (1991)), with the following modifications.
  • binding buffer Hank's buffer containing 280 mM sucrose instead of NaCl and supplemented with 0.25% bovine serum albumin
  • 125 I-TSH in binding buffer was added to the cells (2 hr at 37°C) in the amounts described in the text (250 ml and 50 ml per well in the 24 well and 96 well plates respectively).
  • Bound 1 5 I-TSH was measured as previously described (Filetti, et al, /. Clin. Endocrinol. Metab., 72:1096-1101 (1991)).
  • Non- specific binding to untransfected CHO cells was subtracted to obtain values for specific binding.
  • Solubilized TSH receptor preparation Receptors were prepared from TSHR-10,000 cells in two procedures:
  • buffer A 10 mM Tris, pH 7.5, 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 ⁇ g/ml leupeptin, 1 ⁇ g/ml aprotinin and 2 ⁇ g/ml pepstatin A; Sigma)(3 ml/dish).
  • buffer A 10 mM Tris, pH 7.5, 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 ⁇ g/ml leupeptin, 1 ⁇ g/ml aprotinin and 2 ⁇ g/ml pepstatin A; Sigma
  • 500 - 20,000 x g particulate fraction was processed according to the protocol of Rees Smith et al. (Shewring, et al, Clin.
  • TSH binding inhibition (TB assay using solubilized TSHR: Sera were assayed using TSHR antibody (TRAb) kits purchased from Kronus, San
  • Thyroid stimulating immuno globulin (TSI) assay TSHR-0 cells, grown
  • IgG was precipitated with PEG (see above) and resuspended in the hypotonic medium supplemented with 10 mM Hepes, pH 7.4, 1 mM 3-isobutyl 1-methylxanthine and 0.3% BSA. Cells were incubated in this medium (0.1 ml) for 2 hr at 37°C. Cyclic AMP in the medium, diluted in 50 mM Na acetate, pH 6.2 and acetylated (Rapoport, et al, /. Clin. Endocrinol. Metab., 58:332-338 (1984)), was measured by radioimmunoassay using cAMP, 2'-0-succinyl 125 I-iodotyrosine methyl ester
  • TSI activity was expressed as a percentage of the cyclic AMP
  • TBI assays performed were of two main types (Table 2) involving either intact CHO cells or solubilized TSHR.
  • TSH binding inhibition (TBI) assays performed.
  • TBI values % inhibition of 125 I-TSH binding
  • % inhibition of 125 I-TSH binding were 79%, 91% and 83% with the commercial assay versus 10%, 13% and 57% with the CHO cells, respectively.
  • TSHR-0 cells (150,000 TSHR per cell)(Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)) cultured in microtiter (0.36 cm 2 ) wells provide only - 2-fold more receptors per well than the "4kb" TSHR cell line (16,000 TSHR per cell)(Nagayama, et al, Biochem. Biophys. Res. Comm.,
  • microtiter plates were the use of less serum and a smaller volume of 125 I-TSH with less background binding. By this means, the tracer concentration could be used.
  • TSH binding inhibition assay using detergent-extracted recombinant human TSHR As mentioned above, intact CHO cells expressing large numbers of receptors on their surface cannot be used for TBI assays. However, we wished to determine whether such cells would be a good source of recombinant TSHR in a soluble receptor assay. For this purpose, we used cells (TSHR-10,000), that express very large numbers ( ⁇ 1.9 x 10 6 ) of TSHR on their surface (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)). Cells were suspended by scraping, homogenized in buffer containing 1% Triton X- 100 and compared with the solubilized porcine TSHR in the universally used commercial kit as a standard. Recombinant receptor extracted from 7 x 10 6
  • TBI values obtained with the solubilized porcine TSHR are known to correlate only weakly with thyroid stimulating activity determined in a bioassay (TSI) involving activation of the human TSHR (Filetti, et al, /. Clin. Endocrinol. Metab., 72:1096-1101 (1991); Murakami, et al, Eur. J. Endocrinol, 133:80-86 (1995); Vitti, et al, /. Clin. Endo. Metab., 76:499-503 (1993)).
  • TBI bioassay
  • TSHR-10,000 Chozenbalk, et al, Endocrinology, 137:4586-4591 (1996)
  • TSHRmyc A second cell line, TSHRmyc (Tanaka, et al, Biochem. Biophys. Res. Comm., 228:21-28 (1996)), contains a c-myc epitope tag in the region of the cleavage site.
  • TSHR-10,000 (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)) is a Chinese hamster ovary (CHO) cell line overexpressing the human TSHR ( ⁇ 2 x 10 6 receptors per cell). Overexpression was attained using a dihydrofolate reductase minigene to amplify the stably- transfected TSHR cDNA transgenome.
  • TSHR-0 are CHO cells expressing the same TSHR cDNA, but without transgenome amplification ( ⁇ 1.5 x 10 5 receptors per cell)(Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996); Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)).
  • TSHRmyc are 293 human embryonal kidney (HEK) cells stably expressing the unamplified gene for an epitope-tagged human TSHR (Tanaka, et al, Biochem. Biophys. Res. Comm., 228:21-28 (1996)).
  • Epitope-tagging was achieved by replacing TSHR amino acids 338 to 349 with the human c-myc peptide EEQKLISEEDLL.
  • Cells were propagated in Ham's F-12 medium (CHO cells) or Dulbecco's modified
  • DMEM Eagle's medium
  • FCS fetal calf serum
  • penicillin 100 U/ml
  • gentamicin 50 ⁇ g/ml
  • amphotericin B 2.5 ⁇ g/ml
  • Immunoprecipitation of precursor-labeled TSHR Cells near confluence in 100 mm diameter culture dishes were rinsed with phosphate-buffered saline (PBS) and pre-incubated (0.5 h, twice) in DME-H21 methionine- and cysteine- free medium containing 5% heat-inactivated FCS. The cells were then pulsed
  • PBS phosphate-buffered saline
  • the mixture was centrifuged for 45 min at 100,000 x g and the supernatant was diluted 1:4 in immunoprecipitation buffer (20 mM Hepes pH 7.2, 300 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% Nonidet-P40, 2 mM EDTA).
  • immunoprecipitation buffer (20 mM Hepes pH 7.2, 300 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% Nonidet-P40, 2 mM EDTA).
  • the solubilized cell proteins were precleared for 1 h at 4°C with ⁇ 150 ⁇ g normal mouse serum IgG prebound to 25 ⁇ l packed and washed protein A-agarose (Sigma).
  • the protein A was removed by centrifugation (3 min at 10,000 X g) in a microcentrifuge.
  • Immunoblots of TSHR proteins Stably transfected TSHR-10,000 cells (in two 100 mm diameter dishes) were resuspended by incubation in Ca ++ - and Mg ++ -free PBS with 0.5 mM EDTA. The cells were pelleted (5 min., 100 x g, 4°C), resuspended in 1.5 ml of 10 mM Tris-HCl, pH 7.4, containing the protease inhibitors described above and homogenized with a Polytron homogenizer (Brinkman Instruments, Westbury, CT). After centrifugation for 10 min at 500 x g (4°C), the supernatant was recentrifuged for 20 min at 10,000 x g (4°C). The pellet was resuspended in 0.1 ml of the same buffer, after which Laemmli buffer with 0.7 M ⁇ -mercaptoethanol was added (30 min at
  • Membranes were incubated overnight (4°C) with mAb AlO or All to the A subunit, or with mAb to the B subunit;
  • T3-495 T3-495 (TSH-R1; Transbio, Boulogne, France) or T3-365 (final dilutions of 1:1000).
  • the membranes were incubated for 1 hr at room temperature with alkaline phosphatase conjugated goat anti-mouse immunoglobulin G (1:400 dilution)(Cappel, Durham, NC).
  • the signal was developed with nitroblue tetrazolium and 5-bromo, 4-chloro, 3-indolyl phosphate in lOOmM Tris-HCl buffer, pH 9.5, containing 100 mM NaCl and 5
  • TSH (5 ⁇ g, 30 U/mg protein) was radiolabeled with 125 I to a specific activity of
  • Unbound 125 I-TSH was removed by rinsing the cells three times with ice-cold binding buffer.
  • Disuccinimidyl suberate (DSS; 1 mM; Sigma) in 10 mM Na phosphate buffer, pH 7.4, containing the protease inhibitors described above was then added for 20 min at room temperature.
  • the cross-linking reaction was terminated by the addition of 20 mM ammonium acetate (final concentration).
  • the cells were rinsed twice with PBS and scraped into 10 mM Tris, pH 7.5, containing the same protease inhibitors. Cells were homogenized using a Polytron homogenizer and centrifuged for 5 min at 4°C (500 x g).
  • the supernatant was centrifuged (15 min, 10,000 x g, 4°C) and the pellet was resuspended in 50 ul 10 mM Tris, pH 7.5. After the addition of Laemmli buffer containing 0.7 M ⁇ -mercaptoethanol (30 min at 42°C), the samples were subjected to 10% SDS-PAGE and autoradiography as described above.
  • Immunodetection of the TSHR in TSHR-10.000 cells Immunoprecipitation studies of precursor-labeled TSHR-10,000 cells were performed with mAb AlO (Nicholson, et al, /. Mol Endocrinol, 16:159-170 (1996)) to TSHR amino acid residues 22-35 at the amino terminus of the A subunit. Multiple forms of the TSHR were observed under reducing conditions after chase periods of 3 hr and 16 (Fig. 6A).
  • Two forms of single subunit (uncleaved) TSHR were:- (i) -115 kDa in size (complex carbohydrate resistant to endoglycosidase H) and, (ii) ⁇ 100 kDa in size (immature, high mannose carbohydrate sensitive to endoglycosidase H)(Fig. 6).
  • N-glycosidase F digestion removed both forms of carbohydrate, exposing a ⁇ 84 kDa polypeptide backbone. Cleaved (two subunit) TSHR was also present.
  • mAb T3-495 and T3-365 was confirmed on immunoblotting with untransfected CHO cells (Fig. 7B). As in the immunoprecipitation experiments, the size of the A subunit could clearly be determined by immunoblotting with mAb AlO to the TSHR amino terminus.
  • the -62 kDa mature A subunit contained complex carbohydrate (endoglycosidase H resistant)(Fig. 7C). Most important, deglycosylation with N-glycosidase F confirmed a -35 kDa A subunit backbone. Lesser fragments of ⁇ 39 kDa and -42 kDa were also evident.
  • the specificity of mAb AlO to the A subunit was confirmed on immunoblots with untransfected CHO cells and on immunoblotting of TSHR- 10,000 cells with a mAb to TPO (Fig. 7D).
  • Conundrum of a missing piece of the TSHR The human TSHR, without its 21 amino acid residue signal peptide, has a predicted polypeptide backbone of 84.5 kDa (743 amino acid residues). However, from the immunoprecipitation and immunoblot studies shown above, the sum of the enzymatically deglycosylated A subunit (35 kDa) and the primary B subunit fragment (-42 kDa) was only -77 kDa. A 35 kDa polypeptide backbone for
  • the TSHR A subunit would place the cleavage site in the region of amino acid residue 330, taking into account the absence of the signal peptide. Further, a -42 kDa size for the non-glycosylated B subunit would be consistent with a holoreceptor cleavage site at about residue 380. It, therefore, appeared that a "C peptide" fragment in the vicinity of residues 330 - 380 could be missing from the cleaved TSHR ectodomain (Fig. 8). This deduction is inconsistent
  • TSHR subunits in TSHRmyc cells In order to explore the possibility of
  • TSHRmyc cells that express a receptor with a 12 amino acid human c-myc epitope in place of residues 338-
  • This epitope lies within the segment of the TSHR predicted to be missing if the two cleavage site hypothesis is correct, namely residues - 330-380 (Fig.
  • the TSHRmyc cells do not contain an amplified transgenome and express fewer receptors (-100,000 per cell)(Tanaka, et al, Biochem. Biophys. Res. Comm., 228:21-28 (1996)) than TSHR-10,000 cells. Nevertheless, both anti-myc mAb 9E10 and mAb AlO were equally effective in detecting the single chain forms of the TSHR in these cells (Fig. 9A). It contrast, it was more difficult to detect the diffuse, glycosylated TSHR A subunit band in the TSHRmyc cells
  • EXAMPLE 3 EVIDENCE FOR NEGATIVE COOPERATIVITY
  • ECD A 2.7 kb TSHR cDNA containing the coding region and 0.4 kb of the 3' untranslated region was excised with Sal I and Xba I from pTSHR-5'TR- NEO-ECE (Kakinuma, et al, Endocrinology, (In Press) (1995)). This fragment was restricted with Hinc II to release the 2.3 kb TSHR coding region, which was then inserted into the Xba I (blunted) and Sal I sites in pSV2-DHFR-ECE- TPO (Kaufman, et al, Molec. Cell. Endocrinol, 78:107-114 (1991)) following removal of its Sal I-Xba I insert.
  • TSHR was transfected by the calcium phosphate precipitation method (Chen, et al, Mol. Cell. Biol, 7:2745-2752 (1987)) into dihydrofolate reductase (dhfr)-deficient CHO cells (CHO-DG44; kindly provided by Dr. Robert
  • Stably transfected cells were selected in thymidine-, guanine-, and hypoxanthine-free Ham's F-12 medium
  • MTX Methotrexate
  • TSHR CHO clonal cell lines 0 stably expressing the TSHR were grown to confluence in 100 mm diameter culture dishes. After rinsing with phosphate-buffered saline (PBS), cells were pre-incubated (0.5 h, twice) in DME-H21 methionine- and cysteine-free medium containing 5% heat inactivated fetal calf serum. The cells were then pulsed (1 h at 37 C) in 5 ml fresh medium supplemented with - 0.5 mCi of
  • aprotinin (1 ⁇ g/ml), and pepstatin A (2 ⁇ g/ml) (all from Sigma, St. Louis, MO)(buffer A).
  • the cells were pelleted (5 min, 100 x g), washed twice with PBS and resuspended in buffer A containing 1% Triton X-100. After 90 min at 4C with occasional vortexing, the mixture was centrifuged for 45 min at 100,000 x g and the supernatant was diluted 1:4 in immunoprecipitation buffer (20 mM Hepes pH 7.2, 300 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% Nonidet-P40 and 2 mM EDTA).
  • solubilized cell proteins were precleared by incubation for 1 h at 4C with 150 ⁇ g normal mouse serum IgG prebound to 25 ⁇ l packed and washed protein A-agarose (Sigma). After removal of the protein A by centrifugation (3 min at 10,000 X g) in a microcentrifuge, mouse
  • the cells were rinsed twice with PBS and scraped into 10 mM Tris, pH 7.5, containing the same protease inhibitors.
  • Cells were homogenized using a Polytron homogenizer (Brinkmann Instruments, Westbury CT) and centrifuged for 5 min at 4 C (500 x g). The supernatant was centrifuged (15 min, 10,000 x g, 4C) and the pellet was resuspended in 50
  • TSH binding CHO cells stably transfected with TSHR cDNA were grown to confluence in 96-well culture plates. Cells were then incubated for 2 h at 37°C in 50 ⁇ l binding buffer (see above) containing approximately 50,000 cpm of 125 I-TSH in the presence or absence of increasing concentrations of 5 unlabeled bovine TSH (Sigma).
  • the cells were rapidly rinsed three times with binding buffer (4°C), solubilized with 0.1 ml NaOH and radioactivity measured in a gamma-counter.
  • binding buffer 4°C
  • solubilized with 0.1 ml NaOH radioactivity measured in a gamma-counter.
  • Non- 10 specific 125 I-binding to untransfected CHO cells was subtracted from total counts bound to provide specific counts bound. These values were ⁇ 10% of total counts bound at the highest tracer concentration used (2.5 x 10 7 cpm/ml).
  • TSH stimulation of intracellular cAMP Transfected CHO cells, grown to confluence in 24-well or 96-well culture plates, were incubated for 2 h at 15 37°C in either hypotonic medium (Kasagi, et al, /. Clin. Endocrinol. Metab., 54:108-114 (1982); Rapoport, et al, Metabolism, 31:1159-1167 (1982)) or in Ham's F-12 medium containing 1% bovine serum albumin, 1 mM isobutyl
  • TSHR protein expression in whole CHO cells The process of stable transfection and progressive amplification of the TSHR holoreceptor/ dhfr-minigene complex in the genome of CHO cells took approximately one year. During this period, TSHR expression in the selected clone was confirmed intermittently by 125 I-TSH binding. After completion of the amplification process, we assessed the level of TSHR expression within whole cells by precursor 35 S-methionine and 35 S- cysteine labeling followed by immunoprecipitation under native conditions
  • the immature form of the receptor accumulates within the cell and is degraded. It was, therefore, important to determine whether the TSHR
  • the upper band represents a single chain holoreceptor (Russo, et al, Mol Endocrinol, 5:1607-1612 (1991); Russo, et al, Endocrinology, 130:2135-2138 (1992)) with an apparent mass of - 115 kDa and the lower band a dissociated A subunit (Buckland, et al, FEBS Letters,
  • TSHR Function of the overexpressed TSHR in the absence of ligand: Basal cAMP levels were assessed in stably-transfected cell lines expressing different numbers of TSHR. In cells cultured in hypotonic medium (Kasagi, et al, /. Clin. Endocrinol. Metab., 54:108-114 (1982); Rapoport, et al, Metabolism,
  • Plasmid constructs We generated three plasmids for expression in mammalian cells of limited TSHR ectodomain truncations (Fig. 17): (i) TSHR-
  • Plasmid TSHR-5'TR-NEO-ECE (Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)) contains an Afl II site at codon 260 and an Xba I site in the vector at the 3 end of the insert.
  • the Afl Il-Xba I fragment was excised and replaced with a cassette coding for 6 histidine residues (6H) followed by 2 stop codons.
  • the cassette was created by annealing two oligonucleotides: Sense: 5'-TTAACCATCACCACCACCATCACTGATAAT; Antisense: 5'-CTAGATTATCAGTGATGGTGGTGGTGATGG Ligation at the Afl II site generated an Asn residue upstream of the 6H, hence
  • TSHR-289 A cDNA fragment including the Afl
  • TSHR-309 Construction used the identical strategy to that of TSHR-289 except that the Afl II - Spe cDNA fragment generated by PCR extended up to codon 309. After confirmation of the nucleotide sequences of the relevant areas, the
  • TSHR-261, TSHR-289 and TSHR-309 cDNAs were excised with Sal I and Xba I and transferred to the vector pSV2-ECE-dhfr (Kaufman, et al, Molec. Cell Endocrinol, 78:107-114 (1991)).
  • TSHR ectodomain variants Cell lines, stably transfected with the above TSHR ectodomain cDNA variants were established in CHO dhfr-cells (CHO-DG44; kindly provided by Dr. Robert Schimke, Stanford University, Palo Alto, CA), using procedures described previously (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)). Transgenome amplification was achieved by progressive adaptation to growth in methotrexate (final concentration 10 ⁇ M)(Rapoport, et al, /. Clin. Endocrinol Metab., 81:2525-2533 (1996)).
  • TSHR ectodomain variants in medium and in cells CHO cells to be tested for TSHR ectodomain variant expression were metabolically
  • Radiolabeled proteins were visualized by autoradiography on Kodak XAR-5 X-ray film (Eastman Kodak, Rochester, NY). TSHR secreted into the medium was also detected by means of their 6H tag using Ni-NTA resin (QIAGEN, Ine, Chatsworth, CA) according to the procedure reported previously (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)).
  • TSHR autoantibody kits were purchased from Kronus, San Clemente, CA.
  • the principal of this assay is the ability of autoantibodies to compete for 12S I-TSH binding to TSHR solubilized from porcine thyroid glands ("TSH binding inhibition" or TBI assay) (Shewring, et al, Clin. Endocrinol, 17:409-417 (1982)).
  • solubilized TSHR 50 ml
  • Antibody activity is measured as % inhibition of 125 I-TSH binding relative to a standard serum from a normal individual without autoantibodies. We modified this assay by preincubating (30 min at room temperature) serum from Graves' patients (25 ml) with conditioned medium from cells expressing TSHR ectodomain variants (25 ml).
  • Solubilized TSHR (50 ml) was then added to the serum/medium mixture (50 ml).
  • serum/medium mixture 50 ml
  • lectins was determined for three Sepharose-linked lectins: Wheat germ agglutinin (WGA), Bandeiraea simplificifolia and Concanavalin A (Con A)(Pharmacia, Piscataway, NJ).
  • WGA Wheat germ agglutinin
  • Con A Concanavalin A
  • the beads were then extensively washed in batch with 10 mM Tris, pH 7.5, 150 mM NaCl and adsorbed material released (tumbling for 45 min at room temperature) with 3 ml of the same buffer supplemented with 0.25 M N acetyl-glucosamine
  • the filters were rinsed, incubated (1 hr at room temperature) with alkaline phosphatase-conjugated goat anti-mouse immunoglobulin G and the signal developed as described previously (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)).
  • TSHR-261 partial purification Conditioned medium was harvested from CHO cells expressing TSHR-261 cultured in non-selective F12 medium containing 10% fetal calf serum, antibiotics and 5 mM Na butyrate (Dorner, et al, /. Biol. Chem., 264:20602-20607 (1989)). Medium (2 liters) was applied to a 70 ml Concanavalin A Sepharose column. After washing with 10 mM Tris, pH 7.5, 150 mM NaCl, bound material was eluted with - 80 ml of 0.15 M a- methyl-mannoside in the same buffer.
  • the eluted material was made up to 50 mM imidazole, pH 7.2, and applied to two 5 ml His-Trap columns in series (Pharmacia). Elution was with buffer containing 10 mM Tris, pH 7.4, 50 mM NaCl, and 100 mM EDTA. The sample was concentrated and the buffer exchanged to 10 mM Tris, pH 7.5, 50 mM NaCl using a Centriprep 30 (Amicon, Beverly, MA). At all stages, TSHR-261 recovery was monitored by bioassay (TBI neutralization; see above).
  • TSHR-261 The ectodomain variant with the greatest degree of C-terminal truncation (TSHR-261) was entirely secreted into the medium, as detected by immunoprecipitation after an overnight chase, with no receptor remaining in the cells (Fig. 18).
  • TSHR-289 truncate ' d to a lesser extent was secreted to an intermediate degree.
  • the receptor remaining within the cells was present in multiple forms, the dominant band having a molecular weight lower than the secreted form.
  • TSHR-309 the least truncated ectodomain, secretion into the medium was relatively inefficient. Thus, proportionately less receptor
  • TSH binding inhibition (TBI) assay to test whether conditioned medium from cultured cells expressing TSHR-261, TSHR-289 and TSHR-309 could neutralize 00/05345 1 1 1 autoantibody activity in a Graves' patient's serum.
  • THI TSH binding inhibition
  • TSHR protein from medium using this approach.
  • the Ni-NTA bound to many unlabeled proteins despite attempts to minimize non-specific interactions with imidazole and adsorption at lower pH (data not shown).
  • TSHR-261 in conditioned medium bound poorly to wheat germ agglutinin and Bandeiraea simplicifolia (Fig. 20). Almost all of this material remained in the "flow-through” and minimal amounts could be recovered by elution with specific sugar.
  • concanavalin A Con A was effective in extracting TSHR-261 from the medium.
  • TSHR-289 and TSHR-309 were also extracted from culture medium using Con A. Immunoblotting indicated that TSHR-289 and TSHR-309, like TSHR-261, contained only mature, complex carbohydrate (Fig. 22). Remarkably, TSHR-261 contains - 20 kDa of N-linked glycosylation, 40% of its mass. The apparent molecular weights of the deglycosylated proteins ( ⁇ 30, 32 and 34 kDa for TSHR-261, TSHR-289 and TSHR-309, respectively) were slightly ( ⁇ 2 kDa) greater than predicted from their known amino acid sequences (including 6 H tags).
  • the secreted TSHR variants could be detected qualitatively by immunoprecipitation, immunoblotting or by autoantibody neutralization.
  • TSHR-261 for further study because, of the three ectodomain variants, it was secreted to the greatest extent (Fig. 18) and because its "bioactivity" in terms of autoantibody recognition appeared equal to that of TSHR-289 (Fig. 19).
  • TSHR-261 (20-40% estimated purity)(Fig. 23) was quite stable at -80°C. Partially-purified TSHR-261 was highly potent in neutralizing TSHR
  • TSHR-10,000 Chinese hamster ovary (CHO) cells express high numbers of mature TSHR on their surface in vivo (described in Example 3).
  • TPO thyroid peroxidase
  • Serum BB1 Serum BB1 kindly provided by Dr. Stephanie Lee, New England Medical Center Hospitals, Boston, was from a patient with Graves' disease who subsequently became hypothyroid with the development of blocking antibodies.
  • Thirty sera were generously provided to us by Mr. Juan Tercero, Corning-Nichols Institute, San Juan Capistrano, California. These sera were submitted without clinical information for the assay of autoantibodies to the TSHR (see below), presumably for suspicion of Graves' disease.
  • Ten of the 30 sera were selected for the absence of TSHR autoantibodies, 10 for the presence of moderate TSH binding inhibitory (TBI) activity and a further 10 for their high (>50%) TBI activities.
  • TBI moderate TSH binding inhibitory
  • TSHR autoantibody titers of selected sera were determined by dilution of these sera in a serum from a normal individual without a history of autoimmune thyroid disease and with undetectable TSHR autoantibody activity.
  • Sera were also tested for TPO autoantibodies using 125 I-TPO (recombinant) as described previously (Portolano, et al, /. Clin. Invest., 90:720-726 (1992) ).
  • TPO and TSHR Construction of plasmids and Chinese hamster ovary (CHO) stable transfections for overexpression of the human TSHR and TPO have been described elsewhere (Example 3; Kaufman et al, Molec. Cell. Endocrinol, 78:107-114 (1991)). These cells, as well as untransfected CHO cells (DG44; kindly provided by Dr. Robert Schimke, Stanford University, Palo Alto, CA) were propagated in Ham's F-12 medium supplemented with 10% fetal calf serum, penicillin (100 U/ml), gentamicin (50 ⁇ g/ml) and amphotericin B (2.5 ⁇ g/ml).
  • DG44 untransfected CHO cells
  • FACS Flow cytometric analysis
  • cells were pelleted and rinsed (5 min at 100 x g) in Ham's F-12 medium supplemented with 10% dialyzed fetal calf serum and antibiotics as
  • buffer A phosphate-buffered saline, 10 mM Hepes, pH 7.4, 0.05% Na azide and 2% fetal calf serum heat-inactivated at 56°C for 30 min.
  • Sera (20 ⁇ l)
  • TSHR-10,000 cells using mouse monoclonal antibodies (A9 and A10)(l:100 final concentration)(Nicholson, et al, /. Mol. Endocrinol, 16:159-170 (1996)) and rabbit antiserum (1:60 final concentration) (R8) (Vlase, et al, Endocrinology, 136:4415-4423 (1995)) to the TSHR (all kindly provided by Dr. Paul Banga, London, England) was according to the protocol described for the human sera, except for the use of the use of the following
  • affinity-purified goat anti-mouse IgG 0.8 ⁇ l
  • fluorescein isothiocyanate-conjugated 0.8 ⁇ l
  • affinity-purified goat anti-rabbit IgG 0.5 ⁇ l
  • Flow cytometric analysis of CHO cells expressing the TSHR We have previously been unable to detect the TSHR stably expressed on the surface of CHO cells using Graves' sera. Recently, however, two reagents became available to us; CHO cells expressing very high numbers of TSHR (nearly 2 x 10 6 ) on their surface (Example 3), and a Graves' serum (BB1) particularly potent in the indirect TSH binding inhibition (TBI) assay. Using this serum, a
  • TSHR-0 previously termed 5'3'TR-ECE
  • TSHR-800 Progressively greater specific fluorescence was evident with TSHR-800 and TSHR-10,000 cells expressing - 10 6 and 1.9 x 10 6 receptors per cell, respectively (Example 3) (Fig. 26C and 26D).
  • TSHR antigen on the surface of the transfected CHO cells, previously determined by radiolabeled TSH binding and TSH-mediated signal transduction (Example 3; Nagayama, et al, Biochem. Biophys. Res. Comm.,
  • Murine monoclonal antibodies (A9 and A10)(Nicholson, et al, /. Mol. Endocrinol, 16:159-170 (1996)) were less effective in recognizing the native TSHR on the cell surface (Fig. 27A, 27B).
  • the TSHR-10,000 cells were,
  • TSHR-10,000 cells Use of TSHR-10,000 cells to detect TSHR autoantibodies in different sera: In preliminary studies, we observed that some sera, regardless of whether or not they contained TSHR autoantibodies, elicited high fluorescence on flow cytometry with TSHR-10,000 cells. We observed similar high fluorescence when these sera were incubated with untransfected CHO cells not expressing the TSHR (data not shown). Therefore, some sera contained antibodies against unknown antigens on the surface of CHO cells. For this reason, we instituted a preadsorption step, in which sera were preincubated with untransfected CHO cells prior to addition to the TSHR-10,000 cells. Preadsorption was effective in eliminating, or greatly reducing, this non ⁇
  • this panel included 10 sera (IL - 10L) without TBI activity (1 - 4.2% inhibition); 10 sera (IM - 10M) with moderately high TBI values (17.3 - 39.4% inhibition); 10 sera (1H - 10H) with high TBI levels (52 - 95.1% inhibition); four normal individuals without autoimmune thyroid disease and four patients with systemic lupus erythematosus with anti-DNA and/or anti-cardiolipin antibodies. None of the sera from normal individuals, individuals with negative TBI values or patients with systemic autoimmunity generated a positive signal on flow cytometry.
  • the TSHR autoantibody titers in the four sera positive for the TSHR on flow cytometry were determined in the TBI assay (Table 2). Dilution of these sera indicated that BBl and 10H had similar, high TSHR autoantibody titers, consistent with their strong fluorescence signals on flow cytometry. The lower TBI titer of serum 3H was also consistent with its relatively low fluorescence signal. Surprisingly, serum 10M, with the lowest TSHR autoantibody titer, generated a strong signal on flow cytometry, raising the possibility of the presence in this serum of "neutral" autoantibodies to the TSHR that do not inhibit TSH binding.
  • TPO autoantibodies detected by flow cytometry In view of the small number of sera that could unequivocally recognize the TSHR by flow cytometry, we studied TPO autoantibodies in the same sera by the same approach using CHO cells overexpressing TPO on their surface (Kaufman, et al, Molec. Cell. Endocrinol, 1991; 78:107-114 (1991)). TPO autoantibodies commonly coexist with TSHR autoantibodies. Indeed, of the 20 TBI positive sera (1-lOM and 1-lOH), 19 bound > 13% 125 I-TPO, well above the upper limit detected in the sera of normal individuals (2.6% binding)(Table 1).
  • TBI-negative sera 7L and 10L were also TPO autoantibody positive by this method. Strikingly, all 20 sera with detectable TPO autoantibodies were clearly positive on flow cytometry with CHO-TPO cells. Not only were more sera positive for TPO than for the TSHR by flow cytometry, but the net fluorescence (after subtraction of fluorescence with non- transfected cells) was far higher with TPO-expressing cells than with TSHR- expressing cells (Table 1). Like the TSHR-10,000 cells, the cells overexpressing TPO (TPO-10,000) have - 2 x 10 6 TPO molecules on their surface (unpublished data).
  • TSHR into A and B subunits does not occur at a single site as previously suspected, but at two sites (described in Example 2), a feature unique to currently known members of the family of G protein-coupled receptors with
  • domains "D and E" is replaced with the corresponding region of the LH/CG receptor (Nagayama, et al, Proc. Natl. Acad. Sci. USA, 88:902 (1991); Russo, et al, Endocrinology, 130:2135 (1992))(Fig. 31).
  • cleavage still occurs when either domain D or domain E (residues 261-360 and 363-418; chimeric receptors TSH-LHR-4 and TSH-LHR-5, respectively) are substituted on an individual basis.
  • Plasmids were stably transfected with Lipofectin (Gibco-BRL, Gaithersburg, MD) into Chinese hamster ovary (CHO) cells cultured in Ham's F-12 medium supplemented with 10% fetal calf serum (FCS) and standard antibiotics.
  • Lipofectin Gibco-BRL, Gaithersburg, MD
  • FCS fetal calf serum
  • TSH-LHR-4 For our initial series of mutations in domain E of chimeric receptor TSH-LHR-4, we used the El, E2 and E3 mutations (Fig. 33 A) previously constructed in the wild-type TSHR (Nagayama, et a ⁇ , Endocrinology, 131:548 (1992)). These mutations were transposed into the cDNA for TSH- LHR-4 (Eco RV - Xba I fragment). Subsequent finer mutations in the E domain of TSH-LHR-4 were made by PCR using overlapping primers, with replacement of the Afl II - Spe I fragment.
  • hydrophilic and can be deleted from the wild-type TSHR without loss of ligand binding and function (Wadsworth, et al, Science, 249:1423 (1990)) and without preventing cleavage into A and B subunits (Russo, et al, Mol. Endocrinol, 5:1607 (1991)).
  • the deglycosylated TSHR A subunit is - 35 kDa in size (Example 4; Misrahi, et al, Eur. f. Biochem., 222:711 (1994)), which would place cleavage site 1 at approximately amino acid residue 335 (numbering includes a 21 residue signal peptide).
  • residues 330-338 for alanine scanning mutagenesis Fig. 32A. None of these individual substitutions prevented cleavage of chimeric receptor TSH-LHR-5, as determined by release of the TSH-linked A subunit on disulfide bond reduction (Fig. 32B).
  • Cleavage site 1 could be upstream of amino acid residue 317.
  • the deglycosylated A subunit would be 33 kDa or less, smaller than observed by multiple investigators (Graves, et al, Endocrinology, 137:3915 (1996); Example 4; Misrahi, et al, Eur. J.
  • the mutation that abrogates cleavage at site 2 introduces a consensus sequence for an N-linked glycosylation site.
  • a carbohydrate side-chain in this vicinity could, therefore, prevent ectodomain cleavage, for example by steric hindrance of a proteolytic enzyme.
  • the mutagenesis strategy used to investigate cleavage site 2 in the TSHR involved substitution into the TSHR of the corresponding segments of the non-cleaving LH/CG receptor.
  • the GQE ⁇ . ⁇ NET substitution in the TSHR transposes NET ⁇ ,. ⁇ from the LH/CG receptor, a motif that is glycosylated in the latter receptor (Davis, et al, Mol. Endocrinol, 11:550 (1997)).
  • TSHR-289 was selected by the inventors for use in this example because, while less efficiently secreted than TSHR-261, it appeared to exhibit more stability than TSHR-261. As such, it is presently preferred for this purpose.
  • the TSHR-289 included a 6 histidine tail as described herein (TSHR-289-6His).
  • TSHR-2896His antigen was produced in tissue culture medium harvested from CHO cells secreting TSHR- 289-6His, as described herein. Sepharose-Protein A beads were obtained from Sigma, and other reagents were obtained from Sigma or similar suppliers.
  • Assay buffer was lOmM Tris, pH 7.5, 0.1 M NaCl, 0.1 % Tween, 0.5% bovine serum albumin, and 0.025% Na azide.
  • Anti- histidine mouse monoclonal antibody labeled with Na 125 I was obtained from QIAGEN, Inc., Chatsworth, California. Human serum samples were obtained from normal volunteers and from two confirmed clinically active Graves' patients. Assay Procedure
  • 0.1 ml of human serum (normal or Graves') was diluted with 1.9 ml assay buffer (1:20 dilution) in a 12x75 mm polypropylene tube.
  • 0.1 ml Sepharose-Protein A beads was added, and the tube was rotated overnight at 4°C. The tube was then centrifuged (2 min., 2000 rpm, 4°C), and the assay buffer was aspirated. The pelleted beads were washed by resuspending in 3 ml of assay buffer, followed by centrifugation (2 min., 2000 rpm, 4°C).
  • the beads were resuspended in 0.7 ml of normal human serum and 1.3 ml of buffer, and rotated for 1 hour at 4°C. Following centrifugation (2 min., 2000 rpm, 4°C), the beads were washed once by resuspension in assay buffer and centrifugation (2 min., 2000 rpm, 4°C).
  • the beads were then resuspended in 3 ml of TSHR-289-6His conditioned medium and rotated for 6 hours at 4°C. Following this incubation, the beads were centrifuged (2 min.,
  • TSHR autoantibody levels in the two Graves' disease patients as reflected in counts per minute (cpm) of 125 I activity, exceeded mean normal serum levels by over 600% (Table 3).
  • Such elevated autoantibody levels as measure according to the direct assay methods of the present invention are consistent with TSHR activation, known to result in thyroid overactivity and thyrotoxicosis in Graves 'patients (Rees Smith, et al, Endocr. Rev.,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

TSHR compositions and methods of use are disclosed, useful for diagnostic and therapeutic purposes.

Description

HUMAN THYROTROPIN RECEPTOR COMPOSITIONS AND USE THEREOF
Portions of the subject matter described in the present invention may have been supported by U.S. Government grants. The U.S. Government may
have certain rights to portions of the subject matter described herein.
Field of the Invention The present invention relates generally to the fields of cell physiology, endocrinology and immunology. More particularly, the present invention relates to human thyrotropin receptor compositions and to diagnostic and therapeutic
methods of using them.
Background of the Invention
Autoantibodies to the thyrotropin receptor (TSHR) are the hallmark of the autoimmune response to the thyroid gland in Graves' disease (Rees Smith, et al, Endocr. Rev., 9:106-121 (1988)). In most cases, these TSHR autoantibodies activate
the receptor and lead to hyperthyroidism. More rarely, receptor occupancy by non-stimulatory TSHR autoantibodies can prevent TSH action and cause hypothyroidism (Orgiazzi, et al, /. Clin. Endocήnol. Metab., 42:341-354 (1976);
Endo, et al, /. Clin. Endocrinol. Metab., 46:734-739 (1978); Matsuura, et al, N. Engl. /. Med., 303:738-741 (1980)). In contrast to autoantibodies to other thyroid
autoantigens (thyroid peroxidase and thyroglobulin) there is, at present, no direct clinical assay for TSHR autoantibodies. Instead, these autoantibodies are detected either by their ability to inhibit radiolabeled TSH binding (TSH binding
inhibition; TBI) or in a bioassay of TSHR activation (TSHR stimulatory immunoglobulin assay; TSI)(McKenzie, et al, /. Clin. Endocrinol. Metab., 69:1093-1096 (1989)). The most widely used assay is a TBI involving porcine
TSHR solubilized with detergent from thyroid glands (Shewring, et al, Clin.
Endocrinol, 17:409-417 (1982)).
The molecular cloning of the TSHR cDNA led to the expectation that TBI assays using recombinant human TSHR would soon arise. However, although mammalian cell lines stably transfected with the human TSHR cDNA have been reported (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989); Perret, et al, Biochem. Biophys. Res. Comm., 171:1044-1050 (1990); Harfst, et al,
Molec. Cell. Endocrinol, 83:117-123 (1992); Matsuba, et al, /. Biochem., 118:265-270 (1995); Murakami, et al, Eur. }. Endocrinol, 133:80-86 (1995); Kim, et al, /. Clin. Endocrinol. Metab., 81:1758-1767 (1996)) and although large amounts of receptor protein have been generated in bacteria (Takai, et al, Biochem. Biophys. Res. Comm., 179:319-326 (1991); Loosfelt, et al, Proc. Natl. Acad. Sci. USA., 895:3765-3769 (1992); Harfst, et al, /. Mol. Endocrinol, 9:227-236 (1992); Huang, et al, /. Mol. Endocrinol, 8:137-144 (1992); Costagliola, et al, /. Mol. Endocrinol., 13:11-21 (1994); Graves, et al, Endocrinology, 136:521-527 (1995)) and in insect cells (Huang, et al, /. Mol.
Endocrinol., 10:127-142 (1993); Seetharamaiah, et al, Autoimmunity, 14:315-320 (1993); Vlase, et al, /. Clin. Endocrinol. Metab., 80:46-53 (1995)) or as cell-free translates (Morgenthaler, et al, /. Clin. Endocrinol. Metab., 81:700-706 (1996)), recombinant human TSHR has failed to supplant the use of porcine TSHR in the TBI assay.
TSHR expressed in mammalian cells are well-recognized by autoantibodies in TBI assays involving intact cells (Harfst, et al, Molec. Cell. Endocrinol,
83:117-123 (1992); Filetti, et al, /. Clin. Endocrinol. Metab., 72:1096-1101 (1991)), cell particulate fractions (Matsuba, et al, /. Biochem., 118:265-270 (1995); Libert, et al,
Molec. Cell. Endocrinol., 68:R15-R17 (1990); Costagliola, et al, /. Clin. Endocrinol.
Metab. 75:1540-1544 (1992)) and in detergent-solubilized membranes (Costagliola, et al, /. Clin. Endocrinol. Mclab., 75:1540-1544 (1992)). However, assays using cultured cells are impractical for general use. Further, the small amount of recombinant TSHR recovered from mammalian cell particulate fractions (Matsuba, et al, /. Biochem., 118:265-270 (1995); Costagliola, et al, /. Clin. Endocrinol. Metab., 75:1540-1544 (1992)) makes use of this material prohibitively
expensive. There exists a need, therefore, for improved and practical TSH binding inhibition assays employing recombinant human TSHR compositions.
TSHR is of pivotal importance in the regulation of thyroid gland physiological function and is also the direct cause of hyperthyroidism when targeted by autoantibodies in Graves' disease (Rees Smith, et al, Endocr. Rev.,
9:106-121 (1988); Nagayama, et al, Mol. Endocrinol., 6:145-156 (1992); Vassart, et al, Endocr. Rev., 13:596-611 (1992)). The availability of purified TSHR would be a major advance in understanding the structure-function relationship of the TSHR
and well as in exploring the pathogenesis of Graves' disease. Because of the very small number of TSHR in thyroid tissue (Rees Smith, et al, Endocr. Rev., 9:106-121 (1988)), high level expression of recombinant TSHR has been a goal vigorously sought by numerous investigators over the past six years. Most effort has been
applied to prokaryotic (Takai, et al, Biochem. Biophys. Res. Comm., 179:319-326 (1991); Loosfelt, et al, Proc. Natl. Acad. Sci. USA, 895:3765-3769 (1992); Harfst, et
al, /. Mol. Endocrinol., 9:227-236 (1992); Huang, et al, /. Mol Endocrinol, 8:137-144 (1992); Costagliola, et al, /. Mol. Endocrinol, 13:11-21 (1994); Graves, et al, Endocrinology, 136:521-527 (1995)) and insect cell (Costagliola, et al, /. Mol
Endocrinol, 13:11-21 (1994); Huang, et al, /. Mol. Endocrinol, 10:127-142 (1993); Seetharamaiah, et al, Autoim unity, 14:315-320 (1993); Misrahi, et al, Eur. J. Biochem., 222:711-719 (1994); Chazenbalk, et al, /. Biol. Chem., 270:1543-1549 (1995); Vlase, et al, /. Clin. Endocrinol Metab., 80:46-53 (1995)) systems in which high level expression can be achieved for many proteins. Although there are reports of TSH or TSHR autoantibody binding to such material (Graves, et al, Endocrinology, 136:521-527 (1995))Huang, et al, /. Mol. Endocrinol, 10:127-142 (1993); Vlase, et al, /. Clin. Endocrinol Metab., 80:46-53 (1995); Fan, et al, Autoimmunity, 15:285-291 (1993), as well as to synthetic TSHR peptides (Fan, et al, Autoimmunity, 15:285-291 (1993); Morris, et al, /. Clin. Endocrinol. Metab., 67:707-712 (1988); Atassi, et al, Proc. Natl. Acad. Sci. USA, 88:3613-3617 (1991); Morris, et al, /. Biol. Chem., 268:10900-10905 (1993); Bryant, et al, /. Biol Chem., 269:30935-30938 (1994); Morris, et al, Autoimmunity, 17:287-299 (1994)) and cell-free translation products (Morgenthaler, et al, /. Clin. Endocrinol. Metab., 81:700-706 (1996)), other investigators have encountered serious difficulties in either protein production or ligand recognition (Loosfelt, et al, Proc. Natl Acad. Sci. USA, 895:3765-3769 (1992); Costagliola, et al, /. Mol Endocrinol, 13:11-21 (1994); Harfst, et al, Molec.
Cell Endocrinol, 83:117-123 (1992); Chazenbalk, et al, /. Biol. Chem., 270:1543-1549 (1995)). There exists a need, therefore, for high level expression of TSHR.
Graves' disease is a very common (~ 1% prevalence)(Vanderpump, et al, Clin. Endocrinol, 43:55-68 (1995)), organ-specific autoimmune disease, affecting
only humans. Unlike in diabetes mellitus, type I, a less common organ-specific disease, there is no spontaneous animal model for Graves' disease. Also in contrast to diabetes mellitus, type I, one specific antigen is unequivocally and directly involved in the pathogenesis of Graves' disease, namely the thyrotropin receptor (TSHR). Thus autoantibodies to the TSHR activate the receptor, leading to thyroid overactivity and thyrotoxicosis (Rees Smith, et al, Endocr. Rev.,
5 9:106-121 (1988)). The interaction between autoantibodies and the TSHR is, therefore, of interest from the theoretical, diagnostic and therapeutic points of view.
Because of the importance of the TSHR as an autoantigen, a large effort has been made in the seven years since the molecular cloning of its cDNA
10 (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989); Libert, et al, Biochem. Biophys. Res. Comm., 165:1250-1255 (1989); Misrahi, et al, Biochem. Biophys. Res. Comm., 166:394-403 (1990)) to generate this protein in various expression systems, including bacteria (Takai, et al, Biochem. Biophys. Res. Comm., 179:319-326 (1991); Loosfelt, et al, Proc. Natl Acad. Sci. USA, 895:3765-3769 (1992); Harfst, et
15 al, /. Mol. Endocrinol, 9:227-236 (1992); Huang, et al, /. Mol. Endocrinol, 8:137-144 (1992); Costagliola, et al, /. Mol. Endocrinol, 13:11-21 (1994); Graves, et al, Endocrinology, 136:521-527 (1995)), insect cells (Huang, et al, /. Mol Endocrinol, 10:127-142 (1993); Seetharamaiah, et al, Autoimmunity, 14:315-320 (1993); Vlase, et al, /. Clin. Endocrinol Metab., 80:46-53 (1995); Chazenbalk, et al, /. Biol Chem.,
20 270:1543-1549 (1995); Seetharamaiah, et al, /. Immunol, 158:2798-2804 (1997)),
stably-transfected mammalian cells (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989); Perret, et al, Biochem. Biophys. Res. Comm.,
171:1044-1050 (1990); Harfst, et al, Molec. Cell. Endocrinol, 83:117-123 (1992); Endo, et al, Biochem. Biophys. Res. Comm., 186:1391-1396 (1992); Matsuba, et al, /. Biochem., 118:265-270 (1995); Murakami, et al, Eur. J. Endocrinol, 133:80-86 (1995)) and cell-free translation (Morgenthaler, et al, /. Clin. Endocrinol. Metab., 81:700-706 (1996)), as well as by peptide synthesis (Morris, et al, Autoimmunity, 17:287-299 (1994); Nagy, et al, Biochem. Biophys. Res. Comm., 188:28-33 (1992)). However, the generation of effective TSHR antigen has been extraordinarily difficult. Thus,
despite this major effort and although some of these approaches have appeared promising, it is remarkable that a direct assay for TSHR autoantibodies using recombinant TSHR antigen has not supplanted the indirect, TSH binding- inhibition assay with porcine thyroid extracts (Shewring, et al, Clin. Endocrinol, 17:409-417 (1982)) in use for nearly two decades. Moreover, lack of effective antigen has hampered mechanistic and structural studies of autoantibody-TSHR autoantigen interactions.
An important factor contributing to this difficulty is that TSHR autoantibodies, like TSH, predominantly recognize discontinuous, highly conformational epitopes (Nagayama, et al, Proc. Natl. Acad. Sci. USA, 88:902-905 (1991); Nagayama, et al, /. Clin. Invest., 88:336-340 (1990); Tahara, et al, Biochem. Biophys. Res. Comm., 179:70-77 (1991)). TSHR expressed on the surface of mammalian cells are conformationally intact and are unquestionably recognized by autoantibodies in patients' sera (Wadsworth, et al, Science, 249:1423-1425 (1990); Ludgate, et al, Molec. Cell Endocrinol, 73:R13-R18 (1990); Filetti, et al, /.
Clin. Endocrinol. Metab., 72:1096-1101 (1991)). Moreover, large numbers of TSHR- expressing mammalian cells can be produced in fermentors (Matsuba, et al, /. Biochem., 118:265-270 (1995)) and TSHR overexpression in Chinese hamster ovary (CHO cells) has been achieved by transgenome amplification (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)). However, the seven membrane-spanning segments of the TSHR do not facilitate purification. Contrary to expectations, when the 418 amino acid residue, autoantibody-binding TSHR ectodomain is expressed in CHO cells without its serpentine region, it is not secreted but is
retained within the cell (Rapoport, et al, /. Clin. Endocrinol Metab., 81:2525-2533 (1996); Harfst, et al, Lancet, 339:193-194 (1992)) largely in a form containing high
mannose carbohydrate (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)). Moreover, this TSHR ectodomain with immature carbohydrate is not
recognized by autoantibodies in patients' sera (Rapoport, et al, /. Clin. Endocrinol.
Metab., 81:2525-2533 (1996)). There exists a need, therefore, for antigenically active TSHR.
At present, autoantibodies to TSHR in the sera of patients with Graves'
disease are detected most effectively by an indirect approach, namely their ability to inhibit radiolabeled TSH binding (Shewring, et al, Clin. Endocrinol, 17:409-417
(1982)). Over many years, studies to directly determine TSHR autoantibody binding to its antigen have been fraught with difficulty. For example, immunoblotting or immunoprecipitation of thyroid tissue or cell extracts with patients' sera (Heyma, et al, /. Clin. Invest., 74:1090-1097 (1984); Rapoport, et al, Endocrinology, 115:2137-2144 (1984)) have not revealed antigen consistent with the presently known structure of the TSHR. Indirect immunofluorescence with
thyroid cells in monolayer culture has only been observed with two highly selected sera (De Forteza, et al, /. Clin. Endocrinol. & Metab., 78:1271-1273 (1994)).
Even with recombinant TSHR preparations, it has been difficult to demonstrate a direct interaction between serum autoantibodies and the TSHR. Thus, prior purification of either antigen (Huang, et al, FEBS Letters, 264:193-197 (1990);
Graves, et al, Endocrinology, 136:521-527 (1995); Vlase, et al, /. Clin. Endocrinol Metab., 80:46-53 (1995) ) or antibody (Tonacchera, et al, Eur. J. Endocrinol, 134:97-103 (1996)), or the use of cell-free translates (Morgenthaler, et al, /. Clin. Endocrinol Metab., 81:700-706 (1996)), has been necessary. This difficulty with autoantibodies contrasts with excellent TSHR recognition by antibodies from immunized animals, in particular monoclonal antibodies (Loosfelt, et al, Proc. Natl Acad. Sci. USA, 895:3765-3769 (1992); Johnstone, et al, Molec. Cell Endocrinol, 105.-R1-R9 (1994); Seetharamaiah, et al, Endocrinology, 136:2817-2824 (1995); Nicholson, et al, /. Mol Endocrinol, 16:159-170 (1996) ).
A number of factors may contribute to the difficulty in detecting TSHR autoantibody binding by direct means, including: i) low TSHR concentration, ii) requirement for conformational integrity of the antigen, iii) the high background observed with polyclonal antibodies in human sera and, iv) low autoantibody titer. Autoantibodies to thyroid peroxidase may be present at very high concentrations (Beever, et al, Clin. Chem., 35:1949-1954 (1989)). An early study suggested that TSHR autoantibodies are present at very high concentrations in
serum (2-3% of total IgG). More recently, consistent with the small number of TSHR autoantibody-specific B cells in Graves' patients (Rees Smith, et al, Endocr. Rev., 9:106-121 (1988)), immunofluorescence data suggest that TSHR autoantibody
concentrations may be low (De Forteza, et al, /. Clin. Endocrinol. & Metab.,
78:1271-1273 (1994); McLachlan, et al, /. Int. Med., 234:347-359 (1993)). The use of
different assays to detect TPO and TSHR autoantibodies has precluded a direct
comparison of their concentrations in the same serum. There exists a need, therefore, to directly detect autoantibodies in the sera of patients with Graves' disease.
A two subunit form of TSHR has been recognized for many years. Thus, covalent crosslinking of radiolabeled TSH to thyrocyte membranes revealed a ligand-binding glycoprotein A subunit linked by disulfide bonds to a membrane- spanning B subunit (Buckland, et al, FEBS Letters, 145:245-249 (1982)). Because the TSHR is encoded by a single mRNA species (Parmentier, et al, Science, 246:1620-1622 (1989); Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989); Libert, et al, Biochem. Biophys. Res. Comm., 165:1250-1255 (1989); Misrahi, et al, Biochem. Biophys. Res. Comm., 166:394-403 (1990)), the A and B subunits must be formed by intramolecular cleavage. In addition to the two subunit form of the receptor, an uncleaved single chain TSHR is also present on the surface of cultured thyroid cells (Furmaniak, et al, FEBS Letters, 215:316-322 (1987)) and transfected mammalian cells (Russo, et al, Mol. Endocrinol, 5:1607-1612 (1991)). The functional importance of TSHR cleavage is presently an enigma.
Light trypsinization of cells expressing the TSHR leads to the loss of an epitope at amino acid residues 354-359 concomitant with receptor activation (Van Sande, et al, Mol. & Cellular Endo., 119:161-168 (1996)). On the other hand, TSH can activate chimeric TSH-LH/CG receptors that do not cleave into two subunits (Chazenbalk, et al, Biochem. Biophys. Res. Comm., 225:479-484 (1996)).
Identification of the cleavage site in the TSHR ectodomain would be important for elucidating the structure-function relationship of the TSHR subunits.
Deductions from studies of TSH crosslinking to TSHR mutants and chimeric TSH-LH/CG receptors (Russo, et al, Endocrinology, 130:2135-2138 (1992)) suggested a cleavage site closely upstream to amino acid residue 317 in the 418 residue ectodomain (numbering includes a putative 21 residue signal peptide).
Other data obtained using a rabbit antiserum to the TSHR favored a cleavage site further downstream, in the vicinity of residue 366 (Ban, et al, Endocrinology, 131:815-829 (1992)). Mutagenesis of the three striking arginine- and lysine-rich clusters closely upstream to amino acid residue 317 did not prevent TSHR cleavage into two subunits, suggesting the absence of a role for classical
subtilisin-related proprotein convertases (Chazenbalk, et al, /. Biol. Chem.,
269:32209-32213 (1994)). More recently, matrix metalloproteinases have been implicated in TSHR cleavage (Couet, et al, /. Biol. Chem., 271:4545-4552 (1996)).
There exists a need, therefore, for determining and understanding TSHR cleavage.
TSHR and lutropin/chorionic gonadotropin receptor (LH/CGR) are closely related members of the G protein-coupled receptor family with glycoprotein hormone ligands. Both the TSHR and LH/CGR have large, heavily glycosylated ectodomains with leucine-rich repeats and are encoded by numerous exons (Gross, et al, Biochem. Biophys. Res. Comm., 177:679 (1991); Tsai-Morris, et al, /. Biol Chem., 266:11355 (1991); Koo, et al, Endocrinology, 128:2297 (1991)). Despite their common evolutionary background, these receptors have several remarkable
differences aside from the specificity of their ligands. For example, disease- causing autoantibodies to the TSHR are common, whereas autoantibodies to the
LH/CGR are extremely rare. Thus, engagement of the TSHR by autoantibodies is the direct cause of thyrotoxicosis in Graves' disease. Another striking difference exists at the structural level. As detected by TSH crosslinking to the surface of intact cells, the functional TSHR exists in two forms; a single chain receptor and a receptor with two subunits (Furmaniak, et al, FEBS Letters, 215:316 (1987); Russo, et al, Mol Endocrinol, 5:1607 (1991)). In contrast, the LH/CGR exists only in a single chain form (Segaloff, et al, Endocr. Rev., 14:324 (1993)). Variable proportions of single chain and two-subunit forms of the TSHR are also observed on immunoprecipitation or immunoblotting of mammalian cell extracts (Loosfelt, et al, Proc. Natl. Acad. Sci. USA, 895:3765 (1992); Hata, et al, Biochem.
Biophys. Res. Comm., 164:1268 (1989); Potter, et al, Biochem. Biophys. Res. Comm., 205:361 (1994); Chazenbalk, et al, Endocrinology, 137:4586 (1996); Graves, et al, Endocrinology, 137:3915 (1996)). The two subunit TSHR involves a ligand binding, glycosylated A subunit and a membrane-associated B subunit linked by disulfide bonds (Buckland, et al, FEBS Letters, 145:245 (1982)). Because the TSHR
is encoded by a single mRNA species (Parmentier, et al, Science, 246:1620 (1989); Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184 (1989); Libert, et al, Biochem. Biophys. Res. Comm., 165:1250 (1989); Misrahi, et al, Biochem. Biophys. Res. Comm., 166:394 (1990)), the A and B subunits must be formed by intramolecular cleavage, a process believed to involve a matrix mellatoprotease (Couet, et al, /. Biol Chem., 271:4545 (1996)).
Accordingly, there exists a need for methods and compositions for the therapeutic treatment and detection of autoimmune diseases in patients suffering therefrom which would overcome or obviate the limitations of available approaches.
Brief Description of the Drawings Figure 1: Panel A: Specific 125I-TSH binding to CHO cell monolayers expressing the human TSHR on their surface. In order to obtain similar numbers of TSHR per well, 4 kb TSHR cells and TSHR-0 cells were cultured in 24 well and
96 well cluster dishes, respectively. Cells were incubated with the indicated concentrations of 125I-bTSH (250 ml and 50 ml per well in the 24' well and 96 well plates, respectively). Specific binding was determined by subtraction of tracer bound to untransfected CHO cells in parallel wells. Panel B: TBI assay using 4 kb TSHR and TSHR-0 cells cultured in 24 well and 96 well plates, respectively. The assay was performed with the same Graves' patient serum at a saturating concentration of 125I-bTSH (106 cpm/ml), as described in Example 1. Data shown in both panels are the mean of closely agreeing values from duplicate dishes of cells.
Figure 2: Comparison of radiolabeled human and bovine TSH in a TBI assay. Data are shown for 12 sera assayed using TSHR-0 cells (-150,000 TSHR per cell) cultured in a 96 well microtiter plate. TBI assay was as described in Example 1. Fifty ml of either 125I-bTSH or 125I-hTSH (5 x 104 cpm; 106 cpm/ml) was added to each well. Values shown are the mean of closely agreeing triplicate wells for each tracer. Tracer TSH binding in the presence of normal serum was: ,25I-bTSH, 12,396 cpm (mean of 12,044, 12,323, 12821 cpm); hTSH, 2442 cpm (mean of 2509, 2362, 2454 cpm).
Figure 3: Scraping and homogenizing TSHR-10,000 cells reduces the yield of TSHR extracted with detergent. Cells were scraped from 50 confluent 10 cm
dishes (5 x 10s cells) and pelleted. After extraction with buffer containing 1% Triton X-100 (Example 1), aliquots (50 ml) derived from the indicated number of
cells were substituted for the same volume of porcine TSHR normally used in the kit. In a separate protocol, cells were "directly" extracted with buffer containing 1% Triton X-100 without removing the cells from the culture dishes (Example 1).
Three ml of detergent-containing buffer were added to a 10 cm diameter culture dish (107 cells). During dilution of the cell extracts, the detergent concentration was kept constant. The final concentration of 0.25% Triton X-100 in the assay was found not to affect 125I-TSH binding. The dashed vertical lines indicate the number of CHO cells needed to attain TSH binding equivalent to 50 ml of solubilized porcine TSHR, defined as 100% (horizontal, dashed line).
Figure 4: Comparison of solubilized porcine and human TSHR in a TSH binding inhibition assay. TBI activity was determined in 30 sera sent to a clinical laboratory for known or suspected Graves' disease. Sera were tested with a commercial kit using porcine TSHR. In addition, the same sera were assayed with the same reagents with the exception that solubilized human TSHR was substituted for porcine TSHR (Example 1). The cut-off point for positivity, as defined in the kit (TBI >15%), is indicated. The arrow indicated two sera that have detectable TBI activity with the human TSHR, but not with the porcine TSHR.
Figure 5: Correlation between thyroid stimulating immunoglobulin (TSI) activity and TSH binding inhibitory (TBI) activity determined with solubilized human (panel A) or porcine (panel B) TSHR. TSI activity was determined on 28 of the sera depicted in Fig. 4 using a bioassay involving Chinese hamster ovary
(CHO) cells stably transfected with the human TSHR (Example 1). The hatched area indicates the mean ± 2 S.D. of cAMP levels (130% of basal) determined on sera from normal individuals (n= 20). Figure 6: Panel A: Immunoprecipitation of precursor-labeled TSH receptors in TSHR-10,000 cells. Cell proteins were labeled with 35S-methionine
and 35S-cysteine (one hr pulse; 3 and 16 hr chases) followed by immunoprecipitation using mouse mAb A10 whose epitope is TSHR amino acid
residues 22-35 (Nicholson et al, /. Mol Endocrinol, 16:159-170 (1996))(Example 2). Portions of the immunoprecipitated material were left untreated (Con) or were treated with endoglycosidase H (Endo H) or with N-glycosidase F (Endo F). The products were subjected to polyacrylamide gel electrophoresis (10%) under reducing conditions. Autoradiography was for 16 h. The sizes of the prestained molecular weight markers used in this and subsequent experiments were determined by prior calibration against unstained markers (Example 2). Panel B: Specificity of mAb for the TSHR. Immunoprecipitations were performed after
an overnight chase using both TSHR-10,000 cells and untransfected CHO cells. In addition, precursor-labeled TSHR-10,000 cells were incubated with a mAb to TPO. Immunoprecipitated proteins (not enzymatically deglycosylated) were applied to a 7.5% polyacrylamide gel. Note the non-specificity of the 48 kDa band. Also shown in this figure, immunoprecipitation of the TSR in TSHR-10,000 cells with mAb T3-365 to the B subunit was much less efficient than with mAb A10, possibly because the former recognizes primarily denatured TSHR (Loosfelt et al, Proc. Natl. Acad. Sci. USA, 895:3765-3769 (1992)). The apparent doublet at
48 kDa with mAb T3-365 is a non-reproducible artifact.
Figure 7: Immunoblots of the TSHR overexpressed in TSHR-10,000 cells. Where indicated, crude membrane preparations of these cells, or of untransfected CHO cells ("CHO"), were left untreated (Con) or were treated with N-glycosidase F (Endo F) or with endoglycosidase H (Endo H)(Example 2). The material was then subjected to polyacrylamide gel electrophoresis (10%) under reducing conditions, transferred to PVDF membranes and probed with the indicated mAb.
Panel A: Immunoblots using mAb T3-495 and T3-365, both to the TSHR B subunit (epitope within residues 604-764)(Example 2). Panel B: Specificity of the T3-495 and T3-365 mAb, as determined by their lack of interaction with untransfected cells. Panel C: Confirmation of the size of the deglycosylated A subunit on immunoblotting with mAb AlO (epitope including TSHR amino acid residues 22-35). Similar data were obtained with another mAb to the TSHR A subunit, mAb All (data not shown). Panel D: Specificity of mAb AlO for the TSHR as determined by its lack of recognition of untransfected CHO cells, as well as by the lack of detection of the TSHR by a mAb to a non-relevant antigen (TPO).
Figure 8: Schematic representation of the TSH receptor subunits. The diagram is not drawn to scale and is a modification of our previous version (Chazenbalk et al, /. Biol. Chem., 269:32209-32213 (1994)) based on the new information in the present study. The amino terminal two-thirds of the TSHR
ectodomain contains 9 leucine rich repeats, each with an α -helix and β-sheet, and is based on the three-dimensional structure of ribonuclease A inhibitor (Kobe et al, Nature, 366:751-756 (1993)). A more detailed model of this region has been
performed by Kajava et al, Structure, 3:867-877 (1995). The mass of the A subunit polypeptide backbone is 35 kDa, hence the estimated cleavage site #1 at approximately amino acid residue 330 (Nagayama et al, Biochem. Biophys. Res.
Comm., 165:1184-1190 (1989)). The primary non-glycosylated B subunit is -42 kDa, thereby placing the second cleavage site at about residue 380. Cleavage at these two sites would release a putative C peptide of -50 amino acid residues.
The thick line between residues 317-366 represents a 50 amino acid "insertion" that is unique to the TSHR relative to the other glycoprotein hormone receptors
5 (Nagayama et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989); Wadsworth et al, Science, 249:1423-1425 (1990)). Only 6 of the 8 cysteines in the A subunit are
shown. The cysteines shown to be involved in disulfide bonding are hypothetical, but convey the fact that they maintain A and B subunit linkage after
TSHR cleavage. TSHRmyc contains a c-myc epitope substituted for residues 338-
10 349. Detection by a mAb to this epitope of only the single subunit forms of the TSHR would indicate loss of this epitope consequent to cleavage into two subunits. In this case, cleavage could be upstream of, or within, the c-myc epitope.
Figure 9: Immunoprecipitation of c-myc epitope-tagged TSHR (TSHRmyc)
15 stably expressed in HEK cells. Panel A: Cell proteins were labeled with 35S- methionine and 35S-cysteine (one hr pulse; overnight chase) followed by
immunoprecipitation with either mAb AlO (A subunit) or mAb 9E10 (c-myc epitope). Precipitated samples were left untreated (Con) or were treated with endoglycosidase H (Endo H) or N-glycosidase F (Endo F)(Example 2). The
20 products were subjected to polyacrylamide gel electrophoresis (10%) under
reducing conditions. As a control to emphasize the position of the glycosylated A subunit, immunoprecipitation by mAb AlO of TSHR-10,000 cells
(approximately 1/20 the amount of the TSHRmyc material) is shown in the extreme right hand lane. Note that the glycosylated A subunit is a diffuse band overlapping with a sharper, non-glycosylated band at ~ 62 kDa. Autoradiography of the dried gel was for 17 days. Panel B: An experiment similar to that in Panel A demonstrating a number of additional or subtle features. First, and most important, the deglycosylated A subunit in TSHR-10,000
5 cells is included in the same gel to indicate identity in size with the deglycosylated A subunit in the TSHR myc cells. Second, proportionality of the
different receptor forms varies from experiment to experiment. Also note that in TSHR-10,000 cells, the relative proportion of cleaved to uncleaved receptor, as
well as of the different forms of single chain receptor, varies in the two
10 experiments shown, a feature noted by us in earlier TSH cross-linking experiments (Russo et al, Mol. Endocrinol, 5:1607-1612 (1991)). Autoradiography
was for 17 days. Panel C: Specificity of the deglycosylated, 35 kDa A subunit band recognized by mAb AlO, as determined by immunoprecipitation of untransfected HEK cells, as well as of TSHRmyc cells with a non-relevant mAb
15 to TPO. Note the non-specificity of the 48 kDa band. The diffuse glycosylated A subunit is superimposed on sharper, TSHR components that are not
glycosylated (see Panel A) and may represent precursor or degradation products of the TSHR within the cell. For data on the specificity of mAb 9E10 of the c-myc epitope in the TSHRmyc cells, see Tanaka et al, Biochem. Biophys. Res. Comm.,
20 228:21-28 (1996).
Figure 10: Comparison of 125I-TSH cross-linking to TSHR on the surface of intact TSHRmyc and TSHR-0 cells. Both cell types express similar number of
TSHR ( - 105 and - 1.5 x 105 per cell, respectively). Radiolabeled TSH crosslinking, PAGE (10%) under reducing conditions and autoradiography (18 hr) were as described in Example 2. Note that the ligand, 12SI-TSH, itself contains two subunits linked by disulfide bonds. Under reducing conditions, only one of these subunits (~ 14 kDa) remains covalently linked to the TSHR. Therefore, the size of the TSHR can be deduced by subtracting this mass from the complex. Figure 11: Additional evidence for the existence of two cleavage sites in the TSHR. The ectodomain of the TSHR is shown divided into 5 arbitrary domains (A through E) that were used in creating chimeric TSH-LH/CG receptor molecules (Nagayama et al, Proc. Natl Acad. Sci. USA, 88:902-905 (1991)). Three chimeric receptors that are relevant to the present study are indicated, as well as a TSHR mutant in which amino acid residues 317-366 are deleted (Wads worth et al, Science, 249:1423-1425 (1990)). These 50 amino acids are not present in the LH/CG receptor. Therefore, when domain D of the TSHR is replaced with the
corresponding segment of the LH/CG receptor, residues 317-360 are missing. The site of the c-myc epitope in TSHRmyc is shown relative to the other segments.
Figure 12: Immunoprecipitation of TSHR protein in whole CHO cells. Cell
proteins were precursor-labeled with 35S-methionine and 35S-cysteine (one hour pulse and 8 hour chase in the experiment shown) followed by
immunoprecipitation under native conditions using mouse monoclonal antibodies to the TSHR (A9 + AlO; Dr. Paul Banga, London, U.K.). The following clonal
CHO cell lines were used:- CHO - untransfected cells; TSHR-WT - cell transfected with the 4 kb TSHR cDNA containing both 5'- and 3'-untranslated regions
(Nagayama et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)); TSHR-O - cells transfected with the 2.3 kb TSHR cDNA with deleted untranslated regions (Kakinuma et al, Endocrinology, (In Press) (1995)); TSHR-800 and TSHR-10,000 - cells transfected with the 2.3 kb TSHR cDNA and subsequently adapted to growth in 800 nM or 10,000 nM methotrexate, respectively. Immunoprecipitated proteins were subjected to polyacrylamide gel electrophoresis (7.5%) under reducing conditions. Autoradiography was for 10 days. Essentially identical data were obtained in a second experiment. The arrow indicates the 100 kDa TSHR holoreceptor form previously observed by Misrahi et al, Eur. /. Biochem., 222:711- 719 (1994)) that was quantitated by densitometry.
Figure 13: Crosslinking of ,25I-TSH to TSHR on the surface of intact cells. The cells used are described in the legend to Fig. 12. Radiolabeled TSH crosslinking, PAGE (7.5%) under reducing conditions and autoradiography (20
hr) were as described in Example 3. Equal amounts of cell membrane protein were applied to each lane. Much longer periods of autoradiography (at least 10 days) were required for visualization of the TSHR in the TSHR-WT cells stably transfected with the 4 kb TSHR cDNA (Nagayama et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)). Similar results were obtained in a second experiment.
Figure 14: Cyclic cAMP levels in stably-transfected CHO cell lines expressing different numbers of TSHR. Cells were incubated in hypotonic medium (Fig. 14A) or in isotonic medium (Fig. 14B), as described in Example 3.
These media were either deficient in, or were supplemented with, 1 mU/ml TSH (109 M). This concentration is supramaximal in cells exposed to hypotonic
medium (Kasagi et al, /. Clin. Endocrinol. Metab., 54:108-114 (1982); Rapoport et al, Metabolism, 31:1159-1167 (1982)) and slightly below the EC50 in cells incubated in isotonic medium (Rapoport et al, Endocrinology, 98:1189-1197 (1976);
Wadsworth et al, Science, 249:1423-1425 (1990)). The data shown are the mean +
S.E. of values obtained in 3-4 experiments.
Figure 15: Binding of ,25I-TSH to CHO cells expressing the TSHR in the presence of increasing concentrations of unlabeled TSH. The stably-transfected
cells lines are described in the legend to Fig. 12. Intact cells in monolayer were incubated in medium containing TSH, as described in Example 3. The brackets indicate the mean + S.E. of values obtained in triplicate dishes of cells. In order
to attain partial receptor saturation with ligand, the TSHR-800 and TSHR-10,000
cells were diluted 1:50 with untransfected CHO cells. Because the maximum binding differed for each cell line, the values are expressed as a % of maximum TSH binding in the abence of unlabeled TSH. Similar results were observed when the TSHR-800 and TSHR-10,000 were diluted 1:200 in CHO cells, except that the maximum binding was lower. Figure 16: TSH binding to cells expressing the TSHR by 125I-TSH in the absence of unlabeled TSH. Cells in 96-well plates were incubated in ,25I-TSH concentrations up to 1.25 x 106 cpm/well (2.5 x 107 cpm/well), as described in Example 3. The data shown are the means + S.E. of values obtained in triplicate dishes of cells. The data are representative of three separate experiments. Figure 17: Schematic representation of three TSHR ectodomain variants truncated at their carboxyl-termini. The serpentine transmembrane and cytoplasmic portions of the holoreceptor (764 amino acid residues including
signal peptide) are not shown. Six histidine residues (6H) followed by a stop codon are inserted after the indicated TSHR residues. Insertion of a stop codon at residue 418 has previously been shown to generate an ectodomain containing predominantly high mannose carbohydrate that is largely retained within the cell and is not recognized by TSHR autoantibodies in Graves' patients sera (Rapoport et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)). As shown in the present study, progressive carboxyl-terminal truncations of the TSHR ectodomain lead to a high level of secretion of material with mature, complex carbohydrate that
can completely neutralize TSHR autoantibody activity.
Figure 18: Relative secretion into the culture medium of TSHR ectodomain variants. CHO cells stably expressing TSHR ectodomain variants truncated at amino acid residues 261, 289 and 309 were precursor labeled for 1 hr followed by a chase of 16 hr (Example 4). TSHR in medium (M) and cells (C) was then
immunoprecipitated with a murine mAb (AlO) to amino acid residues 22-35 (Nicholson et al, /. Mol. Endocrinol, 16:159-170 (1996)). TSHR in medium was also recovered using Ni-NTA resin that binds to the 6 histidine residues inserted at the C-termini of the ectodomain variants. Ni-NTA is not an effective method for identifying precursor-labeled TSHR in cells because of its interaction with a large number of CHO cell proteins. Autoradiography in the experiment shown was for 12 hr.
Figure 19: Recognition of TSHR ectodomain variants by TSHR autoantibodies in Graves' disease serum. The assay involves the ability of
autoantibodies to compete for 125I-TSH binding to TSHR in solubilized porcine thyroid membranes (Shewring et al, Clin. Endocrinol, 17:409-417 (1982))(Example
4). Left panel: In the absence of conditioned medium from CHO cells, serum from a Graves' patient, unlike serum from a normal individual, reduces 125I-TSH binding by ~ 60%. Right panel: Conditioned medium from a non-relevant cell culture secreting thyroid peroxidase (TPO) has no effect on TSH binding inhibitory (TBI) activity. In contrast, conditioned medium from TSHR-261 and TSHR-289 cell cultures (unlike TSHR-309) nearly completely reverses the TBI activity. Bars indicate the mean + range of duplicate determinations. See Fig. 25 for data on 18 Graves' sera using TSHR-261 after partial purification from conditioned medium.
Figure 20: Lectin specificity for TSHR-261 ectodomain variant. Conditioned medium from CHO cell cultures expressing TSHR-261 was adsorbed with Sepharose linked to the indicated lectins (Example 4). Both unadsorbed
("Flow-through") and material recovered from the beads ("Eluate") was spotted (neat or after dilution) on nitrocellulose filters and probed with mAb AlO to the amino terminus of the TSHR.
Figure 21: Immunoblots of TSHR-261 enriched from conditioned medium using lectins. Material obtained from equivalent volumes of the same medium using Bandeiraea simplificifolia, Concanavalin A or Wheat germ agglutinin was either left untreated (-) or was subjected to endoglycosidase H (Endo H) or endoglycosidase F (Endo F) digestion (Example 4). The samples were electrophoresed on a 10% polyacrylamide gel. Proteins were transferred to PVDF membrane and probed with murine mAb AlO (Example 4).
Figure 22: Immunoblot of TSHR ectodomain variants. TSHR-261, TSHR- 289 and TSHR-309 were affinity-enriched from conditioned medium using
Concanavalin A (Example 4). Material was either left untreated (-) or was subjected to endoglycosidase H (Endo H) or endoglycosidase F (Endo F) digestion (Example 4). The samples were electrophoresed on a 10% polyacrylamide gel. Proteins were transferred to PVDF membrane and probed with murine mAb AlO to amino acid residues 22-35 (Nicholson, et al, /. Mol
Endocrinol, 16:159-170 (1996)) using the ECL system (Example 4). Figure 23: Direct visualization and quantitation of TSHR-261. Left panel:
Polyacrylamide gel electrophoresis and Coomassie blue staining of material recovered after capture from the conditioned medium with Concanavalin A (first lane) and after the subsequent Ni-chelate chromatography step (second lane).
Right panel: Estimation of the TSHR-261 concentration by polyacrylamide gel electrophoresis of enzymatically deglycosylated, Coomassie blue-stained material. Deglycosylation yields a sharper, more intense band than the glycosylated protein. The recombinant endoglycosidase F present in the reaction provides an internal standard of 0.7 mg protein. The TSHR-261 polypeptide represents 60% of the mass of the glycosylated protein (see also Figs. 5 and 6). Figure 24: Titration of TSHR autoantibody neutralization by TSHR-261.
Serum from a Graves' patient with moderate TSH binding inhibitory (TBI) activity was assayed using the commercial autoantibody kit (Example 4) in the presence of increasing concentrations of partially purified TSHR-261. Serum from a normal individual does not inhibit 125I-TSH binding to solubilized porcine thyroid TSHR (hatched bar). In the absence of TSHR-261, TSH binding is
reduced to ~ 40% of maximum. Incubation volume in the assay is 0.2 ml. Bars indicate the mean ± range of duplicate determinations.
Figure 25: Neutralization of TSHR autoantibodies by TSHR-261 partially purified from conditioned medium. TSH binding inhibition (TBI) activity of autoantibodies in the sera of 18 Graves' patients was measured using a commercial kit (Example 4). These sera, unlike two sera from normal individuals, compete for 125I-TSH binding to solubilized membranes from porcine thyroids (hatched bars). Inclusion of TSHR-261 (50 ng per tube) neutralizes all or most of the autoantibody activity in the 18 sera. Bars indicate the mean + range of duplicate determinations.
Figure 26: Flow cytometric analysis of IgG-class TSHR autoantibody binding to CHO cells expressing different numbers of TSHR on their surface. TSHR-WT cells are stably transfected with the 4 kb TSH cDNA (Nagayama et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)). TSHR-0 cells contain the 2.3 kb translated region of the TSHR cDNA (Kakinuma, et al, Endocrinology, 137:2664- 2669 (1996)). In the TSHR-800 and TSHR-10,000 cells, the transgenome has been amplified and TSHR expression has been increased to ~ 106 and ~ 1.9 x 106 per cell, respectively, as shown in Example 3. Cells were incubated with serum (1:10) from a normal individual (open histogram) and from a patient with Graves' disease (BB1) containing high levels of TSHR autoantibodies as measured by the
TSH binding inhibition assay (shaded histogram). Fluorescence was developed as described in Example 5.
Figure 27: How cytometric analysis of TSHR-10,000 cells using mouse monoclonal and rabbit polyclonal antisera to the TSHR. TSHR-10,000 cells were
incubated with mouse monoclonal antibodies A9 (l:100)(panel A) and AlO (l:100)(panel B), as well as with rabbit serum R8 (l:60)(panel C)(shaded
histograms). Controls sera (open histograms) were a mouse monoclonal antibody to thyroid peroxidase and normal rabbit serum, all at the same the dilutions used for the specific sera. Fluorescence was developed as described in Example 5.
Figure 28: Effect of adsorption of sera with untransfected CHO cells on the specificity of the autoantibody fluorescence signal on flow cytometry with TSHR-expressing cells. Representative examples are shown of sera from two individuals, 7H and BB1 (shaded histograms), each with very high TBI values
(81.7% and 100% inhibition, respectively). Sera (1:10 dilution) were either not preadsorbed (upper panels) or preadsorbed on untransfected CHO cells (lower panels) prior to incubation with TSHR-10,000 cells (Example 5). Included as a negative control is serum from a normal individual without TSHR autoantibodies detectable by the TBI assay (open histogram).
Figure 29: Adsorption of TSHR autoantibodies using cells expressing the recombinant TSHR on their surface. Sera BB1, 10H, 3H and 10M that generated a fluorescent signal on FACS analysis with TSHR-10,000 cells (Table 1) were preadsorbed (0.5 hours at room temperature, three times) on TSHR-10,000 cells prior to analysis using the same cells (open histograms). Fluorescence generated
by the same sera after preadsorption on untransfected CHO cells is shown by the shaded histograms. To optimize adsorption of TSHR autoantibodies, sera were diluted according to their respective titers in the TSH binding inhibition (TBI) assay (Table 2).
Figure 30: Relative titers of TPO and TSHR autoantibodies in the BB1 serum, as determined by flow cytometry on CHO cells expressing either the
TSHR or TPO on their surface. Both TSHR-10,000 cells (as described in Example 3) and CHO-TPO cells, previously described as C4C cells (Kaufman et al, Molec. Cell Endorcinol, 78:107-114 (1991)), contain genes amplified using the dihydrofolate reductase gene with cells resistant to 10,000 nM methotrexate.
These two cell lines express similar numbers (~ 2 x 106) of TSHR or TPO molecules on their surface. Serum BB1 (shaded histograms) and serum from a normal individual without TSHR or TPO autoantibodies detectable by clinical assay (open histograms) were tested at dilutions between 1:10 and 1:1000.
Figure 31: The ectodomain of the TSHR is shown divided into 5 arbitrary domains (A through E) that were used in creating chimeric TSH-LH/CG receptor
molecules (Nagayama et al, Proc. Natl. Acad. Sci. USA, 88:902 (1991)). Three chimeric receptors that are relevant to the present study are indicated. Note that amino acid residues 317-366 are not present in the LH/CG receptor. Therefore, when domain D of the TSHR is replaced with the corresponding segment of the LH/CG receptor, residues 317-360 are missing.
Figure 32: .A Amino acid substitutions introduced in the region of putative cleavage site 1 in the TSHR. Mutations were made in the D domain of chimeric receptor TSH-LHR-5 (Fig. 31). The dashed line for the LH/CG receptor indicates that this region is unique to the TSHR and is absent in the LH/CG receptor. B^Radiolabeled TSH crosslinking to CHO cells stably expressing the receptors described in A. Cross-linked products were subjected to PAGE (7.5%) under reducing conditions followed by autoradiography. Note that the ligand,
, 5I-TSH, binds to the uncleaved TSH holoreceptor or to the ligand-binding A subunit in the cleaved TSHR, indicating the presence of both cleaved and
uncleaved TSHR on the cell surface. The mass of the hormone ligand complex includes one subunit of the ligand, which itself contains two subunits linked by disulfide bonds. Under reducing conditions, only one ligand subunit (~ 14 kDa) remains covalently linked to the TSHR.
Figure 33: A. Amino acid substitutions introduced in the region of putative cleavage site 2 in the TSHR. Mutations were made in the E domain of chimeric receptor TSH-LHR-4 (Fig. 31). The mutations shown in bold prevent cleavage, as determined by TSH cross-linking. In the El, E2 and E3 mutations,
"-" represents no substitution because the amino acid residues are the same in both receptors. In E3, "." represents the absence of an amino acid which is not
present in the LH/CG receptor. R Radiolabeled TSH crosslinking to intact CHO cells stably expressing the receptors described in A. Cross-linked products were reduced in order to dissociate the subunits in cleaved receptors. The upper two panels depict autoradiograms of 7.5% gels, the lower two panels show material electrophoresed in 10% gels.
Figure 34: The presence of the GQE267.269NET mutation does not prevent cleavage of the wild-type TSHR. Cross-linked 125I-TSH-TSHR products were reduced and subjected to PAGE (10%) and autoradiography.
Summary of the Invention
In a broad aspect, the present invention is directed to novel human thyrotropin compositions which are useful in diagnostic and therapeutic methods for the diagnosis and treatment of autoimmune diseases, particularly Graves' disease.
Detailed Description of the Invention
Technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies known to those of skill in the art. Publications and other materials setting forth such known methodologies to which reference is made are incorporated herein by reference in their entireties as though set forth in full. Standard reference works setting forth the general principles of recombinant DNA technology include Sambrook, J., et al, Molecular Cloning: A Laboratory
Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Plainview, New York (1989); Kaufman, P. B., et al, Eds., Handbook of Molecular and Cellular Methods in Biology and Medicine. CRC Press, Boca Raton (1995); McPherson, M. J., Ed., Directed Mutagenesis: A Practical Approach. IRL Press, Oxford (1991); Jones, J., Amino Acid and Peptide Synthesis. Oxford Science Publications, Oxford (1992);
Austen, B. M. and Westwood, O. M. R., Protein Targeting and Secretion, IRL Press, Oxford (1991). Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention; however, preferred materials and/or methods are described. Materials, reagents and the like to
which reference is made in the following description and examples are obtainable
from commercial sources, unless otherwise noted.
According to an aspect of the present invention, it has now been found that in an intact cell TBI assay, (i) the use of cells with more TSHR reduces, rather than improves, the sensitivity of the assay and, (ii) the species of
radiolabeled TSH (bovine vs. human) can influence the TBI value obtained. On the other hand, cells expressing very large numbers of receptors are an excellent
source of detergent-solubilized TSHR, but only when the extraction procedure is modified according to the present invention. One result of the present invention is the previously unknown ability to use recombinant human TSHR, rather than porcine TSHR, in practical and cost-efficient TBI assays.
The present invention is directed broadly to methods for the therapeutic treatment of autoimmune disease, and particularly, Graves' disease, involving administration of the therapeutic compositions described herein and such variants thereof as will be appreciated by those of skill. Accordingly, in one aspect, the invention is directed to a method for the treatment of Graves' disease comprising administering to a patient suffering from Graves' disease an effective amount of
a composition comprising one or more of the substantially isolated human thyrotropin compositions of the invention, or a variant thereof, alone or in conjunction with one or more other active ingredients. Such compositions useful according to the methods of the invention are preferably selected for use according to the invention by means of one or more assay methods disclosed herein or known to those of skill. Compositions useful in the methods of the invention are preferably substantially isolated human thyrotropin receptor, which may be recombinantiy produced according to the invention, or variants or mutants thereof, capable of modulating Graves' disease in a patient, and may be selected, as described herein,
by means of appropriate assays. TSH compositions so selected may be administered by methods known to those of skill in order to achieve the desired therapeutic result.
Other variations in the compositions of the invention may be desirable, for example, to increase or decrease the half life of the resulting peptide in the bloodstream or tissue. Thus, it is within the contemplated scope of the present invention to produce variants of compositions useful according to the methods of the invention, by introducing therein alterations, such as are known in the art, which may include the use of synthetic or non-traditional arriino acid residues, side chains, non-amide bonds as in peptides, and the like, which may act as blocking groups to protect the peptide against degradation. These and other methods of modifying compositions are well known in the art.
Compositions useful according to the invention may be isolated from natural sources and purified. However, it is preferred to synthesize the
compositions by means well known in the art. Preferred is solid phase synthesis, although any suitable method of synthesis may be employed.
Advances in the diagnosis and potential immunotherapy of Graves' disease are dependent on the availability of relatively large amounts of immunoreactive, recombinant antigen. Many studies have explored the interaction of Graves' sera with TSHR material generated in bacteria, insect cells, cell-free translates or as synthetic peptides. Most of these studies involved detection of recombinant material by immunoblotting, immunoprecipitation or
ELISA, procedures that do not evaluate the ability of this material to interact with functional autoantibodies. Trace amounts of "functional" TSHR ectodomain material are present in insect cells infected with recombinant baculovirus containing the TSHR cDNA (Chazenbalk, et al, /. Biol Chem., 270:1543-1549 (1995)), as well as in stably transfected CHO cells (Rapoport, et al, /. Clin. Endocrinol Metab., 81:2525-2533 (1996); Harfst, et al, Lancet, 339:193-194 (1992)).
Very recently, there has been confirmation that the TSHR ectodomain generated in a baculovirus system can neutralize TSH binding inhibition (TBI) activity in Graves' patients' sera (Seetharamaiah, et al, /. Immunol, 158:2798-2804 (1997)).
However, this material was largely insoluble, the active component was not identified or quantitated and the nature of the carbohydrate (complex vs. high mannose) was not determined.
In our experience, the recombinant TSHR of mammalian cell origin is the most effective in interacting with autoantibodies. The strongest testimony to this
conclusion is that crude porcine thyroid extracts are still used in the standard clinical TBI assay. TSH holoreceptor overexpression in CHO cells (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)) can generate a crude detergent extract that rivals, or surpasses, the efficacy of porcine thyroid extracts (Example 1). However, this membrane-associated material cannot be used for large scale purification for structural studies and will be difficult to use in a future direct (as opposed to an indirect TBI) assay for TSHR autoantibodies.
We have now overcome the previous inability (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996); Harfst, et al, Lancet, 339:193-194 (1992) to generate in mammalian cells a secreted, soluble, complex carbohydrate-containing
form of the TSHR ectodomain. Unlike the non-secreted, high mannose-containing ectodomain (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)), secreted, C-terminal truncated TSHR ectodomain variants are recognized by autoantibodies. Whether the complex carbohydrate comprises part of the
epitope(s) for TSHR autoantibodies, or whether lack of autoantibody recognition of the "high mannose" ectodomain is secondary to incorrect polypeptide folding
(and, hence, retention in the endoplasmic reticulum)(Robbins, et al, Cell, 12:893 -900 (1977); Kornfeld, et al, Annu. Rev. Biochem., 54:631-646 (1985)) is presently unknown. It is of interest (and paradoxical) that C-terminal truncation of the LH/CG receptor ectodomain at a position (amino acid residue 294) similar to the TSHR variants generates a non-secreted protein (Koo, et al, Endocrinology, 134:126 (1994)). On the other hand, the LH/CG receptor truncated at residue 329 or further downstream is secreted to a limited extent (VuHai-LuuThi, et al, Biochem., 31:8377-8383 (1992); Tsai-Morris, et al, /. Biol. Chem., 265:19385-19388 (1990)). Alternately-spliced truncated forms of TSHR mRNA have been detected in thyroid tissue (Graves, et al, Biochem. Biop hys. Res. Comm., 187:1135-1143 (1992); Takeshita, et al, Biochem. Biophys. Res. Comm., 188:1214-1219 (1992)), however whether these transcripts are actually expressed and, if so, secreted by thyrocytes is unknown.
The lectin specificity of TSHR-261 is consistent, in part, with previous data on the extraction of TSH holoreceptor activity from detergent-solubilized thyroid membranes. In this earlier study, B. simplificifolia was effective for bovine, but not for human, TSHR (Kress, et al, Endocrinology, 118:974-979 (1986)). Unlike the human TSHR ectodomain variants, the bovine TSH holoreceptor was also bound well by Wheat germ agglutinin and was irreversibly bound by Concanavalin A (Kress, et al, Endocrinology, 118:974-979 (1986)). Lectin chromatography by itself
was insufficient for TSHR-261 purification. In the future, single-step affinity purification with a mAb will be a preferable approach. At present, murine IgG
class mAb have been generated by immunization with TSHR of prokaryotic or insect cell origin (Seetharamaiah, et al, Endocrinology, 136:2817-2824 (1995);
Johnstone, et al, Molec. Cell. Endocrinol, 105:R1-R9 (1994); Nicholson, et al, /. Mol Endocrinol, 16:159-170 (1996); Loosfelt, et al, Proc. Natl Acad. Sci. USA, 895:3765-3769 (1992)). Unfortunately, most mAb (including the 6 that we have tried from two different laboratories)(Nicholson, et al, /. Mol. Endocrinol,
16:159-170 (1996); Loosfelt, et al, Proc. Natl. Acad. Sci. USA, 895:3765-3769 (1992)) do not recognize the native, mature mammalian TSHR that is necessary for
immunological studies in Graves' disease. Future immunization with complex
carbohydrate-containing TSHR-261, or with mammalian cells expressing the
TSHR in association with MHC class II molecules (Shimojo, et al, Proc. Natl. Acad.
Sci. USA, 93:11074-11079 (1996)), may overcome this difficulty.
It has now been determined that TSHR-289 shares many of the advantages
of TSHR-261, and may be more stable than TSHR-261, which loses activity over
several hours at room temperature. Thus, TSHR-289 may be preferred according to the present invention although TSHR-261 is somewhat more effectively secreted. Also within the scope of the present invention are other truncations between 261 and 309, which may be utilized by those of skill without undue
experimentation who have read and understood the teachings of the present invention.
Accordingly, in another aspect, the present invention is directed to methods of selecting truncated forms of TSHR, preferably mammalian TSHR, and more preferably human TSHR, useful according to the invention in that they exhibit one or more of the qualities or characteristics described herein for representative truncated forms TSHR-261, TSHR-289 and TSHR-309. Employing the methods and teachings of the present invention, those of skill will be able to select, express and screen suitable candidates based upon the desired degree (or presence or absence) of stability, solubility secretion and other characteristics as will be appreciated when the teachings of the present invention are understood, without undue experimentation. In this regard, it will be appreciated that truncated TSHR variants shorter than TSHR- 261 and longer than TSHR-309 may be evaluated according to the methods of invention, and may be identified and screened for suitability in accordance with the teachings of the invention, and that such suitable variants are within the contemplated teachings and scoped of the invention. Thus, for example, if it is desired to select truncated TSHR variants satisfying the characteristic that only an extracellular portion of the TSHR is produced for use in an assay for TSHR autoantibodies, several different screening approaches may be employed as described herein. One exemplary method to achieve this is by precursor- labeling of TSHR cDNA-transfected mammalian cells withradiolabled amino acids, such as 35S-methionine/cysteine, followed by immunoprecipitation with a monoclonal antibody to the TSHR. In brief, after a one hour pulse and overnight chase with 35S-methionine/cysteine, medium is precleared with mouse IgG and Protein A, prior to the addition of mouse monoclonal antibody to the TSHR. TSHR-antibody complexes are precipitated with Protein A, electrophoresed on polyacrylaminide gels and visualized by autoradiography. An alternative exemplary screening approach according to the invention is to use an agent, such as Nickel-chelate resin, to bind to a 6 histidine tag engineered into the TSHR ectodomain, or fragment thereof. Another screening approach which will be readily understood and appreciated by those of skill is immunoblotting of proteins transferred electrophoretically to a membrane, such as by western blotting.
Another screening approach, particularly useful in identifying truncated TSHR variants longer than TSHR-309 that retain TSH binding, employs flow cytometry to detect these proteins on the surface of transfected cells. An example of such a direct detection procedure for TSH receptors is described in detail herein. In brief, after detachment by mild trypsinization, cells are pelleted and rinsed and incubated in medium containing TSHR antibodies (which may be, for example, mouse monoclonal antibodies or Graves' patient serum) for 60 min at 4°C. The cells are rinsed three times and fluorescent-tagged anti-mouse or antihuman IgC added for 45 minutes at 4°C. After three washes, the cells are analyzed using the Becton Dickinson FACScan-CELLQuest system or other suitable device.
Yet another exemplary screening method according to the invention utilizes neutralization of TSHR autoantibodies in the serum of Graves' patients. As described herein in more detail, the principle of this assay is the ability of autoantibodies to compete for 125I-TSH binding to solubilized TSHR ("TSH binding inhibition," or TBI assay). In brief, solubilized TSHR (50 μl) are preincubated (15 min) with patient's serum (50 μl). Buffer containing 125I-TSH is then added (2 hours at room temperature). Solubilized TSHR complexed with TSH is precipitated by, for example, polyethylene glycol. Antibody activity is measured as % inhibition of 125I-TSH binding relative to a standard serum from a normal individual without autoantibodies. For autoantibody neutralization, the assay may be conveniently
SUBSTITUTE SHEET flttJLE 26) modified by preincubating (30 min at room temperature) serum from Graves' patients (25 μl) with conditioned medium from cells expressing TSHR ectodomain variants (25 μl). Solubilized TSHR (50 μl) is then added to the serum /medium mixture (50 μl). As controls, serum from normal individuals and conditioned medium from CHO cells secreting a truncated form of thyroid peroxidase may be used.
Another screening approach useful in identifying truncated TSHR variants longer than TSHR-309 that retain TSH binding and remain attached to the cell membrane is detection of protein on the surface of a cell by specific 125I-TSH binding or monoclonal antibody binding. As described in herein in more detail, transfected cells (e.g., in monolayer or suspension culture) are incubated (2 hr at 37°C) in "binding buffer" (Hank's buffer with 280 mM sucrose instead of NaCl and supplemented with 0.25% bonvine serum albumin) with 125I-TSH. After rinsing, the cells are solubilized in 1 N NaOH and radioactivity counted in a gamma counter. Non-specific binding to untransfected cells is subtracted to obtain values for specific binding. From these screening results, suitable truncated TSHR variants may be identified.
Autoantibody-reactivity of TSHR-261 is reminiscent of the observation nearly three decades ago that freezing and thawing thyroid tissue releases a water soluble factor (LATS absorbing activity; LAA) that neutralizes TSHR
autoantibodies (Dirmikis, et al, /. Endocrinology, 58:577-590 (1973); Smith, /. Endocrinology, 46:45-54 (1970)). LAA (like TSHR-261) was estimated to be - 50 kDa (Dirmikis, et al, /. Endocrinology, 58:577-590 (1973)). More recently, a fragment of the TSHR released by trypsin has been observed to neutralize TSHR autoantibodies (Foti, et al, /. Clin. Endocrinol. Metab., 73:710-716 (1991)). However, the segment of the TSHR with LAA activity, produced either by freeze-thawing or with trypsin, is unknown.
There are no previous studies on the quantitative neutralization of TSHR autoantibodies in Graves' patients' sera using defined amounts of mammalian
antigen. The very small (ng) amounts TSHR-261 required for autoantibody neutralization is orders of magnitude lower than those used in studies with synthetic peptides (Morris, et al, Autoimmunity, 17:287-299 (1994)). This quantitative information will be useful as a future benchmark by which to judge
the potency of purified TSHR of bacterial and insect cell origin. A corollary of
the minute amount of antigen necessary for TSHR autoantibody neutralization is that the autoantibody concentration in patients' sera is very low, consistent
with previous flow cytometry data (Jaume, et al, /. Clin. Endocrinol. Metab.,
82:500-507 (1997)). The large difference between TSHR and thyroid peroxidase autoantibody concentrations is of potential significance in understanding the
pathogenesis of Graves' disease (McLachlan, et al, /. Int. Med., 234:347-359 (1993)).
In another aspect, the invention is directed to TSH receptor assays for the detection and/ or quantitation of autoantibodies against TSHR in a biological fluid, employing secreted, soluble, complex carbohydrate-containing forms of the TSHR ectodomain as taught herein. Preferably, the secreted, soluble, complex carbohydrate-containing form of the TSHR ectodomain will be truncated at its C- terminal end. Secreted, soluble, complex carbohydrate-containing forms of the TSHR ectodomain useful in TSH receptor assays may preferably be selected by those of skill employing screening methods as taught herein, or variants of such methods, without undue experimentation. Secreted, soluble, complex carbohydrate-containing TSHR ectodomain variants useful in TSH receptor assays according to the invention and which may be selected using the screening methods taught herein include, but are not limited to, truncations between 261 and 309, preferably, truncations between 261 and 289. It will be appreciated that in selecting secreted, soluble, complex carbohydrate-containing TSHR ectodomain variants for use in accordance with the diagnostic and therapeutic aspects of the invention, the skilled person may employ screening methods such as those described herein, mindful of selection criteria including the capability of being secreted, of solubility, and of the presence of complex carbohydrate, that will result in TSHR ectodomain variants and composition containing them which are suitable for the intended use or purpose. Assays according to the invention may include indirect assays or direct assays, with direct assays presently preferred. Methods and reagents for assays according to the invention which employ the secreted, soluble, complex carbohydrate-containing form of the TSHR ectodomain taught herein may be conventional, and will admit of design and selection by skilled person who understands the present disclosure, mindful of well accepted principles of diagnostic and immunodiagnostic methodology and interpretation. Such principles are set forth, for example, in Rose, Noel R., et al., eds., Manual of Clinical Laboratory Immunology. Fifth Edition, ASM Press, Washington D.C. (1997), and prior editions; Rich, R. et al., eds., Clinical Immunology. Mosby, Publisher, St. Louis (1995); Osterlund, C.K., "Laboratory diagnosis and monitoring in chronic systemic autoimmune diseases," Clin. Chem. 40:2146-2153 (1994); and Shearer, W. T., et al., "Core content outline for clinical and laboratory immunology," J. Allergy Clin. Immunol. 94:933-941 (1994). Direct assay formats according to the invention include, but are not limited to, flow cytometric assays and direct TSHR receptor assays, with the latter being presently preferred. A nonlimiting example of a preferred direct TSHR receptor assay according to the invention is described herein, for example, in Example 7, which describes how serum samples from normal and Graves' patients may be assayed directly for autoantibodies against human TSHR using TSHR-289. The TSHR-289 (or other TSHR ectodomain variant selected for use) preferably includes a 6 histidine tail as described hererin (TSHR-289-6His). TSHR-289-6His antigen is preferably produced in tissue culture medium harvested from CHO cells secreting TSHR-289-6His, as described herein. Use of a histidine tail is presently preferred because it allows use of labeled anti-histidine antibody, available from commercial sources, to detect and/ or quantitate the secreted, soluble, complex carbohydrate- containing TSHR ectodomain variant which, in the preferred direct assay format, binds to TSHR autoantibodies in the sample, thereby affording the investigator means of directly detecting and/or quantitating TSHR autoantibodies. It will be appreciated that any suitable epitope capable of being recognized by a specific antibody or other ligand in a manner similar to that of όHis may be used. Non-limiting examples of such epitopes include the Flag, c-myc and bir (Altman, J.D., et al, Science 274:94-96 (1996)) epitopes, available from commercial sources or from known depositories such as the American Type Culture collection. Labeled anti-histidine antibody may be monocloncal or polyclonal, preferably monoclonal, more preferably, mouse monoclonal, and most preferably, anti-histidine mouse monoclonal antibody labeled with Na125I obtained from QIAGEN, Inc., Chatsworth, California. Although Na125I is presently preferred for use as a label in a direct assay according to the invention, those of skill will appreciate that any suitable label may be employed which allows detection and/ or quantitation. There are many different labels and methods of labeling known in the art. Examples of the types of labels which can be used in the present invention include, but are not limited to, enzymes, radioisotopes, fluorescent compounds, chemiluminescent compounds, bioluminescent compounds and metal chelates. Those of ordinary skill in the art will know of other suitable labels, or will be able to ascertain the same be the use of routine experimentation. Furthermore, the binding of these labels to antigens and antibodies can be accomplished using standard techniques commonly known to those of ordinary skill in the art.
One of the ways in which TSHR ectodomain variant antigens and antibodies according to the present invention can be detectably labeled is by linking them to an enzyme. This enzyme, in turn, when later exposed to its substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected as, for example, by spectrophotometric or fluorometric means. Examples of enzymes which can be used to detectably label antibodies include malate dehydrogenase, staphylococcal nuclease, delta- V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, biotin-avidin peroxidase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, betagalactosidase, ribonuclease, urease, catalase, glucose- Vl-phosphate dehydrogenase, glucoamylase and acetylcholine esterase.
The presence of detectably labeled TSHR ectodomain variant antigens and antibodies also can be detected by labeling the TSHR ectodomain variant antigens and antibodies and a radioactive isotope which then can be determined by such means as the use of a gamma counter or scintillation counter. Isotopes in addition to 125I which are particularly useful for the purpose of the present invention are 3H, 32P, 35P, 14C, 5ICr, 36C1, 57Co, 58Co, 59Fe and 75Se. For in vivo, in vitro or in situ diagnosis, labels such as radiolabels may be bound to antigens and antibodies according to the present invention either directly or by using and intermediary functional group. An intermediary group which is often used to bind radioisotopes which exist as metallic cations to anti-bodies is diethylenetriaminepentaacetic acid (DTP A). Typical examples of metallic cations which are bound in this manner are: 99nTc, 123I, IN, 13 '1, 97Ru, 67Cu, 67Ga and 68Ga. The antigens and antibodies of the invention can also be labeled with non-radioactive isotopes for purposes of diagnosis. Elements which are particularly useful in this manner are 157Gd, 55Mn, 162Dy, 52Cr and 56Fe.
It is also possible to detect the binding of detectably labeled TSHR ectodomain variant antigens and antibodies by labeling the antigens and antibodies with a fluorescent compound. When a fluorescently labeled antibody is exposed to light of the proper wave length, its presence then can be detected due to the fluorescence of the dye. Among the most commonly used fluorescent labeling compounds are fluoroscein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
The TSHR ectodomain variant antigens and antibodies of the invention also can be detectably labeled using fluorescent emitting metals such as 152Eu, or others of the anthanide series. These metals can be attached to the antibody molecule using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).
TSHR ectodomain variant antigens and antibodies also can be detectably labeled by coupling them to a chemiluminescent compound. The presence of the chemiluminescent-tagged antigen or antibody is then determined by detecting the presence of luminescence that arises during the course of the chemical reaction.
Examples of particularly useful chemiluminescent labeling compounds are luminal, isoluminol, aromatic acridinium ester, imidazole, acridinium salts, oxalate ester, and dioxetane.
Likewise, a bioluminescent compound may be used to label the TSHR ectodomain variant antigens and antibodies according to the present invention.
Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent antigen or antibody is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling include luciferase and aequorin.
The TSHR ectodomain variant antigens and antibodies of the present invention are ideally suited for the preparation of a kit. Such a kit may comprise a carrier means being compartmentalized to receive in close confinement therewith one or more container means such as vials, tubes and the like, each of said container means comprising the separate elements of the assay to be used.
The types of assays which can be incorporated in kit form are many, and include, for example, competitive and non-competitive assays. Typical examples of assays which can utilize the antibodies of the invention are radioimmunoassays
SUBSTITUTE SHEET flUJLE 26) (RIA), enzyme immunoassays (EIA), enzyme-linked immunosorbent assays (ELISA), and immunometric, or sandwich, immunoassays.
By the term "immunometric assay" or "sandwich immunoassay," it is meant to include simultaneous sandwich, forward sandwich and reverse sandwich immunoassays. These terms are well understood by those skilled in the art. Those of skill will also appreciate that TSHR ectodomain variant antigens and antibodies according to the present invention will be useful in other variations and forms of assays which are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention. Forward sandwich assays are described, for example, in United States Patent
Numbers 3,867,517, 4,012,294 and 4,376,110. Reverse sandwich assays have been described, for example, in United States Patent Numbers 4,098,876 and 4,376,110.
In the preferred mode for performing the assays it is important that certain
"blockers" be present in the incubation medium (usually added with the labeled soluble antigen or antibody). The "blockers" are added to assure that non-specific proteins, protease, or human antibodies to mouse (or other) immunoglobulins present in the experimental sample do not cross-link or destroy the antigens or antibodies on the solid phase support, or the radiolabeled indicator antigen or antibody, to yield false positive or false negative results. The selection of "blockers" therefore can add substantially to the specificity of the assays described in the present invention, and will be carefully considered by those of skill designing such assays.
There are many solid phase immunoadsorbents which have been employed and which can be used in the present invention. Well known materials which may be employed include glass, polystyrene, polypropylenes dextran, nylon, agarose, dextran, acrylamide and other materials, in the form of tubes, beads, and microtiter plates formed from or coated with such materials, and the like. The immobilized TSHR ectodomain variant antigens or antibodies can be either covalently or physically bound to the solid phase immunoadsorbent, by techniques such as covalent bonding via an amide or ester linkage, or by adsorption. Those skilled in the art will know many other suitable solid phase immunoadsorbents and methods for immobilizing antibodies thereon, or will be able to ascertain such, using no more than routine experimentation.
Presently preferred for use as a solid phase are SEPHAROSE beads obtained from commercial suppliers such as Sigma Chemical Co., St. Louis, Missouri. In the presently preferred direct assay as described, for example, in Example 7, the Sepharose beads are coated with Protein A, a polypeptide isolated from Staphylococcus aureus, that is known to bind to the Fc region of immunoglobulin molecules without interacting at the antigen binding site, Surolia, A., et al., Trends Biochem. Sci. 7:14 (1981), allowing formation of tertiary complexes of Protein A, antibody and antigen. Protein A-coated Sepharose beads bind human IgG present in the biological fluid sample, which is preferably a human serum sample in the preferred direct assay format of the invention. Following incubation of the serum sample and washing of the Sepharose Protein A beads, the beads will retain IgG, possibly including autoantibodies against TSHR. The beads are thereafter resuspended in medium which has been conditioned with a TSHR ectodomain variant according to the invention. The TSHR ectodomain variant is prepared so that it is capable of being visualized. As described herein, presently preferred is the addition of a 6 histidine "tail" to the TSHR ectodomain variant. Labeled antibody against the 6His tail is then used to detect and/or quantitate the TSHR ectodomain variant antigen retained on the Sepharose Protein A bead, thereby detecting and/ or quantitating TSHR autoantibodies present in the sample.
It will be appreciated that a first antibody against the TSHR ectodomain variant antigen may be used instead of the 6His tail, against which a second, detectably labeled antibody is generated for visualization, as is conventional, and that the first antibody will be selected such that its binding does not interfere with autoantibody binding to the TSHR ectodomain variant selected for the assay. Use of the 6His tail and a detectably labeled antibody thereagainst, however, it is believed to conveniently avoid interference with autoantibody binding, and to improve the assay by reducing background, which is particularly advantageous since, as described herein, the absolute amounts of TSHR autoantibodies in human serum are believed to be quite low, and accordingly the 6His tail is presently preferred for use in a direct assay according to the invention for these reasons. As described in Example 7, a particularly preferred TSHR ectodomain variant for use in a direct assay according to the invention is TSHR-289-6His. It will also be appreciated that antibody (which may be polyclonal or, preferably, monoclonal) against TSHR autoantibodies may be used for more specific solid phase capture than is presently accomplished with Protein A, and may offer reduced nonspecific binding and background, and that liquid-liquid phase assay formats may be employed which offer improved reaction kinetics as compared to solid-liquid phase assay formats.
As shown in Example 7, using the direct assay of the invention, human serum autoantibodies against human TSHR were shown to be markedly elevated in patients with confirmed clinical Graves' disease as compared to normal human serum (Table 3), with mean TSHR autoantibody levels in the two Graves' disease patients, as reflected in counts per minute (cpm) of 125I activity, exceeding mean normal serum levels by over 600%. Such elevated autoantibody levels as measured according to the direct assay methods of the present invention are consistent with TSHR activation, known to result in thyroid overactivity and thyrotoxicosis in Graves' patients ( Rees Smith, et al, Endocr. Rev., 9: 106-121 (1988)). Since the present invention is the first description of a direct assay for TSHR autoantibodies, it will be appreciated that improvements in the assay method are to be expected, including streamlining of incubation and washing procedures and selection of reageants to simplify and shorten the time required for the assay, use of a standard curve for improved quantitation of test results and correlation of results to pathophysiological state, and the like, which will be accomplished employing known principles of clinical diagnostic practice.
In a particular embodiment, the TSHR ectodomain variants of the invention may be used to detect or measure antibody to TSH receptor in a biological fluid sample, such as serum, lymph or urine, using an automated diagnostic system. In a particularly preferred embodiment, the automated diagnostic system is a microsystem platform suitable to manipulate the sample.
The TSHR ectodomain variant TSHR-261, despite its potent autoantibody
neutralizing activity, does not bind TSH. The TSH binding site on the TSHR is
discontinuous and involves multiple segments throughout the entire ectodomain,
including segments downstream of residue 261 (Nagayama, et al, Biochetn. Biophys. Res. Comm., 173:1150-1156 (1990); Nagayama, et al, Proc. Natl. Acad. Sci.
USA, 88:902-905 (1991)). The TSHR autoantibody epitope(s) may, therefore, be more limited than the TSH binding site. Support for this notion is provided by
data from most (Rapoport, et al, /. Clin. Endocrinol Metab., 81:2525-2533 (1996);
Harfst, et al, Lancet, 339:193-194 (1992); Chazenbalk, et al, /. Biol. Chem., 270:1543-1549 (1995); Huang, et al, /. Mol. Endocrinol, 8:137-144 (1992)), but not all (Seetharamaiah, et al, Endocrinology, 134:549-554 (1994); Shi, et al, Thyroid,
3:129-133 (1993)), laboratories that TSH binding to the full TSHR ectodomain is negligible or absent. Remarkably, in contrast to TSH, hCG binds with high
affinity to the isolated ectodomain of its cognate receptor, even when the latter lacks carbohydrate (Segaloff, Endocr. Rev., 14:324-347 (1993)). The reason for this major difference between such closely related receptors is an enigma. The present data with TSHR-261 must also be reconciled with previous evidence obtained using chimeric TSH-LH/CG receptors that the epitope(s) for
autoantibodies are also discontinuous and extend downstream of residue 261
(Nagayama, et al, /. Clin. Invest., 88:336-340 (1990)). One possible explanation for this paradox is that TSHR-261 contains the dominant portion of a discontinuous epitope, sufficient to neutralize most TSHR reactivity in Graves' patients sera.
In summary, progressive carboxyl-terminal truncations lead to the secretion by CHO cells of modified TSHR ectodomains with mature, complex carbohydrate. Most important, TSHR-261 is highly potent in interacting with TSHR autoantibodies. Antigenically active TSHR will provide a major impetus for future studies on the diagnosis, pathogenesis and immunotherapy of Graves' disease.
Those of skill will appreciate that when treating populations of cells, such
as thyroidal tissue sells, a therapeutic effect may be observed by any number of known clinical endpoints. The compounds of the present invention also have utility in combatting drug resistance, which may be a problem with current
treatments. In this embodiment, the compounds of the invention may be used
SUBSTITUTE SHEET Q^ULE 26) in conjunction with other agents. Mechanisms of drug resistance are described, for example, in Remington's Pharmaceutical Sciences, 18th Edition, supra.
The quantities of active ingredient necessary for effective therapy will depend on many different factors, including means of administration, target site, physiological state of the patient, and other medicaments administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the active ingredients. Animal testing of effective doses for
treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, for example, Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th Ed., MacMillan Publishing Co,, New York (1985), and Remington's Pharmaceutical Sciences 18th Ed., Mack Publishing Co., Easton, Penn (1990). Methods for administration are discussed therein, including oral, intravenous, intraperitoneal, intramuscular, transdermal, nasal, iontophoretic administration, and the like.
In selecting a dose for use in treating a patient according to the present invention, a treatment regimen will be selected which will achieve a sufficient concentration of the composition(s) to achieve the desired therapeutic effect in the
target cells. Those of skill will be able to determine an effective dose, which will vary depending upon the manner and mode of administration, in order to
achieve effective concentrations.
One method for administering the compositions of the present invention
is inhalation of dry-powder formulations comprising the composition(s). In order to allow for absorption of the active components through the alveoli into the bloodstream, the powder must be very fine; on the order of 1-5 micron particles.
The highly disbursable powder is delivered via an inhaler which generates an aerosol cloud containing the bolus of drug at the top of the inhalation chamber.
The compositions of the present invention will lend themselves to injection into the bloodstream of a patient. The half life of the active compositions so administered may be manipulated for best therapeutic effect by employing known drug technologies. One example of such technologies is known as DEPOFOAM phospholipid spheres (Depo Tech Corp., San Diego, CA), which gradually release the active component(s) over a period of days to weeks. This allows for a constant level of systemic concentration with lower initial drug levels and injection frequency.
Known methods of entrapping and stabilizing the compositions of the present invention may be employed to accommodate several different routes of drug delivery. One example of such technologies is the TECHNOSPHERE
powder (Pharmaceutical Discovery Corp., Elmsford, NY), which reliably forms two micron diameter spheres under conditions preserving the structural and
functional integrity of the active peptide component. The pH-sensitive spheres, when injected into the blood, dissolve and release the active component, which
is rapidly absorbed. Fine powders such as these are suitable for pulmonary, oral, intravenous and intraperitoneal administration.
The site of administration and cells will be selected by one of ordinary skill in the art based upon an understanding of the particular disorder being treated.
In addition, the dosage, dosage frequency, and length of course of treatment, can be determined and optimized by one of ordinary skill in the art depending upon the particular disorder being treated. The particular mode of administration can also be readily selected by one of ordinary skill in the art and can include, for example, oral, intravenous, subcutaneous, intramuscular, etc. Principles of pharmaceutical dosage and drug delivery are known and are described, for
example, in Ansel, H. C. and Popovich, N. G., Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Ed, Lea & Febiger, Pub., Philadelphia, PA (1990). It is possible, for example, to utilize liposomes to specifically deliver the agents of the invention. Such liposomes can be produced so that they contain additional
bioactive compounds and the like such as drugs, radioisotopes, lectins and toxins, which would act at the target site.
Nucleic acid compositions encoding the compositions and variants thereof useful according to the invention will generally be in RNA or DNA forms, mixed polymeric forms, or any synthetic nucleotide structure capable of binding in a base-specific manner to a complementary strand of nucleic acid. Such a nucleic acid embodiment is typically derived from genomic DNA or cDNA, prepared by synthesis, or derived from combinations thereof. The DNA compositions
generally include the complete coding region encoding the compositions, or fragments thereof.
By "functional equivalent" is meant a peptide possessing a biological activity or immunological characteristic substantially similar to that of a
composition of the invention, and is intended to include "fragments," "variants," "analogs," "homologs," or "chemical derivatives" possessing such activity or characteristic. Functional equivalents of a peptide according to the invention, then, may not share an identical amino acid sequence, and conservative or non- conservative amino acid substitutions of conventional or unconventional amino acids are possible.
Reference herein to "conservative" amino acid substitution is intended to mean the interchangeability of amino acid residues having similar side chains.
For example, glycine, alanine, valine, leucine and isoleucine make up a group of amino acids having aliphatic side chains; serine and threonine are amino acids having aliphatic-hydroxyl side chains; asparagine and glutamine are amino acids having amide-containing side chains; phenylalanine, tyrosine and tryptophan are amino acids having aromatic side chains; lysine, arginine and histidine are amino
acids having basic side chains; and cysteine and methionine are amino acids having sulfur-containing side chains. Interchanging one amino acid from a given group with another amino acid from that same group would be considered a conservative substitution. Preferred conservative substitution groups include asparagine-glutamine, alanine-valine, lysine-arginine, phenylalanine-tyrosine and valine-leucine-isoleucine.
A "mutant" as used herein refers to a peptide having an amino acid sequence which differs from that of a known peptide or protein by at least one amino acid. Mutants may have the same biological and immunological activity as the known protein. However, the biological or immunological activity of
mutants may differ or be lacking. For example, a mutant may lack the biological activity which characterizes a TSHR of the invention, but may be useful as an eptitopic determinant for raising antibodies or for the detection or purification of antibodies thereagainst, or as an agonist (competitive or non-competitive),
antagonist, or partial agonist of the function thereof. Suitable labels for use in assays according to the invention include a detectable label such as an enzyme, radioactive isotope, fluorescent compound, chemiluminescent compound, or bioluminescent compound. Those of ordinary skill in the art will know of other suitable labels or will be able to ascertain such using routine experimentation. Furthermore, the binding of these labels to the peptides is accomplished using standard techniques known in the art.
The further isolation, purification and sequencing of TSHR according to the invention may be accomplished by standard biochemical methods such as,
for example, those described in Cantor, C, ed., Protein purification: Principles and Practice, Springer Verlag, Heidelberg, Publisher (1982); Hancock, W., ed.,
New Methods in Peptide Mapping for the Characterization of Proteins, CRC Press, Boca Raton, Florida, Publisher (1996), following the teachings of the present invention.
Peptidomimetic agents are of use in the therapeutic treatment of disease. Such peptidomimetics are also provided by the present invention, and can act as drugs for the modulation of autoimmune disease, such as Graves' disease. Peptidomimetics are commonly understood in the pharmaceutical industry to include non-peptide drugs having properties
analogous to those of those of the mimicked peptide. The principles and practices of peptidomimetic design are known in the art and are described, for
example, in Fauchere J., Adv. Drug Res. 15: 29 (1986); and Evans, et al, J. Med. Chem. 30: 1229 (1987). Peptidomimetics which bear structural similarity to
therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Typically, such peptidomimetics have one or more peptide linkages optionally replaced by a linkage which may convert desirable properties such as resistance to chemical breakdown in vivo. Such linkages may include -CH2NH-, -CH2S-, -CH2-CH2-, -CH=CH-, -COCH2-, -CH(OH)CH2-, and -CH2SO-. Peptidomimetics may exhibit enhanced pharmacological properties (biological half life, absorption rates, etc.), different specificity, increased stability, production economies, lessened antigenicity and
the like which makes their use as therapeutics particularly desirable.
It will be appreciated by those of skill that the precise chemical structure
of compositions according to the invention may will vary depending upon a number of factors. For example, a given protein may be obtained as an acidic or basic salt, or in neutral form, since ionizable carboxyl and amino groups are
found in the molecule. For the purposes of the invention, then, any form of peptide comprising human TSHR which retains the therapeutic or diagnostic activity of the compositions of the present invention is intended to be within the scope of the invention.
The compositions of the present invention may be produced by
recombinant DNA techniques known in the art. For example, nucleotide sequences encoding human TSHR of the invention may be inserted into a suitable
DNA vector, such as a plasmid, and the vector used to transform a suitable host. The recombinant human TSHR is produced in the host by expression. The
transformed host may be a prokaryotic or eukaryotic cell. Preferred nucleotide sequences for this purpose encoding a human TSHR are disclosed herein.
Synthetic polynucleotide sequences may be constructed by known chemical synthetic methods for the synthesis of oligonucleotides. Such synthetic methods are described, for example, in Blackburn, G.M. and Gait, M.J., Eds., Nucleic Acids in Chemistry and Biology, IRL Press, Oxford, England (1990), and it will be evident that commercially available oligonucleotide synthesizers also may be used according to the manufacturer's instructions. One such manufacturer is Applied Bio Systems.
Polymerase chain reaction (PCR) using primers based on the nucleotide sequence data disclosed herein may be used to amplify DNA fragments from mRNA pools, cDNA clone libraries or genomic DNA. PCR nucleotide amplification methods are known in the art and are described, for example, in Erlich, H.A., Ed., PCR Technology: Principles and Applications for DNA Amplification, Stockton Press, New York, New York (1989); U.S. Patent No. 4,683,202; U.S. Patent No. 4,800,159; and U.S. Patent No. 4,683,195. Various nucleotide deletions, additions and substitutions may be incorporated into the polynucleotides of the invention as will be recognized by those of skill, who will also recognize that variation in the nucleotide sequence encoding human TSHR may occur as a result of, for example, allelic polymorphisms, minor sequencing errors, and the like. The polynucleotides encoding the peptides of the invention
may include short oligonucleotides which are useful, for example, as hybridization probes and PCR primers. The polynucleotide sequences of the invention also may comprise a portion of a larger polynucleotide and, through
polynucleotide linkage, they may be fused, in frame, with one or more polynucleotide sequences encoding different proteins. In this event, the expressed protein may comprise a fusion protein. Of course, the polynucleotide sequences of the invention may be used in the PCR method to detect the presence of mRNA encoding autoantibodies in the diagnosis of disease or in forensic analysis.
The sequence of amino acid residues in a protein or peptide is designated herein either through the use of their commonly employed three-letter designations or by their single-letter designations. A listing of these three-letter and one-letter designations may be found in textbooks such as Lehninger, A., Biochemistry, 2d Ed, Worth Publishers, New York, New York (1975). When the amino acid sequence is listed horizontally, the amino terminus is intended to be
on the left end whereas the carboxy terminus is intended to be at the right end. The residues of amino acids in a peptide may be separated by hyphens. Such hyphens are intended solely to facilitate the presentation of a sequence.
Suitable agents for use according to the invention include human TSHR and mimetics, fragments, functional equivalents and/or hybrids or mutants thereof, as well as mutants, and vectors containing cDNA encoding any of the foregoing. Agents can be administered alone or in combination with and/or
concurrently with other suitable drugs and/or courses of therapy.
The agents of the present invention are suitable for the treatment of autoimmune diseases which are characterized by inappropriate cell death. Autoimmune diseases are disorders caused by an immune response directed against self antigens. Such diseases are characterized by the presence of
circulating autoantibodies or cell-mediated immunity against autoantigens in conjunction with inflammatory lesions caused by immunologically competent cells or immune complexes in tissues containing the autoantigens. Such diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis, and Graves' disease.
Standard reference works setting forth the general principles of immunology include Sell, S., Immunology, Immunopathology & Immunity, 5th Ed., Appleton & Lange, Publ., Stamford, CT (1996); Male, D., et al, Advanced Immunology, 3d Ed., Times Mirror Int'l Publishers Ltd., Publ., London (1996); Stites, D. P., and Terr, A. I., Basic and Clinical Immunology, 7th Ed., Appleton & Lange, Publ., Norwalk, CT (1991); and Abbas, A. K., et al, Cellular and
Molecular Immunology. W. B. Saunders Co., Publ., Philadelphia, PA (1991). The human TSHR peptides, mimetics, agents and the like disclosed herein, as well as vectors comprising nucleotide sequences encoding them or their corresponding antisense sequences, and hosts comprising such vectors, may be used in the manufacture of medicaments for the treatment of diseases including autoimmune diseases.
In another aspect, the present invention describes improved assays for the detection of TSHR autoantibodies. Surprisingly and unexpectedly, it has been found that mammalian cells expressing more TSHR on their surface provide a less sensitive TBI assay when this assay is performed with intact cells in monolayer culture. Although not intending to be bound by any particular theory, one likely reason for this phenomenon is the very low absolute
concentration in serum of TSHR autoantibodies. Although previously suspected, only very recently has it been shown by flow cytometric analysis that TSHR
autoantibodies are generally present at much lower concentrations than thyroid peroxidase (TPO) autoantibodies in the same serum (Example 5). The efficacy of an occupancy assay such as the TBI assay depends on an excess of antibody over antigen. Thus, the combination of a large amount of antigen (TSHR) and a low concentration of antibody leads to low occupancy of the antigen. This, in turn, will reduce the sensitivity of the TBI assay, because many TSHR unoccupied
by antibody are available for 125I-TSH binding. An optimum TBI assay according to the present invention, therefore, should utilize a small amount of receptor and a very effective ligand, as is the case with the affinity-purified bovine 12SI-TSH in the procedure developed by Rees-Smith (Shewring, et al, Clin. Endocrinol, 17:409-417 (1982); Rees Smith, et al, Methods in Enzymology, 74:405-420 (1981)).
A TBI assay using cell monolayers is at a serious practical disadvantage relative to assays utilizing solubilized TSHR. However, although solubilized porcine TSHR preparations are clearly effective, human TSHR have been suggested to be the most appropriate for study of TSHR autoantibodies (Rees Smith, et al, Methods in Enzymology, 74:405-420 (1981)). To date, however, seven years after its molecular cloning (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989); Libert, et al, Biochem. Biophys. Res. Comm., 165:1250-1255 (1989); Misrahi, et al, Biochem. Biophys. Res. Comm., 166:394-403 (1990)), it is surprising that recombinant human TSHR has not supplanted the use of porcine material in a practical TBI assay. The most important contribution of the present invention is the demonstration for the first time that soluble, recombinant human
TSHR can readily be obtained from mammalian cells in large amounts and in a form suitable for an effective TBI assay. Soon after a stably-transfected CHO cell
line was generated (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)), we found that TSH binding to cells scraped from culture dishes was greatly reduced when compared to binding to cells in monolayer culture; hence our initial use of intact cells in a TBI assay (Filetti, et al, /. Clin. Endocrinol. Metab., 72:1096-1101 (1991)). Similarly, examination of the data of Costagliola et al, /. Clin. Endocrinol. Metab., 75:1540-1544 (1992), reveals that the yield of solubilized TSHR from scraped JP09 cells is much lower than expected. The yield of solubilized TSHR from stably-transfected mouse myeloma cells grown to high density in a fermentor (Matsuba, et al, /. Biochem., 118:265-270 (1995)) has not been reported. The present invention demonstrates this low recovery of effective
TSHR from resuspended cells and indicates that the direct extraction of TSHR from cell monolayers can overcome the evident fragility of this very difficult receptor. However, only a cell line such as TSHR-10,000, that expresses very high, levels of TSHR, can provide TSHR suitable for direct use in a TBI assay according to the invention without further purification or concentration, and is preferred on that basis.
There is evidence that TSHR species may be important in bioassays for stimulatory autoantibodies (Murakami, et al, Eur. J. Endocrinol, 133:80-86 (1995); Vitti, et al, /. Clin. Endo. Metab., 76:499-503 (1993); Endo, et al, Biochem. Biophys. Res. Comm., 186:1391-1396 (1992)). Whether or not the use of human, rather than
porcine, TSHR would be advantageous in a TBI assay has not heretofore been established. This factor was considered during the original development of the
TBI assay using solubilized porcine TSHR (Rees Smith, et al, Methods in Enzymology, 74:405-420 (1981)). However, because TBI values in 18 sera did not
differ greatly when TSHR of either species was used, and because of the easier access to porcine than to human thyroid tissue, porcine TSHR became the standard in TBI assays. It is worth noting that most sera in this study had relatively high TBI values, making discrimination at the very important low end of the assay difficult to discern.
The availability of solubilized recombinant human TSHR according to the present invention allowed reassessment of this question. Consistent with previous data on non-recombinant material (Rees Smith, et al, Methods in Enzymology, 74:405-420 (1981)), TBI values of 30 sera were generally comparable with solubilized porcine and human TSHR. However, our data indicate that a
few sera that were negative in the porcine TSHR assay are positive when human TSHR is used.
Finally, the question arises whether, in addition to TSHR species, the species of the ligand (TSH) used in TBI assays is important. Human TSH is a very difficult ligand to use in a TBI assay because of its lower specific activity relative to bovine TSH, even when interacting with the human TSHR. Nevertheless, in a TBI assay using intact cells, human TSH and bovine TSH ligands did not produce identical results with all sera. The reason for the variable background that, together with low absolute binding, precluded us from using human TSH in a solubilized TSHR TBI assay is uncertain.
The present invention also provides evidence for two cleavage sites in the TSHR ectodomain. This evidence must be viewed in the context of previous data
that (in retrospect) support this notion. Thus, for a number of years, we were puzzled by a phenomenon that we observed in TSH crosslinking studies with certain chimeric TSH-LH/CG receptors. Neither substitution of TSHR residues 261-360 ("D domain"; chimeric receptor TSH-LHR-4) nor residues 363-418 ("E domain"; chimeric receptor TSH-LHR-5) with those of the related LH/CG receptor prevented TSHR cleavage into A and B subunits (Russo, et al, Endocrinology, 130:2135-2138 (1992))(Fig. 11). Only the simultaneous substitution of domains D and E abrogated cleavage. These findings are consistent with the D and E domains each containing a cleavage site.
The smaller than expected sum of the sizes of the deglycosylated TSHR A subunit and the non-glycosylated B subunit support the concept of two cleavage sites in the TSHR, with the loss of an intervening portion of the polypeptide chain. While we recognize that size estimations cannot be absolutely precise, they are sufficiently reproducible among different laboratories, using different methodologies for TSHR detection, to suggest that a piece of the TSHR has been lost during intramolecular cleavage. We observed the deglycosylated A subunit and the B subunit to be -35 kDa and -42 kDa, respectively. Others have reported A and B subunits of similar sizes (Loosfelt, et al, Proc. Natl. Acad. Sci. USA, 895:3765-3769 (1992); Misrahi, et al, Eur. J. Biochem., 222:711-719 (1994); Graves,. et al, Endocrinology, 137:3915-3920 (1996)). In all studies, the sum of the two subunits is approximately 5 kDa smaller than the 84kDa holoreceptor. Our data also raise the possibility that cleavage at both sites is not an all or none
phenomenon. Thus, detection of smaller amounts of A and B subunits of slightly
greater size than the predominant subunit forms could represent a minor degree
of incomplete cleavage at either site. Alternatively, these minor A subunit components could represent incomplete deglycosylation.
A third line of evidence suggesting two cleavage sites in the TSHR ectodomain is the present observation of the selective loss of a strategically situated c-myc epitope in the two subunit, but not in the single chain, form of the TSHR. There are three possible explanations for this phenomenon: (i) loss of a peptide fragment containing the c-myc epitope during intramolecular cleavage at two different sites, (ii) cleavage at a single cleavage site within the c-myc epitope leading to loss of antibody recognition, (iii) a combination of these two events (two cleavage sites, one of these within the c-myc epitope). Of these possibilities, cleavage at a single site within the c-myc epitope is unlikely, for a number of reasons. Thus: (i) single cleavage within amino acid residues 338-349
(the c-myc epitope) would generate a B subunit of 46-47 kDa, clearly larger than the actual size (42 kDa) observed experimentally (see Figs. 7A and 7B); (ii) Chimeric receptor TSH-LHR-4 (Nagayama, et al, Proc. Natl. Acad. Sci. USA, 88:902-905 (1991)) and a deletion mutant (residues 317-366) of the wild-type TSHR (Wadsworth, et al, Science, 249:1423-1425 (1990)) lack the region in which the c-myc epitope was inserted (Fig. 11), yet both receptors still cleave into two subunits (Russo, et al, Mol. Endocrinol, 5:1607-1612 (1991); Russo, et al, Endocrinology, 130:2135-2138 (1992)); (iii) The c-myc epitope sequence differs substantially from that of the wild-type receptor. Persistent cleavage in such a highly mutated region would, therefore, indicate lack of amino acid sequence specificity for a TSHR cleavage site. For all these reasons, there are likely to be two cleavage sites in the TSHR ectodomain, the more upstream of which may,
or may not, be with the region of the c-myc epitope.
The unsuspected possibility of two cleavage sites in the TSHR explains why we were previously misled into deducing that TSHR cleavage occurred
closely upstream, rather than closely downstream, of amino acid residue 317
SUBSTITUTE SHEET Q*ULE 26) (Russo, et al, Mol Endocrinol, 5:1607-1612 (1991); Russo, et al, Endocrinology, 130:2135-2138 (1992); Ban, et al, Endocrinology, 131:815-829 (1992)). We made this erroneous deduction because TSHR cleavage into A and B subunits was still evident on TSH cross-linking to a receptor with residues 317-366 deleted by mutagenesis (Russo, et al, Mol. Endocrinol, 5:1607-1612 (1991); Wadsworth, et al, Science,249:1423-l4Z5 (1990)), a finding that would exclude a single, but not two, cleavages sites in this region (Fig. 11). Moreover, the A subunit in this TSHR mutant was similar in size to that of the wild-type TSHR. In retrospect, cleavage
a few residues upstream or downstream of pivotal residue 317 would be difficult to discern from a relatively large (~74 kDa) cross-linked product.
It is of interest that the c-myc epitope lies within a 50 amino acid segment (residues 317-366) that we observed to be unique to the TSHR when compared to other glycoprotein hormone receptors (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)). Although the precise boundaries of this 50 amino acid "insertion" are uncertain (because of low homology among the receptors in adjacent regions), this TSHR segment has been the subject of intense study. The very hydrophilic nature of residues 317-366 led us to speculate that it was a projection on the exterior of the TSHR molecule, perhaps important in ligand specificity (Wadsworth, et al, Science, 249:1423-1425 (1990)). Surprisingly, however, its deletion had no effect on TSH binding or on TSH-mediated signal
transduction (Wadsworth, et al, Science, 249:1423-1425 (1990)). The deduced superficial topography of TSHR residues 317-366 was also the reason for selection
of this region for c-myc epitope tagging. Other investigators have used synthetic
peptides corresponding to portions of this region for generating antisera to the TSHR. One peptide in particular (residues 352-367) is highly immunogenic and is reported to be recognized by TSHR autoantibodies in the majority of Graves' sera (Kosugi, et al, Thyroid, 1:321-330 (1991); Kosugi, et al," /. Biol. Chem., 266:19413-19418 (1991)). Further, an antiserum to a closely related synthetic peptide (residues 352-366) recognizes the A subunit in FRTL-5 rat thyroid cells, but very poorly in transfected COS cells (Ban, et al, Endocrinology, 131:815-829
(1992)). It will be interesting to correlate these findings with the possible absence of a part of this region in the cleaved TSHR.
Multiple lines of evidence, taken together, suggest that there are two cleavage sites in the ectodomain of the TSHR. To our knowledge, the TSHR would be the first member of the family of G protein coupled receptors whose ectodomain appears to contain multiple cleavage sites. Purification and characterization of the putative TSHR C peptide would provide proof for the two cleavage site hypothesis. However, it is not presently feasible to detect the release of a small TSHR polypeptide fragment into the culture medium from the TSHRmyc cell line that is not overexpressing the TSHR. Nevertheless, the evidence for two cleavage sites in the TSHR ectodomain provides an impetus to future studies on the structure-function of the TSHR subunits.
In another aspect, the present invention achieves high level of expression of the human TSHR in mammalian cells. The extent of TSHR overexpression on the surface of TSHR-10,000 cells, -1.9 x 106 receptors per cell, is quite remarkable considering the estimate of only ~ 5 x 103 TSHR on thyrocytes (Rees Smith, et al, Endocr. Rev., 9:106-121 (1988)). This level of expression, 10-12-fold higher than previously attained in stably-transfected mammalian cells (Costagliola, et al, /. Clin. Endocrinol. Metab., 75:1540-1544 (1992); Matsuba, et al, /. Biochem., 118:265-270 (1995); Harfst, et al, Molec. Cell. Endocrinol, 83:117-123 (1992)), is of value because it will facilitate studies on the native TSHR. Although there are reports of TSH and TSHR autoantibody interaction with recombinant TSHR
produced in bacterial (Graves, et al, Endocrinology, 136:521-527 (1995); Vlase, et al, /. Clin. Endocrinol Metab., 80:46-53 (1995)), insect cell (Fan, et al, Autoimmunity, 15:285-291 (1993); Vlase, et al, /. Clin. Endocrinol. Metab., 80:46-53 (1995); Huang, et al, /. Mol. Endocrinol, 10:127-142 (1993)) and cell-free translation (Morgenthaler, et al, /. Clin. Endocrinol. Metab., 81:700-706 (1996)) expression systems, or as peptides (Fan, et al, Autoimmunity, 15:285-291 (1993); Morris, et al, /. Clin. Endocrinol. Metab., 67:707-712 (1988); Atassi, et al, Proc. Natl. Acad. Sci. USA, 88:3613-3617 (1991); Morris, et al, /. Biol Chem., 268:10900-10905 (1993); Bryant, et al, /. Biol. Chem., 269:30935-30938 (1994); Morris, et al, Autoimmunity, 17:287-299 (1994)), our preference is to focus on the native protein as produced in mammalian cells. TSHR generated in bacteria or insect cells is typically insoluble and requires solubilization in chaotropic agents followed by renaturation (Graves, et al, Endocrinology, 136:521-527 (1995); Huang, et al, /. Mol. Endocrinol, 10:127-142
(1993); Seetharamaiah, et al, Autoimmunity, 14:315-320 (1993); Vlase, et al, /. Clin. Endocrinol. Metab., 80:46-53 (1995)). Our ultimate goal in expressing the TSHR at high levels in mammalian cells is to determine the three-dimensional structure of the TSHR. Even with overexpression, however, it remains uncertain whether or not crystals of purified TSHR will ever be attained in view of the daunting problems of the holoreceptor being a membrane-associated protein with a very large carbohydrate component. Crystallization of the purified ectodomain would be more feasible. However, in our experience, the ectodomain by itself does not mature correctly in mammalian cells and cannot be overexpressed (Rapoport, et al, /. Clin. Endocrinol. Metab., (In Press) (1996)). In the meanwhile, however, the holoreceptor expressed by TSHR- 10,000 cells will facilitate study of subunit structure, carbohydrate composition, interaction with its physiological ligand, TSH, as well as intracellular trafficking. It should be appreciated that, until the present invention, and even with the availability of mouse mAb (Nicholson, et al, /. Mol Endocrinol, 16:159-170 (1996);
Seetharamaiah, et al, Endocrinology, 136:2817-2824 (1995); Loosfelt, et al, Proc. Natl. Aωd. Sci. USA, 895:3765-3769 (1992)), the recombinant TSHR expressed in mammalian cells has required prior affinity purification for efficient immunological detection (Misrahi, et al, Eur. f. Biochem., 222:711-719 (1994)).
The TSHR-10,000 cells are also of potential value in providing antigen for the study of TSHR autoantibodies. Among these uses are the development of new assays for TSHR autoantibodies, flow cytometric analysis of TSHR autoantibodies in patients' sera and the isolation of human monoclonal autoantibodies from immunoglobulin gene combinatorial libraries derived from patients' B cells. However, the high basal cAMP levels in these cells reduces their
sensitivity and makes them suboptimal for the bioassay of TSHR functional activity.
Besides the practical aspects of high level TSHR expression in mammalian cells, the application of which will require long-term development, the present
study of the TSHR-10,000 cells provides insight into the function of the TSHR, at least as expressed in CHO cells. First, the data on stably-transfected cell lines strongly support transient transfection data (Van Sande, et al, Eur. }. Biochem., 229:338-343 (1995)) that the TSHR maintains a moderate level of activity in the absence of ligand. Such spontaneous activity was first observed with the αlB- adrenergic receptor (Kjelsberg, et al, /. Biol. Chem., 267:1430-1433 (1992)). The potential importance of this activity in the case of the thyroid gland, is that, as suggested by us previously (Kakinuma, et al, Endocrinology, (In Press) (1995)), thyroid overactivity could result from an increased number of TSHR expressed on the thyrocytes of a particular individual consequent to mutations in the mRNA untranslated region in the same way as mutations in the mRNA coding region can increase the increased constitutive activity of an unchanged number of receptors (Duprez, et al, Nature Genet., 7:396-401 (1994); Parma, et al, Mol. Endocrinol, 9:725-733 (1995)).
A second interesting feature of the TSHR overexpressed in the TSHR- 10,000 cells is the ability of TSH to bind to single chain TSHR expressed on the cell surface. The proportion of single chain and two-subunit TSHR on the surface of CHO cells is independent of the number of receptors expressed. However, the stronger signal with the TSHR-10,000 cells makes the phenomenon much more clear and supports our previous evidence using chimeric TSH-LH/CG receptors that cleavage into A and B subunits is not a requirement for TSH binding (Russo, et al, Endocrinology, 130:2135-2138 (1992)). This evidence raises the possibility that
the single chain TSHR is, at least in part, a physiological receptor, a concept disputed by other investigators (Loosfelt, et al, Proc. Natl. Aωd. Sci. USA, 895:3765-3769 (1992)). The most surprising feature of the CHO cells overexpressing the TSHR was the progressive reduction in affinity for TSH observed with increasing numbers of TSHR. In retrospect, we observed but did not appreciate, a similar but less dramatic decrease in TSH affinity in studies examining the role of the 5'- 3'-untranslated regions of the TSHR (Kakinuma, et al, Endocrinology, (In Press) (1995)). We considered it artifactual that the affinity of the wild-type TSHR cDNA appeared to decrease from 2 x 10"10 M to 5 x 10"10 M Kd when TSHR expression increased after deletion of the untranslated regions. However, the
further decreases in TSH affinity with the TSHR-800 and TSHR-10,000 cells make this conclusion inescapable. The TSH affinities in these cell lines cannot be estimated accurately because they are only about one order of magnitude higher than that for non-specific TSH binding. Prior to the molecular cloning of the TSHR, this remarkably high affinity of non-specific binding, observed also to plastic (Yamamoto, et al, Endocrinology, 103:2011-2019 (1978)), was considered to be a second, lower affinity type of TSHR (Kohn, L.D., Aloj, S.M., Tombaccini, D., et al. The thyrotropin receptor. In: Biochemiωl actions of hormones, Vol. XII, Anonymous Academic Press, Inc. 1985, p. 457-512; Atassi, et al, Proc. Natl. Acad. Sci. USA, 88:3613-3617 (1991)). Nevertheless, on the basis of the TSH concentrations causing half-maximal displacement, the affinities for TSH of the TSHR-10,000 and TSHR-800 cells are clearly lower than for the TSHR-0 cells.
The most likely explanation for the phenomenon of decreasing affinity with receptor number is, in our opinion, negative cooperativity between TSHR. It is possible that the TSHR aggregate or "patch" in the fluid plasma membrane, especially at high density. Conformational changes in the TSHR itself or steric hindrance to TSH binding could also lead to an apparent reduction in affinity, as could adducts between holoreceptors and TSHR B subunits. Excess B subunits have been observed previously in cells expressing the TSHR (Couet, et al, /. Biol Chem., 271:4545-4552 (1996); ). The lower affinity TSHR affinity could also, perhaps, occur if a greater proportion of TSHR were coupled to G proteins. Further studies are required to explore which, if any, of these alternatives is the underlying mechanism. We recognize that the functional changes observed in the TSHR expressed at high density will require caution in extrapolating structural information on these receptors to the TSHR present in thyrocytes. Nevertheless, it is feasible that TSHR negative cooperativity could represent another type of autoregulation, so typical of the thyroid, associated with maintaining stable thyroid function.
The present invention, facilitated by the availability of CHO cells overexpressing the human TSHR (Example 3), also describes and demonstrates that IgG class autoantibodies to the TSHR can be detected directly by flow cytometry. However, an unequivocal signal by flow cytometry was obtained
with only 4 of 21 TBI positive sera, including some selected on the basis of their high TSHR autoantibody activity. Indeed, 11 of these sera had high TBI levels
(>50% inhibition). In contrast to TSHR autoantibodies, all 20 sera with TPO autoantibodies detected by , 5I-TPO binding gave strongly positive signals on flow cytometry using TPO-expressing CHO cells.
Several lines of evidence suggest that the factor responsible for the low frequency and amplitude of TSHR autoantibody detection by flow cytometry relative to TPO autoantibodies is the very low levels in serum of the former. First, the availability of cells expressing very large numbers of TSHR in native conformation eliminates the limiting factor of insufficient antigen for adequate detection. Thus, both the TSHR-10,000 cells and the TPO-ovefexpressing CHO cell line have similar numbers (~ 2 x 106) of specific antigen molecules on their surface. Second, the weak signal observed with TSHR autoantibodies cannot be attributed to a low affinity for antigen. Thus, even though their affinities have
not been directly determined, they are capable of competing for high affinity (~ 10"10 M) TSH binding to the TSHR. TPO autoantibodies are known to be of
similar affinity for their antigen (McLachlan, et al, Clin. Exp. Immunol, 101:200-206 (1995)). Finally, a 1:1000 dilution of a potent serum for TSHR autoantibodies
nearly eliminated its signal on flow cytometry, whereas at the same dilution, TPO autoantibodies in this serum continued to produce a very strong signal.
The reason for the "net negative" fluorescence for TSHR-10,000 cells observed with some sera is unknown. One possible explanation for this phenomenon is that the high level of TSHR or TPO expression diminishes expression of another, unknown antigen in CHO cells recognized by these sera (Kaufman, et al, /. Clin. Invest., 84:394-403 (1989)). Expression of this antigen could, for example, be diminished by disruption of its gene by one of the many transgenome copies produced by the amplification process. Presumably, the very high fluorescence observed with TPO autoantibody-positive sera masks the phenomenon of a negative net fluorescence.
The present findings confirm our previous hypothesis (McLachlan, et al, /. Int. Med., 234:347-359 (1993)) of low TSHR autoantibody levels in serum, based on the inability to detect TSHR autoantibodies by indirect immunofluorescence on CHO cells stably expressing the TSHR cDNA. Our data are in accordance with the detection of an immunofluorescence signal on cultured thyroid cells by only two exceptionally potent Graves' sera (De Forteza, et al, /. Clin. Endocrinol & Metab., 78:1271-1273 (1994). Of interest, detection of TSHR autoantibodies by
flow cytometry in a serum (10M) with only moderate TBI activity, provides support for the concept that, in addition to autoantibodies to the TSH binding
site, some TSHR autoantibodies recognize epitopes outside of this region.
The very low concentration of TSHR autoantibodies in serum carries a number of implications. First, our findings explain the previous difficulties in using Graves' sera to detect the TSHR by immunoblotting or by immunoprecipitation. Second, the data also explain the lesser ability, relative to TPO and thyroglobulin autoantibodies, to detect TSHR autoantibody synthesis and secretion by patients' lymphocytes in vitro (McLachlan, et al, Nature, 270:447-449 (1977); McLachlan, et al, Clin. Endocrinol, 24:223-230 (1986)). This low frequency of TSHR-specific B lymphocytes and plasma cells is also likely to contribute to the great difficulty in obtaining IgG-class human monoclonal autoantibodies to the TSHR (McLachlan, et al, /. Clin. Endocrinol. Metab., 81:3152- 3154 (1996)). Third, flow cytometry cannot be used as an alternative to currently used clinical assays to detect TSHR autoantibodies. Fourth, and of greater importance, it is likely to be difficult to establish direct binding assays for TSHR autoantibodies of clinical relevance, even with purified antigen.
The present data provide the strongest support for the notion that TSHR autoantibodies in the sera of patients with autoimmune thyroid disease are present at much lower levels than are TPO autoantibodies. This finding carries
SUBSTITUTE SHEET Q ULE 26) important implications for future studies to understand the pathogenesis of Graves' disease. Thus, as hypothesized previously (McLachlan, et al, /. Int. Med., 234:347-359 (1993)), the low concentration in serum of TSHR autoantibodies suggests that, although often present for many years, they arise at an early stage
of the autoimmune process. Support for this concept is provided by restricted kappa or lambda light chain usage (Zakarija, /. Clin. Lab. Immunol, 10:77-85 (1983); Knight, et al, /. Clin. Endocrinol. Metab., 62:342-347 (1986); Williams, et al, /. Clin. Invest., 82:1306-1312 (1988)) and relative restriction to the IgGl subclass (Weetman, et al, /. Clin. Invest., 86:723-727 (1990)) of TSHR autoantibodies in some patients.
The present invention also demonstrates and describes that the evolutionary divergence of the TSHR into a receptor that cleaves into two subunits is unique and enigmatic. Unlike thrombin (Vu, et al, Cell, 64:1057 (1991)), TSH does not cleave its receptor; two subunit TSHR are present in transfected cells cultured in the absence of TSH (Misrahi, et al, Eur. J. Biochem., 222:711 (1994); Koo, et al, Endocrinology, 128:2297 (1991)). TSH binds to both cleaved and uncleaved forms of the TSHR. Moreover, TSH action does not require a cleaved receptor (Russo, et al, Endocrinology, 130:2135 (1992);
Chazenbalk, et al, Biochem. Biophys. Res. Comm., 225:479 (1996)). One possibility is that TSHR receptor cleavage, including the release of a small polypeptide between cleavage sites 1 and 2, may be related to the very common occurrence of disease-causing autoantibodies, a phenomenon rarely, if ever, encountered with other members of the G protein-coupled receptor family. Data obtained from thirty three new TSHR variants stably expressed in CHO cells (i) provide proof for the existence of two cleavage sites in the TSHR, (ii) identify three amino acid residues in the TSHR that, when substituted with the homologous residues of the LH/CG receptor, prevent cleavage at the second, downstream cleavage site (site 2) and, (iii) reveal that cleavage or non-cleavage at this second site is related to N-linked glycosylation. To our knowledge, the presence or absence of glycosylation represents a novel mechanism by which two closely-related receptors have evolved into having a difference in subunit structure. Greater understanding of its structural features will also contribute to a better understanding of why the TSHR is a pivotal autoantigen in human autoimmune disease.
EXAMPLES The invention may be appreciated in certain aspects with reference to the following examples, offered by way of illustration, not by way of limitation.
Example 1 describes TSH binding inhibition assays employing recombinant human TSHR compositions.
Example 2 presents the surprising and novel finding for G protein- coupled receptors that contrary to the prevailing concept of one cleavage site in the TSHR, there are, in fact, two such sites. The TSHR, like insulin, may
release a C peptide during intramolecular cleavage into two subunits.
Example 3 describes high level expression of TSHR in CHO cells, as well as high constitutive activity of the TSHR in the absence of ligand, and the binding of TSH to the single subunit, uncleaved TSHR. Moreover, high level expression is associated with apparent negative co-operativity among the TSHR in terms of their affinity for ligand.
Example 4 demonstrates that carboxyl-terminal truncation of the human
TSHR ectodomain generates a secreted protein with complex carbohydrate
that neutralizes autoantibodies in Graves' patients' sera. Antigenically active TSHR is useful for the diagnosis, pathogenesis and immunotherapy of Graves'
disease.
Example 5 presents data providing the strongest support for the notion
that TSHR autoantibodies in the sera of patients with autoimmune thryoid disease are present at much lower levels than are TPO autoantibodies. This finding has important implications for the diagnostic detection of TSHR
autoantibodies and for understanding the pathogenesis of Graves' disease.
Example 6 identifies the amino acid residues related to the putative cleavage sites of TSHR.
Example 7 presents data from a direct assay for TSHR autoantibodies in normal and Graves' patient serum, using truncated TSHR antigen according to the invention.
EXAMPLE 1: Human Thyrotropin Receptor in a TSH Binding
Inhibition (TBI) Assay for Thyrotropin Receptor Autoantibodies
Cell cultures: Three different, stably-transfected Chinese hamster ovary
(CHO) cell lines were used, each expressing different numbers of human TSHR on their cell surface (Table 1). The transgenome in the "4 kb" TSHR cells contains the full-length cDNA with both the 5' and 3' untranslated ends
(Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)). TSHR-0 cells, expressing only the coding region of the TSHR cDNA, were renamed from the previously cumbersome pTSHR-5'3TR-NEO-ECE (Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)). The zero implies that the TSHR cDNA transgenome in these cells has not been amplified. The transgenome in the
TSHR-10,000 cells was amplified by adaptation of these cells to 10,000 nM methotrexate (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)). For this study, all cell lines (cloned by limiting dilution in selection medium) were grown in Ham's F-12 medium supplemented with 10% fetal calf serum and standard antibiotics. Cells were cultured to confluence in either 10 cm
diameter, 24 well cluster or 96 well microtiter culture dishes, as described in the text.
Table 1: Characteristics of cell lines expressing the human TSH receptor
Figure imgf000079_0001
(a) Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)
(b) Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)
(c) Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)
Sera: 42 sera were used. All were kindly provided by Mr. Juan
Tercero of Corning Nichols Institute, a reference laboratory to which the sera were sent for known or suspected Graves' disease. Sera were selected to provide a balanced spectrum TBI values (high, medium and low or negative) as determined by Corning Nichols. Sera were reassayed in our laboratory as described below. TSH binding inhibition CTBD assay using intact cells: Highly purified bovine TSH (N.I.H.) or recombinant human TSH (Sigma, St. Louis, MO)(5 μg) was radiolabeled with 125I to a specific activity of ~ 80 μCi/μg protein using
the Bolton-Hunter reagent (4400 Ci/mmol; DuPont-New England Nuclear,
Boston, MA) according to the protocol of the manufacturer, followed by Sephadex G-100 chromatography (Goldfine, et al, Endocrinology, 95:1228-1233 (1974)). "4kb" TSHR and TSHR-0 cells were grown to confluence in 24 well and 96 cells culture dishes, respectively. TBI activity was determined in a "two-step" assay as described previously (Filetti, et al, /. Clin. Endocrinol Metab., 72:1096-1101 (1991)) using polyethylene glycol (PEG)-precipitated IgG (Filetti, et al, /. Clin. Endocrinol. Metab., 72:1096-1101 (1991)), with the following modifications. Cells were preincubated for 1.5 hr at 37°C with 0.25 ml (24 well plate) or 0.1 ml (96 well plate) of the IgG preparation in phosphate-buffered saline (PBS). In some assays using 96 well plates, when indicated, cells were preincubated in whole serum (50 ml) prior to rinsing and the addition of 12SI- TSH. With the two-step assay, we found no difference between whole serum and PEG-precipitated IgG. After 2 rinses with "binding buffer" (Hank's buffer containing 280 mM sucrose instead of NaCl and supplemented with 0.25% bovine serum albumin) (Tramontano, et al, Endocrinology, 118:1945-1951 (1986)), 125I-TSH in binding buffer was added to the cells (2 hr at 37°C) in the amounts described in the text (250 ml and 50 ml per well in the 24 well and 96 well plates respectively). Bound 1 5I-TSH was measured as previously described (Filetti, et al, /. Clin. Endocrinol. Metab., 72:1096-1101 (1991)). Non- specific binding to untransfected CHO cells was subtracted to obtain values for specific binding.
Solubilized TSH receptor preparation: Receptors were prepared from TSHR-10,000 cells in two procedures:
(i) Cells removed from the culture dishes: Fifty confluent 10 cm diameter dishes of cells (107 cells per dish) were rinsed once with PBS and
cells were resuspended by scraping into buffer A (10 mM Tris, pH 7.5, 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin and 2 μg/ml pepstatin A; Sigma)(3 ml/dish). After brief homogenization with a Polytron (10 seconds x 3 at 4°C), the 500 - 20,000 x g particulate fraction was processed according to the protocol of Rees Smith et al. (Shewring, et al, Clin. Endocrinol., 17:409-417 (1982); Rees Smith, et al, Methods in Enzymology, 74:405-420 (1981)). The final extraction was with 5 ml of 10 mM Tris, pH 7.5, 50 mM NaCl and 1% Triton X-100. This material was used for TSH binding either directly or after dilution in the same buffer, as described in the text, (ii) Direct extraction of cells in monolayer: Culture medium in one confluent 10 cm diameter dish of cells was removed and replaced with 3 ml of the 1% Triton X-100 buffer described above, supplemented with 5 mM EDTA,
5 mM EGTA, 5 mM N-ethylmaleimide, 10% glycerol, 0.5% BSA and 0.5% gelatin. After rocking for 2 hr at 4°C, the buffer was recovered, centrifuged (1
hr, 100,000 x g) and the supernatant used in the TBI assay as described above. The supplements to the buffer were found not to alter TSH binding in the
assay. TSH binding inhibition (TB assay using solubilized TSHR: Sera were assayed using TSHR antibody (TRAb) kits purchased from Kronus, San
Clemente, CA. Reagents from this kit (from RSR Ltd., Cardiff, U.K.) were also used in conjuction with solubilized human TSHR, obtained as described above. TBI values were calculated as:
1 - (cpm serum sample - cpm in the absence of TSHR) x 100
(cpm negative reference serum - cpm in the absence of TSHR)
Thyroid stimulating immuno globulin (TSI) assay: TSHR-0 cells, grown
to confluence in 96 well culture plates, were assayed as previously described for human thyroid cells (Hinds, et al, /. Clin. Endocrinol. Metab., 52:1204-1210 (1981); Rapoport, et al, /. Clin. Endocrinol. Metab., 58:332-338 (1984)). This procedure employs the modification of using hypotonic medium (Kasagi, et al,
/. Clin. Endocrinol. Metab., 54:108-114 (1982)). For this study, the following additional modifications were introduced: IgG was precipitated with PEG (see above) and resuspended in the hypotonic medium supplemented with 10 mM Hepes, pH 7.4, 1 mM 3-isobutyl 1-methylxanthine and 0.3% BSA. Cells were incubated in this medium (0.1 ml) for 2 hr at 37°C. Cyclic AMP in the medium, diluted in 50 mM Na acetate, pH 6.2 and acetylated (Rapoport, et al, /. Clin. Endocrinol. Metab., 58:332-338 (1984)), was measured by radioimmunoassay using cAMP, 2'-0-succinyl 125I-iodotyrosine methyl ester
(Dupont, Boston MA) and a rabbit anti-cAMP antibody (Calbiochem, San Diego CA). TSI activity was expressed as a percentage of the cyclic AMP
value in the test serum relative to cAMP measured after concurrent incubation with serum from normal individuals. The TBI assays performed were of two main types (Table 2) involving either intact CHO cells or solubilized TSHR.
Table 2: Types of TSH binding inhibition (TBI) assays performed.
Figure imgf000083_0001
TSH binding inhibition (TBI) assay using cells in monolayer
Previously, we reported data on a TBI assay using intact CHO cells stably transfected with the full-length 4 kb human TSHR cDNA (Filetti,. et al, /. Clin. Endocrinol Metab., 72:1096-1101 (1991)). The cells used in this assay (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)), which expressed about 16,000 receptors per cell (Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)), were equal, if not better, in sensitivity to the commercially available, solubilized porcine TSHR assay (Shewring, et al, Clin. Endocrinol, 17:409-417 (1982)). However, the availability of CHO cells expressing larger numbers of TSHR (Kakinuma, et al, Endocrinology, 137:2664-2669 (1996); Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)) prompted us to examine whether these cells would provide an even more effective TBI assay. To the contrary, in preliminary experiments, we unexpectedly found that the pig TSHR TBI assay was far superior to an assay
5 using intact CHO cells overexpressing the human TSHR. For example, TBI values (% inhibition of 125I-TSH binding) with three potent sera were 79%, 91% and 83% with the commercial assay versus 10%, 13% and 57% with the CHO cells, respectively.
The deleterious effect on TBI sensitivity of a large number of TSHR per
10 cell could be overcome, in part, by culturing fewer cells with more receptors in smaller wells. Thus, TSHR-0 cells (150,000 TSHR per cell)(Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)) cultured in microtiter (0.36 cm2) wells provide only - 2-fold more receptors per well than the "4kb" TSHR cell line (16,000 TSHR per cell)(Nagayama, et al, Biochem. Biophys. Res. Comm.,
15 165:1184-1190 (1989); Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)) cultured in 24 well cluster plates (1.77 cm2 wells). Two major advantages of
microtiter plates were the use of less serum and a smaller volume of 125I-TSH with less background binding. By this means, the tracer concentration could
be increased up to 100-fold, with a progressive increase in TSHR saturation
20 (Fig. IA). Nevertheless, TBI values with the TSHR-0 cells were lower than
with the 4 kb TSHR cell line, reflecting the greater number of TSHR per well with the former cells (Fig. IB).
Finally, in studies on intact human TSHR-expressing CHO cells, we compared the use of ,25I-bovine (b) with 125I-human (h) TSH in a TBI assay using TSHR-0 cells plated in microtiter wells. With 12 patients' sera covering a wide range of TBI. values, the data obtained were generally similar regardless of the species of radiolabeled TSH used (Fig. 2). Nevertheless, of interest and potential importance, a few sera (for example, #1, 3 and 6) produced greater inhibition of radioligand binding with human than with bovine TSH. It must be emphasized, however, that the use of hTSH in a TBI
assay is presently limited because this species of TSH is a less effective ligand than bTSH (Pierce, et al, Ann. Rev. Biochem., 50:465-495 (1981)). Indeed, in the
experiment shown, maximal 125I-TSH binding was 5-fold lower with hTSH than with bTSH (4.9% vs. 24.8%).
TSH binding inhibition assay using detergent-extracted recombinant human TSHR: As mentioned above, intact CHO cells expressing large numbers of receptors on their surface cannot be used for TBI assays. However, we wished to determine whether such cells would be a good source of recombinant TSHR in a soluble receptor assay. For this purpose, we used cells (TSHR-10,000), that express very large numbers (~ 1.9 x 106) of TSHR on their surface (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)). Cells were suspended by scraping, homogenized in buffer containing 1% Triton X- 100 and compared with the solubilized porcine TSHR in the universally used commercial kit as a standard. Recombinant receptor extracted from 7 x 106
cells was required to obtain 125I-bTSH binding comparable to that of the porcine TSHR standard (Fig. 3). Surprisingly and unexpectedly, in contrast to
this low yield, far more TSHR capable of TSH binding was recovered when monolayers of the same cells were incubated with detergent-containing buffer without detaching the cells from the culture dishes. In this case, TSHR from 70-fold fewer (~ 10s) cells produced binding similar to the porcine TSHR standard. Indeed, a single 10 cm diameter dish of cells provided sufficient
TSHR for 100-200 replicate determinations when substituted for the porcine TSHR in the kit.
The efficacy of the solubilized human and porcine TSHR was compared in a TBI assay using sera from 30 individuals with known or suspected Graves' disease. Ten of these sera had undetectable TSHR autoantibodies
using the porcine TSHR in the kit (TBI < 15%). The remaining 20 sera contained a wide range of TSHR autoantibody activity (Fig. 4). TBI values obtained when human TSHR was substituted in the kit correlated very well with values determined with porcine TSHR (r = 0.954; p < 0.001). However, two sera that were negative with porcine TSHR antigen were now positive with the human TSHR (Fig. 4). Radiolabeled human TSH could not be used in the soluble TSHR assay because, unlike I25I-bTSH, polyethylene glycol precipitation of the tracer was strongly and variably influenced by the individual sera.
TBI values obtained with the solubilized porcine TSHR are known to correlate only weakly with thyroid stimulating activity determined in a bioassay (TSI) involving activation of the human TSHR (Filetti, et al, /. Clin. Endocrinol. Metab., 72:1096-1101 (1991); Murakami, et al, Eur. J. Endocrinol, 133:80-86 (1995); Vitti, et al, /. Clin. Endo. Metab., 76:499-503 (1993)). We, therefore wished to determine whether TBI values obtained with solubilized human TSHR correlated better with the bioactivity of IgG in the same sera. Sufficient serum was available from 28 of the 30 samples depicted in Fig. 4 to permit determination of TSI activity using CHO cells stably transfected with the human TSHR. The correlation between TBI and TSI activities was no better when human, rather than bovine, TSHR was used in the TBI assay (r =
0.732 and 0.709, respectively)(Fig. 5A and B).
EXAMPLE 2: THE THYROTROPIN DOMAIN CONTAINS TWO
CLEAVAGE SITES
In the present study, we have used two new mammalian cell lines expressing the recombinant TSHR to refine further the site of cleavage in the
ectodomain. One line (TSHR-10,000) (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)) overexpresses the TSHR, thereby overcoming the handicap of a low signal to noise ratio experienced on direct immunodetection (without prior affinity purification) using conventional TSHR-expressing mammalian cell lines. A second cell line, TSHRmyc (Tanaka, et al, Biochem. Biophys. Res. Comm., 228:21-28 (1996)), contains a c-myc epitope tag in the region of the cleavage site. Data obtained with these cell lines provide a surprising and novel finding for G protein-coupled receptors; namely there appear to be two, not one, cleavage sites in the human TSHR ectodomain. A corollary of this finding is that the TSHR, like insulin, may release a C peptide during intramolecular cleavage.
Cells expressing the TSHR: (i) TSHR-10,000 (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)) is a Chinese hamster ovary (CHO) cell line overexpressing the human TSHR (~ 2 x 106 receptors per cell). Overexpression was attained using a dihydrofolate reductase minigene to amplify the stably- transfected TSHR cDNA transgenome. (ii) TSHR-0 are CHO cells expressing the same TSHR cDNA, but without transgenome amplification (~1.5 x 105 receptors per cell)(Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996); Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)). (iii) TSHRmyc are 293 human embryonal kidney (HEK) cells stably expressing the unamplified gene for an epitope-tagged human TSHR (Tanaka, et al, Biochem. Biophys. Res. Comm., 228:21-28 (1996)). Epitope-tagging was achieved by replacing TSHR amino acids 338 to 349 with the human c-myc peptide EEQKLISEEDLL. Cells were propagated in Ham's F-12 medium (CHO cells) or Dulbecco's modified
Eagle's medium (DMEM)(293 HEK cells), supplemented with 10% fetal calf serum (FCS), penicillin (100 U/ml), gentamicin (50 μg/ml) and amphotericin B (2.5 μg/ml).
Immunoprecipitation of precursor-labeled TSHR: Cells near confluence in 100 mm diameter culture dishes were rinsed with phosphate-buffered saline (PBS) and pre-incubated (0.5 h, twice) in DME-H21 methionine- and cysteine- free medium containing 5% heat-inactivated FCS. The cells were then pulsed
(1 h at 37 C) in 5 ml fresh medium supplemented with ~ 0.5 mCi of 35S- methionine/cysteine (> 1000 Ci/mmole, DuPont NEN, Wilmington DE). After aspiration of the medium and rinsing the cells once with PBS, chase was
performed for the indicated times in standard, non-selective medium with 10% FCS. Cells were washed twice with PBS and scraped into 1 ml ice-cold 20
mM Hepes, pH 7.2, 150 mM NaCl (buffer A) containing the protease inhibitors phenylmethylsulfonyl fluoride (PMSF) (100 μg/ml), leupeptin (1 μg/ml) aprotinin (1 μg/ml), and pepstatin A (2 μg/ml) (all from Sigma, St. Louis, MO). The cells were pelleted (5 min, 100 x g), washed twice with PBS and resuspended in buffer A containing 1% Triton X-100. After 90 min at 4°C with occasional vortexing, the mixture was centrifuged for 45 min at 100,000 x g and the supernatant was diluted 1:4 in immunoprecipitation buffer (20 mM Hepes pH 7.2, 300 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% Nonidet-P40, 2 mM EDTA). The solubilized cell proteins were precleared for 1 h at 4°C with ~ 150 μg normal mouse serum IgG prebound to 25 μl packed and washed protein A-agarose (Sigma). The protein A was removed by centrifugation (3 min at 10,000 X g) in a microcentrifuge. Mouse monoclonal antibodies (mAb) were then added, as described in the text. AlO and All (kind gifts of Dr Paul Banga, London, U.K.) both recognize TSHR amino acid residues 22-35 (Nicholson, et al, /. Mol. Endocrinol, 16:159-170 (1996)) and were used at a final dilution of 1:1000. The anti-myc mAb 9E10 (obtained from ATCC) was used at a final dilution of 1:500. T3-365, a mAb to the TSHR B subunit (kindly provided by Drs. E. Milgrom and H. Loosfelt, Le Kremlin- Bicetre, France) and a mAb to human thyroid peroxidase (kindly provided by Dr. Scott Hutchison, Nichols Institute, San Juan Capistrano, CA, USA) were used at a dilution of 1:1000. After 3 h at 4°C, 25 μl packed and washed protein A-agarose was added and the tubes were tumbled for 1 h at 4°C. The
protein A was recovered by centrifugation for 3 min at 10,000 X g (4°C), washed 5 times with 1 ml immunoprecipitation buffer, and then once with 10
mM Tris, pH 7.4, 2 mM EDTA and 0.5% sodium dodecyl sulfate (SDS). Finally the pellet was resuspended in Laemmli sample buffer (Laemmli, Nature, 227:680-685 (1970)) with 0.7 M β-mercaptoethanol (30 min at 50°C) and electrophoresed on 7.5 % or 10% SDS-polyacrylamide gels (BioRad, Hercules, CA). Prestained molecular weight markers (BioRad) were included in parallel lanes. We precalibrated these markers against more accurate unstained markers to obtain the molecular weights indicated in the text. Radiolabeled proteins were visualized by autoradiography on Kodak XAR-5 X-ray film (Eastman Kodak, Rochester, NY).
Immunoblots of TSHR proteins: Stably transfected TSHR-10,000 cells (in two 100 mm diameter dishes) were resuspended by incubation in Ca++- and Mg++-free PBS with 0.5 mM EDTA. The cells were pelleted (5 min., 100 x g, 4°C), resuspended in 1.5 ml of 10 mM Tris-HCl, pH 7.4, containing the protease inhibitors described above and homogenized with a Polytron homogenizer (Brinkman Instruments, Westbury, CT). After centrifugation for 10 min at 500 x g (4°C), the supernatant was recentrifuged for 20 min at 10,000 x g (4°C). The pellet was resuspended in 0.1 ml of the same buffer, after which Laemmli buffer with 0.7 M β-mercaptoethanol was added (30 min at
50°C) and the sample electrophoresed on 10% SDS-polyacrylamide gels. Prestained molecular weight markers are described above. Proteins were transferred to ProBlott membranes (Applied Biosystems, Foster City, CA), which were processed as described previously (Rapoport, et al, /. Clin.
Endocrinol. Metab., 81:2525-2533 (1996)). Membranes were incubated overnight (4°C) with mAb AlO or All to the A subunit, or with mAb to the B subunit;
T3-495 (TSH-R1; Transbio, Boulogne, France) or T3-365 (final dilutions of 1:1000). After rinsing, the membranes were incubated for 1 hr at room temperature with alkaline phosphatase conjugated goat anti-mouse immunoglobulin G (1:400 dilution)(Cappel, Durham, NC). The signal was developed with nitroblue tetrazolium and 5-bromo, 4-chloro, 3-indolyl phosphate in lOOmM Tris-HCl buffer, pH 9.5, containing 100 mM NaCl and 5
mM MgCl2.
Enzymatic deglycosylation of TSHR protein: The Protein A/IgG/TSHR
complex or the 10,000 x g crude membrane fraction (see above) were incubated (10 min., 100°C) in denaturing buffer containing 0.5% SDS, 1% β- mercaptoethanol. Enzymatic deglycosylation was performed according to the protocol of the manufacturer (N.E. Biolabs, Beverly MA). N-glycosidase F digestion (100 U for 2 h at 37°C) was in 50 mM Na phosphate, pH 7.5, 1% NP- 40. Endoglycosidase H digestion (50 U for 2 h at 37°C) was in 50 mM Na citrate, pH 5.5. Samples were then subjected to SDS-PAGE, as described above. Covalent cross-linking of radiolabeled TSH: Highly purified bovine
TSH (5 μg, 30 U/mg protein) was radiolabeled with 125I to a specific activity of
~ 80 μCi/μg protein using the Bolton-Hunter reagent (4400 Ci/mmol; DuPont- NEN) according to the protocol of the manufacturer, followed by Sephadex G- 100 chromatography (Goldfine, et al, Endocrinology, 95:1228-1233 (1974)). Confluent 100 mm diameter dishes of TSHR-expressing cells were incubated
for 2h at 37 C with 5 μCi ,25I-TSH in 5 ml modified Hank's buffer (without NaCl), supplemented with 280 mM sucrose and 0.25% BSA (binding buffer).
Unbound 125I-TSH was removed by rinsing the cells three times with ice-cold binding buffer. Disuccinimidyl suberate (DSS; 1 mM; Sigma) in 10 mM Na phosphate buffer, pH 7.4, containing the protease inhibitors described above was then added for 20 min at room temperature. The cross-linking reaction was terminated by the addition of 20 mM ammonium acetate (final concentration). After cross-linking, the cells were rinsed twice with PBS and scraped into 10 mM Tris, pH 7.5, containing the same protease inhibitors. Cells were homogenized using a Polytron homogenizer and centrifuged for 5 min at 4°C (500 x g). The supernatant was centrifuged (15 min, 10,000 x g, 4°C) and the pellet was resuspended in 50 ul 10 mM Tris, pH 7.5. After the addition of Laemmli buffer containing 0.7 M β-mercaptoethanol (30 min at 42°C), the samples were subjected to 10% SDS-PAGE and autoradiography as described above.
Immunodetection of the TSHR in TSHR-10.000 cells: Immunoprecipitation studies of precursor-labeled TSHR-10,000 cells were performed with mAb AlO (Nicholson, et al, /. Mol Endocrinol, 16:159-170 (1996)) to TSHR amino acid residues 22-35 at the amino terminus of the A subunit. Multiple forms of the TSHR were observed under reducing conditions after chase periods of 3 hr and 16 (Fig. 6A). Two forms of single subunit (uncleaved) TSHR were:- (i) -115 kDa in size (complex carbohydrate resistant to endoglycosidase H) and, (ii) ~100 kDa in size (immature, high mannose carbohydrate sensitive to endoglycosidase H)(Fig. 6). N-glycosidase F digestion removed both forms of carbohydrate, exposing a ~84 kDa polypeptide backbone. Cleaved (two subunit) TSHR was also present. The extracellular A subunit was visible as a broad -62 kDa band with complex carbohydrate, which upon deglycosylation became a more focused 35 kDa band. The largely transmembrane B subunit could not be visualized in these immunoprecipitation experiments (Fig. 6 A), presumably because of its
detachment from the antibody-bound A subunit and consequent loss during the very stringent washing procedure. The specificity of mAb for the TSHR
was evident in control experiments using untransfected CHO cells and with a mAb to thyroid peroxidase (TPO)(Fig. 6B).
In contrast to the immunoprecipitation experiments, the B subunit was clearly visualized in immunoblots of TSHR-10,000 cells using B subunit- specific mAb T3-495 and T3-365 (Loosfelt, et al, Proc. Natl. Aωd. Sci. USA, 895:3765-3769 (1992))(Figs. 7A, 7B). Thus, in addition to single subunit forms of the TSHR, a primary B subunit band of -42 kDa was evident, as well as some minor bands of slightly greater size. Incubation with endoglycosidases F and H did not affect the mobility of the B subunit bands, consistent with their lack of N-linked glycosylation sites (Fig. 7A). Specificity of mAb T3-495 and T3-365 was confirmed on immunoblotting with untransfected CHO cells (Fig. 7B). As in the immunoprecipitation experiments, the size of the A subunit could clearly be determined by immunoblotting with mAb AlO to the TSHR amino terminus. The -62 kDa mature A subunit contained complex carbohydrate (endoglycosidase H resistant)(Fig. 7C). Most important, deglycosylation with N-glycosidase F confirmed a -35 kDa A subunit backbone. Lesser fragments of ~39 kDa and -42 kDa were also evident. Again, the specificity of mAb AlO to the A subunit was confirmed on immunoblots with untransfected CHO cells and on immunoblotting of TSHR- 10,000 cells with a mAb to TPO (Fig. 7D).
Conundrum of a missing piece of the TSHR: The human TSHR, without its 21 amino acid residue signal peptide, has a predicted polypeptide backbone of 84.5 kDa (743 amino acid residues). However, from the immunoprecipitation and immunoblot studies shown above, the sum of the enzymatically deglycosylated A subunit (35 kDa) and the primary B subunit fragment (-42 kDa) was only -77 kDa. A 35 kDa polypeptide backbone for
the TSHR A subunit would place the cleavage site in the region of amino acid residue 330, taking into account the absence of the signal peptide. Further, a -42 kDa size for the non-glycosylated B subunit would be consistent with a holoreceptor cleavage site at about residue 380. It, therefore, appeared that a "C peptide" fragment in the vicinity of residues 330 - 380 could be missing from the cleaved TSHR ectodomain (Fig. 8). This deduction is inconsistent
with the prevailing concept of a single cleavage site in the TSHR ectodomain. TSHR subunits in TSHRmyc cells: In order to explore the possibility of
two cleavage sites in the TSHR, we used TSHRmyc cells that express a receptor with a 12 amino acid human c-myc epitope in place of residues 338-
349. This epitope lies within the segment of the TSHR predicted to be missing if the two cleavage site hypothesis is correct, namely residues - 330-380 (Fig.
8). Detection by a mAb to c-myc of only the single subunit forms of the TSHR, and not the cleaved A subunit, would support the concept that a portion of the ectodomain is lost during intramolecular cleavage. Cleavage within the c-myc epitope could also lead to loss of this epitope. The two cleavage site hypothesis would also predict detection in TSHRmyc cells of the
A subunit with mAb AlO to the amino terminus of this subunit, or, even more definitively, by crosslinking with radiolabeled TSH.
The TSHRmyc cells do not contain an amplified transgenome and express fewer receptors (-100,000 per cell)(Tanaka, et al, Biochem. Biophys. Res. Comm., 228:21-28 (1996)) than TSHR-10,000 cells. Nevertheless, both anti-myc mAb 9E10 and mAb AlO were equally effective in detecting the single chain forms of the TSHR in these cells (Fig. 9A). It contrast, it was more difficult to detect the diffuse, glycosylated TSHR A subunit band in the TSHRmyc cells
than in the TSHR-10,000 cells. However, after deglycosylation with N- glycosidase F, the 35 kDa A subunit in the TSHRmyc cells became more focused and was clearly visible on immunoprecipitation with mAb AlO to the TSHR amino terminus. In contrast, the A subunit was not detected in the same material with the anti-myc mAb 9E10. Because of the importance of this
finding, a similar experiment is also shown in which the deglycosylated A subunit in TSHR-10,000 cells is included (Fig. 9B). The 35 kDa deglycosylated A subunit band detected by mAb AlO in the TSHRmyc and TSHR-10,000 cells
was not an artifact because no such band was detected by immunoprecipitation with mAb 10 of precursor-labeled, untransfected HEK cells, nor did a non-relevant mAb (to TPO) detect this band in TSHRmyc cells (Fig. 9C).
Finally, we applied the most sensitive method (in our hands) to confirm
the presence of the TSHR A subunit in TSHRmyc cells, namely the covalent cross-linking of radiolabeled TSH to the surface of intact cells in monolayer culture. By this means, the A subunit was clearly evident in TSHRmyc cells (Fig. 10). Further, the proportion between the A subunit and the uncleaved, single subunit receptor detected by TSH cross-linking was the same in the TSHRmyc cells as in a cell line expressing similar numbers of wild-type TSHR
(TSHR-0) (Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)).
EXAMPLE 3: EVIDENCE FOR NEGATIVE COOPERATIVITY
AMONG HUMAN THYROTROPIN RECEPTORS OVEREXPRESSED IN MAMMALIAN CELLS
Previously, because of our success in using dihydrofolate reductase (dhfr) minigene amplification to overexpress thyroid peroxidase in Chinese hamster ovary (CHO) cells (Kaufman, et al, Molec. Cell. Endocrinol, 78:107-114 (1991)), we had attempted the same approach with the TSH holoreceptor. However, we did not attain a high level of expression (Kaufman et al., unpublished data). Disillusionment in our subsequent sojourn with bacterial and baculovirus approaches led us to re-attempt overexpression, by dhfr- minigene amplification, of the TSHR ectodomain in CHO cells. However, most of this protein was retained within the cell in a form with immature carbohydrate which was not recognized by either TSH or functional TSHR
autoantibodies (Rapoport, et al, /. Clin. Endocrinol. Metab., (In Press) (1996)).
We have come to realize that the 5'- and 3'-untranslated regions of the
human TSHR have a major suppressive effect on TSHR expression in CHO cells (Kakinuma, et al, Endocrinology, (In Press) (1995)). Because our initial attempt at TSH holoreceptor amplification by the dhfr-minigene approach had utilized a full-length (4 kb) TSHR cDNA (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)) containing both untranslated regions, we repeated, once again, TSHR cDNA amplification using only the 2.3 kb translated region. We now report the high level of expression of TSHR in CHO cells and confirm the high constitutive activity of the TSHR in the absence of ligand (Parma, et al, Nature, 365:649-651 (1993); Van Sande, et al, Eur. }. Biochem., 229:338-343 (1995)), and the binding of TSH to the single
subunit, uncleaved TSHR. Moreover, we find that higher levels of expression are associated with apparent negative co-operativity among the TSHR in terms of their affinity for ligand. Construction of plasmid for high level expression of the human TSHR-
ECD: A 2.7 kb TSHR cDNA containing the coding region and 0.4 kb of the 3' untranslated region was excised with Sal I and Xba I from pTSHR-5'TR- NEO-ECE (Kakinuma, et al, Endocrinology, (In Press) (1995)). This fragment was restricted with Hinc II to release the 2.3 kb TSHR coding region, which was then inserted into the Xba I (blunted) and Sal I sites in pSV2-DHFR-ECE- TPO (Kaufman, et al, Molec. Cell. Endocrinol, 78:107-114 (1991)) following removal of its Sal I-Xba I insert. The new plasmid, termed pSV2-DHFR-ECE-
TSHR, was transfected by the calcium phosphate precipitation method (Chen, et al, Mol. Cell. Biol, 7:2745-2752 (1987)) into dihydrofolate reductase (dhfr)-deficient CHO cells (CHO-DG44; kindly provided by Dr. Robert
Schimke, Stanford University, Palo Alto, CA). Stably transfected cells were selected in thymidine-, guanine-, and hypoxanthine-free Ham's F-12 medium
supplemented with 10% dialyzed fetal calf serum, penicillin (100 U/ml), gentamicin (50 μg/ml) and amphotericin B (2.5 μg/ml). After limiting dilution, 14 different clones were tested for TSHR expression by measurement of intracellular cAMP after TSH stimulation (see below). The clone with the greatest response was selected for transgenome amplification. Methotrexate (MTX) was added to the selective cell culture medium at an initial
5 concentration of 20 nM and surviving cells were expanded. The methotrexate concentration was sequentially increased until a final concentration of 10,000 nM (10 μM) was reached. Cells were recloned by limiting dilution at 800 nM and 10,000 nM methotrexate.
Immunoprecipitation of precursor-labeled TSHR: CHO clonal cell lines 0 stably expressing the TSHR were grown to confluence in 100 mm diameter culture dishes. After rinsing with phosphate-buffered saline (PBS), cells were pre-incubated (0.5 h, twice) in DME-H21 methionine- and cysteine-free medium containing 5% heat inactivated fetal calf serum. The cells were then pulsed (1 h at 37 C) in 5 ml fresh medium supplemented with - 0.5 mCi of
15 35S-methionine/cysteine (> 1000 Ci/mmole, DuPont NEN, Wilmington DE). After aspiration of the medium and rinsing the cells once with PBS, chase was
performed for 8 h in standard, non-selective F12 medium with 10% fetal calf serum. Cells were washed twice with PBS and scraped into 1 ml ice-cold 20 mM Hepes, pH 7.2, 150 mM NaCl containing the protease inhibitors
20 phenylmethylsulfonyl fluoride (PMSF) (100 μg/ml), leupeptin (1 μg/ml)
aprotinin (1 μg/ml), and pepstatin A (2 μg/ml) (all from Sigma, St. Louis, MO)(buffer A). The cells were pelleted (5 min, 100 x g), washed twice with PBS and resuspended in buffer A containing 1% Triton X-100. After 90 min at 4C with occasional vortexing, the mixture was centrifuged for 45 min at 100,000 x g and the supernatant was diluted 1:4 in immunoprecipitation buffer (20 mM Hepes pH 7.2, 300 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% Nonidet-P40 and 2 mM EDTA). The solubilized cell proteins were precleared by incubation for 1 h at 4C with 150 μg normal mouse serum IgG prebound to 25 μl packed and washed protein A-agarose (Sigma). After removal of the protein A by centrifugation (3 min at 10,000 X g) in a microcentrifuge, mouse
monoclonal antibodies to the TSHR (mixture of A9 and AlO, a kind gift of Dr Paul Banga, London, U.K., final dilution of 1:1000) were added. A9 and AlO
recognize TSHR regions between amino acids 147-229 and 22-35, respectively (Nicholson, et al, /. Mol. Endocrinol, 16:159-170 (1996)). After 3 h at 4C, 25 μl
packed and washed protein A-agarose was added and the tubes were tumbled
for 1 h at 4C. The protein A was recovered by centrifugation for 3 min at 10,000 X g (4 C), washed 5 times with 1 ml immunoprecipitation buffer, and then once with 10 mM Tris, pH 7.4, 2 mM EDTA and 0.5% sodium dodecyl sulfate (SDS). Finally the pellet was resuspended in Laemmli sample buffer (Laemmli, Nature, 227:680-685 (1970)) with 0.7 M β-mercaptoethanol (30 min at
42 C) and electrophoresed on 7.5% SDS-polyacrylamide gels (BioRad, Hercules, CA). Prestained molecular weight markers (BioRad) were included in parallel lanes. Radiolabeled proteins were visualized by autoradiography on Kodak XAR-5 X-ray film (Eastman Kodak, Rochester, NY). Densitometric analysis was performed with a BioRad scanning densitometer.
Covalent cross-linking of radiolabeled TSH: Highly purified bovine TSH (5 μg, 30 U/mg protein) was radiolabeled with 125I to a specific activity of ~ 80 μCi/μg protein using the Bolton-Hunter reagent (4400 Ci/mmol; DuPont- 00/05345
NEN) according to the protocol of the manufacturer, followed by Sephadex G- 100 chromatography (Goldfine, et al, Endocrinology, 95:1228-1233 (1974)). CHO clonal cell lines stably expressing the TSH receptor at different levels of amplification with methotrexate, were grown to confluence in 100 mm
diameter culture dishes. Cells were incubated for 2h at 37 C with 5 μCi 125I- TSH in 5 ml modified Hank's buffer (280 mM sucrose substituting for NaCl to maintain isotonicity) supplemented with 0.25% BSA (binding buffer). Unbound 12SI-TSH was removed by rinsing the cells three times with ice-cold binding buffer. Disuccinimidyl suberate (DSS; 1 mM; Sigma) in 10 mM Na phosphate buffer, pH 7.4, containing the protease inhibitors described above was then added for 20 min at room temperature. The cross-linking reaction was terminated by the addition of 20 mM ammonium acetate (final concentration).
After cross-linking, the cells were rinsed twice with PBS and scraped into 10 mM Tris, pH 7.5, containing the same protease inhibitors. Cells were homogenized using a Polytron homogenizer (Brinkmann Instruments, Westbury CT) and centrifuged for 5 min at 4 C (500 x g). The supernatant was centrifuged (15 min, 10,000 x g, 4C) and the pellet was resuspended in 50
μl 10 mM Tris, pH 7.5. Protein concentrations were determined by the method of Bradford (Bradford, Anal. Biochem., 72:248-254 (1976)). After the
addition of Laemmli buffer (Laemmli, Nature, 227:680-685 (1970)), in the presence of 0.7 M β-mercaptoethanol (30 min at 42 C), the samples were subjected to 7.5% SDS-PAGE gels and analyzed as described before. TSH binding: CHO cells stably transfected with TSHR cDNA were grown to confluence in 96-well culture plates. Cells were then incubated for 2 h at 37°C in 50 μl binding buffer (see above) containing approximately 50,000 cpm of 125I-TSH in the presence or absence of increasing concentrations of 5 unlabeled bovine TSH (Sigma). At the end of the incubation period, the cells were rapidly rinsed three times with binding buffer (4°C), solubilized with 0.1 ml NaOH and radioactivity measured in a gamma-counter. Experiments using increasing concentrations of 12SI-TSH were performed in cells cultured under the same conditions except that no unlabeled TSH was added. Non- 10 specific 125I-binding to untransfected CHO cells was subtracted from total counts bound to provide specific counts bound. These values were < 10% of total counts bound at the highest tracer concentration used (2.5 x 107 cpm/ml).
TSH stimulation of intracellular cAMP: Transfected CHO cells, grown to confluence in 24-well or 96-well culture plates, were incubated for 2 h at 15 37°C in either hypotonic medium (Kasagi, et al, /. Clin. Endocrinol. Metab., 54:108-114 (1982); Rapoport, et al, Metabolism, 31:1159-1167 (1982)) or in Ham's F-12 medium containing 1% bovine serum albumin, 1 mM isobutyl
methylxanthine, with or without added bovine TSH (Sigma). Cyclic AMP was
measured directly in the hypotonic medium. For cells exposed to TSH in 20 isotonic Ham's F12 medium, the medium was aspirated, intracellular cAMP
was extracted with 95% ethanol, evaporated to dryness and resuspended in 50 mM Na acetate, pH 6.2. Cyclic AMP was measured by radioimmunoassay
using cAMP, 2'-0-succinyl 125I-iodotyrosine methyl ester (Dupont NEN) and a rabbit anti-cAMP antibody from Calbiochem, San Diego CA. Quantitation by immunoprecipitation of TSHR protein expression in whole CHO cells: The process of stable transfection and progressive amplification of the TSHR holoreceptor/ dhfr-minigene complex in the genome of CHO cells took approximately one year. During this period, TSHR expression in the selected clone was confirmed intermittently by 125I-TSH binding. After completion of the amplification process, we assessed the level of TSHR expression within whole cells by precursor 35S-methionine and 35S- cysteine labeling followed by immunoprecipitation under native conditions
using mouse monoclonal antibodies to the TSHR (A9 + A10)(Nicholson, et al, /. Mol Endocrinol, 16:159-170 (1996)). In this comparison (Fig. 12), we used clonal cell lines stably transfected with (i) 4 kb TSHR cDNA containing both 5'- and 3'-untranslated regions (wild-type TSHR)(Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)), (ii) 2.3 kb TSHR cDNA with deleted untranslated regions (5'3'TR-ECE) (Kakinuma, et al, Endocrinology, (In Press) (1995)), renamed TSHR-0 for this report), (iii) 2.3 kb TSHR cDNA after growth stabilization in 800 nM methotrexate (TSHR-800) and (iv) 2.3 kb TSHR cDNA after growth stabilization in 10,000 nM methotrexate (TSHR-10,000). Untransfected CHO cells were included as a negative control.
Analysis of the immunoprecipitation products under reducing conditions revealed multiple specific bands, consistent with the pattern of
TSHR holoreceptors, subunits and precursors previously reported by Misrahi et al. (Misrahi, et al, Eur. J. Biochem., 222:711-719 (1994)) in whole cell homogenates. Of importance from the perspective of the present study was the clear increase in expression of all TSHR-specific bands in association with the dhfr amplification process. For the present study, densitometric quantitation of the 100 kDa holoreceptor band (Fig. 12, shown by the arrow), indicated that TSHR expression in TSHR-10,000 cells was 10.3 ± 2.0 (range in two separate experiments) greater than in TSHR-0 cells.
Crosslinking of TSH to TSHR on the cell surface: In stably-transfected mouse L-cells, unlike in thyroid cells, it is reported that most TSHR do not undergo normal maturation (Misrahi, et al, Eur. J. Biochem., 222:711-719 (1994)).
Instead, the immature form of the receptor accumulates within the cell and is degraded. It was, therefore, important to determine whether the TSHR
amplification observed by immunoprecipitation of cell lysates was also associated with an increase in mature TSHR expression on the cell surface. Radiolabeled TSH crosslinking to intact CHO cells in monolayer culture revealed a progressive increase in TSH binding sites with dhfr-minigene amplification (Fig. 13). By densitometric analysis, TSHR binding to TSHR-
10,000 cells increased 12.8 ± 2.8-fold (mean + S.E.; n = 3 experiments) over that to TSHR-0 cells. Based on the previous determination of -150,000 TSHR molecules on the surface of TSHR-0 (formerly 5'3'TR-ECE) cells (Kakinuma, et
al, Endocrinology, (In Press) (1995)), the present data suggest that TSHR-10,000 cells express -1.9 x 106 TSHR on their surface. Two additional features regarding these cross-linking data should be pointed out. First, the autoradiogram exposure is relatively short (16 hours), at which time a signal cannot be seen with the wild-type TSHR cDNA expressed in CHO cells. Second, two ligand-TSHR complexes (-130 kDa and -75 kDa) are evident under reducing conditions. After subtraction of the molecular mass of a TSH subunit, the upper band represents a single chain holoreceptor (Russo, et al, Mol Endocrinol, 5:1607-1612 (1991); Russo, et al, Endocrinology, 130:2135-2138 (1992)) with an apparent mass of - 115 kDa and the lower band a dissociated A subunit (Buckland, et al, FEBS Letters,
5 145:245-249 (1982)) of - 60 kDa.
Function of the overexpressed TSHR in the absence of ligand: Basal cAMP levels were assessed in stably-transfected cell lines expressing different numbers of TSHR. In cells cultured in hypotonic medium (Kasagi, et al, /. Clin. Endocrinol. Metab., 54:108-114 (1982); Rapoport, et al, Metabolism,
10 31:1159-1167 (1982)) without TSH, cAMP levels were 18.5-fold higher in the TSHR-10,000 cells (20.3 ± 1.5 S.E. pmoles/well, n=3) relative to the TSHR-0 cells (1.10 ± 0.21 pmoles/well)(Fig. 14A). In isotonic medium (Fig. 14B), basal cAMP levels were increased to a lesser extent (6.0-fold) in TSHR-10,000 cells (3.04 + 0.36 S.E. pmoles/well, n=3) relative to the TSHR-0 cells (0.52 ± 0.05
15 pmoles/well). These data indicate that the unliganded TSHR has significant constitutive activity. Incidentally, under hypotonic conditions and in association with the higher basal cAMP levels in the cell lines with more TSHR, the increase in cAMP levels in response to TSH stimulation was
reduced from 17-fold in the TSHR-0 cells to 2.9-fold in the TSHR-800 cells and
20 1.4-fold in the TSHR-10,000 cells)(Fig. 14A). Similar, but less dramatic
decreases in the cAMP response to the same TSH concentration were observed when cells were cultured in isotonic medium.
Kinetics of TSH binding to the surface of cells overexpressing the TSHR: In initial experiments, we determined the kinetics of TSH binding to CHO cells overexpressing the TSHR using 125I-TSH in the presence of increasing concentrations of unlabeled TSH. Surprisingly, in contrast to TSHR-0 cells (Kd - 5 x 10"10 M) (Kakinuma, et al, Endocrinology, (In Press) (1995)), we observed progressively lower half-maximal inhibition values for TSH binding by TSHR-800 cells - 10"9 M) and TSHR-10,000 cells (-2 x 10"9 M)(Fig. 154). All of these values are lower than those observed for cells transfected with the wild-type, full-length TSHR cDNA (TSHR-WT)(2 x 10'10 M). Scatchard analysis of TSH affinity and, in particular, TSHR number could
not be performed with accuracy in the TSHR-800 and TSHR-10,000 cells because their lower affinity of specific TSH binding approached that of nonspecific TSH binding to untransfected CHO cells (Chazenbalk, et al, Endocrinology, 127:1240-1244 (1990)) and even plastic (Yamamoto, et al, Endocrinology, 103:2011-2019 (1978)) (Kd - 6 x 10'8 M). Indeed, it must be emphasized that in order to attain partial receptor saturation with ligand for the studies shown in Fig. 15, it was necessary to reduce the number of TSHR in each culture well. Therefore, the TSHR-800 and TSHR-10,000 cells were
diluted 1:50 with untransfected cells.
In order to reduce the error introduced by subtraction of a non-specific
binding component whose affinity is only approximately one order of magnitude lower than specific binding, we attempted to determine the TSH
binding kinetics to TSHR-800 and TSHR-10,000 cells overexpressing the TSHR by saturation analysis using increasing amounts of 125I-TSH in the absence of unlabeled TSH. Scatchard analysis of these data was non-revealing because insufficient TSHR saturation could be attained even when adding tracer as high as 1.25 x 106 cpm/well (50 ul medium)(Fig. 16). Nevertheless, it is clear that specific TSH binding to the surface of TSHR-10,000 cells is approximately
10-fold higher than to TSHR-0 cells, consistent with the 125I-TSH cross-linking data (Fig. 13).
EXAMPLE 4: ENGINEERING THE HUMAN THYROTROPIN
RECEPTOR ECTODOMAIN FROM A NON-SECRETED FORM TO A SECRETED, HIGHLY IMMUNOREACTIVE GLYCOPROTEIN THAT NEUTRALIZES AUTOANTIBODIES IN GRAVES'
PATIENTS' SERA
In this Example, it is demonstrated that progressive carboxyl-terminal truncations lead to the secretion by CHO cells of a modified TSHR ectodomain
with mature, complex carbohydrate. Further, by epitope-tagging this autoantigen and by amplifying its transgenome in CHO cells, we report the first direct visualization and quantification of TSHR of mammalian cell origin. Most important, this material can neutralize all or most TSHR binding activity in Graves' patients' sera. Antigenically active TSHR will provide a major impetus for future studies on the pathogenesis of Graves' disease.
Plasmid constructs: We generated three plasmids for expression in mammalian cells of limited TSHR ectodomain truncations (Fig. 17): (i) TSHR-
261: Plasmid TSHR-5'TR-NEO-ECE (Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)) contains an Afl II site at codon 260 and an Xba I site in the vector at the 3 end of the insert. The Afl Il-Xba I fragment was excised and replaced with a cassette coding for 6 histidine residues (6H) followed by 2 stop codons. The cassette was created by annealing two oligonucleotides: Sense: 5'-TTAACCATCACCACCACCATCACTGATAAT; Antisense: 5'-CTAGATTATCAGTGATGGTGGTGGTGATGG Ligation at the Afl II site generated an Asn residue upstream of the 6H, hence
the nomenclature "261". (ii) TSHR-289: A cDNA fragment including the Afl
II site at codon 260 continuing to codon 289 followed by an Spe I site was generated by PCR using Pfu DNA polymerase (Stratagene, San Diego, CA).
This fragment was used to replace the Afl II - Spe II segment in TSHR-5'TR-
NEO-ECE (the Spe I site is at codon 418)(Nagayama, et al, Proc. Natl. Acad. Sci. USA, 88:902-905 (1991)). Subsequently, an oligonucleotide cassette coding for
6H followed by 2 stop codons with Spe I and Xba I adhesive ends was inserted into the same sites of the intermediate construct.
Sense: 5'-CTAGCCATCACCACCACCATCACTGATAAT; Antisense: as described above for TSHR-261. (iii) TSHR-309: Construction used the identical strategy to that of TSHR-289 except that the Afl II - Spe cDNA fragment generated by PCR extended up to codon 309. After confirmation of the nucleotide sequences of the relevant areas, the
TSHR-261, TSHR-289 and TSHR-309 cDNAs were excised with Sal I and Xba I and transferred to the vector pSV2-ECE-dhfr (Kaufman, et al, Molec. Cell Endocrinol, 78:107-114 (1991)).
Expression of TSHR ectodomain variants: Cell lines, stably transfected with the above TSHR ectodomain cDNA variants were established in CHO dhfr-cells (CHO-DG44; kindly provided by Dr. Robert Schimke, Stanford University, Palo Alto, CA), using procedures described previously (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)). Transgenome amplification was achieved by progressive adaptation to growth in methotrexate (final concentration 10 μM)(Rapoport, et al, /. Clin. Endocrinol Metab., 81:2525-2533 (1996)).
Detection of TSHR ectodomain variants in medium and in cells: CHO cells to be tested for TSHR ectodomain variant expression were metabolically
5 labeled with 35S-methionine/ cysteine, exactly as described previously (1 hr pulse and overnight chase) (Chazenbalk, et al, Endocrinology, 137:4586-4591 (1996)). The medium was harvested for immunoprecipitation of secreted TSHR protein and the cells were processed further for analysis of intracellular TSHR protein, as described previously (Chazenbalk, et al, Endocrinology,
10 137:4586-4591 (1996)), with the following modifications. Cells, lysed in buffer containing 1% Triton X-100, were centrifuged for 45 min at 100,000 x g prior to pre-clearing with mouse IgG and Protein A, followed by immunoprecipitation using mouse monoclonal antibody (mAb) AlO (Nicholson, et al, /. Mol. Endocrinol, 16:159-170 (1996)) (kindly provided by Dr Paul Banga, London,
15 U.K.; epitope at amino acid residues 22-35; final dilution of 1:1000). Medium was precleared in the same manner except that in later experiments mouse IgG was not prebound to the protein A. Samples were subjected to 10% polyacrylamide gel electrophoresis under reducing conditions. Prestained
molecular weight markers (BioRad, Hercules, CA) were precalibrated against
20 more accurate unstained markers to obtain the molecular weights indicated in
the text. Radiolabeled proteins were visualized by autoradiography on Kodak XAR-5 X-ray film (Eastman Kodak, Rochester, NY). TSHR secreted into the medium was also detected by means of their 6H tag using Ni-NTA resin (QIAGEN, Ine, Chatsworth, CA) according to the procedure reported previously (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)).
Assay for neutralization of TSHR autoantibodies in the serum of Graves' patients: TSHR autoantibody kits were purchased from Kronus, San Clemente, CA. The principal of this assay is the ability of autoantibodies to compete for 12SI-TSH binding to TSHR solubilized from porcine thyroid glands ("TSH binding inhibition" or TBI assay) (Shewring, et al, Clin. Endocrinol, 17:409-417 (1982)). In brief, solubilized TSHR (50 ml) are preincubated (15
min) with patient's serum (50 ml). Buffer containing 12SI-TSH is then added (2 h at room temperature). Solubilized TSHR complexed with TSH is
precipitated by polyethylene glycol. Antibody activity is measured as % inhibition of 125I-TSH binding relative to a standard serum from a normal individual without autoantibodies. We modified this assay by preincubating (30 min at room temperature) serum from Graves' patients (25 ml) with conditioned medium from cells expressing TSHR ectodomain variants (25 ml).
Solubilized TSHR (50 ml) was then added to the serum/medium mixture (50 ml). As controls, we used serum from normal individuals and conditioned medium from CHO cells secreting a truncated form of thyroid peroxidase
(Kaufman, et al, Molec. Cell. Endocrinol, 78:107-114 (1991)). Lectin adsorption: Binding of TSHR in conditioned medium to different
lectins was determined for three Sepharose-linked lectins: Wheat germ agglutinin (WGA), Bandeiraea simplificifolia and Concanavalin A (Con A)(Pharmacia, Piscataway, NJ). Medium (40 ml) was slowly stirred for 2 hr at room temperature with 0.4 ml of Sepharose-lectin. The beads were then extensively washed in batch with 10 mM Tris, pH 7.5, 150 mM NaCl and adsorbed material released (tumbling for 45 min at room temperature) with 3 ml of the same buffer supplemented with 0.25 M N acetyl-glucosamine
(WGA), 20 mM a-methyl-galactopyranoside (B. Simplificifolia) and 0.5 M a- methyl-mannoside (Con A). Material (3 ml) was diluted as indicated in the text and spotted on nitrocellulose filters (Schleicher and Schuell, Keene, NH). After air drying, the filters were incubated (45 min) in 50 mM Tris buffer, pH 7.5, and 150 mM NaCl (TBS) containing 5.0% skim milk powder, rinsed and incubated (2 hr at 37°C) in TBS containing mAb AlO (1:1000) and 0.5% bovine serum albumin (BSA). The filters were rinsed, incubated (1 hr at room temperature) with alkaline phosphatase-conjugated goat anti-mouse immunoglobulin G and the signal developed as described previously (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)).
Immunoblots of TSHR ectodomain variants: Lectin-bound TSHR-261, TSHR-289 and TSHR-309 was eluted (see above) and Laemmli sample buffer (Laemmli, Nature, 227:680-685 (1970)) with 0.7 M (final concentration) β- mercaptoethanol was added (30 min at 45°C). Enzymatic deglycosylation with N-glycosidase F and endoglycosidase H was as described previously (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)). After electrophoresis on SDS, 10% polyacrylamide gels, proteins were electophoretically transferred to PVDF membranes, which were then processed as described above with the exception that incubation in mAb AlO was overnight and the second antibody was added for 1-2 hr. In some experiments (e.g. Fig. 22), the immunoblots were developed using the BioMax- CDS-PRO kit (Eastman Kodak, Rochester, NY) according to the protocol of the manufacturer. Autoradiography was with Hyperfilm ECL (Amersham, Arlington Heights, IL).
TSHR-261 partial purification: Conditioned medium was harvested from CHO cells expressing TSHR-261 cultured in non-selective F12 medium containing 10% fetal calf serum, antibiotics and 5 mM Na butyrate (Dorner, et al, /. Biol. Chem., 264:20602-20607 (1989)). Medium (2 liters) was applied to a 70 ml Concanavalin A Sepharose column. After washing with 10 mM Tris, pH 7.5, 150 mM NaCl, bound material was eluted with - 80 ml of 0.15 M a- methyl-mannoside in the same buffer. The eluted material was made up to 50 mM imidazole, pH 7.2, and applied to two 5 ml His-Trap columns in series (Pharmacia). Elution was with buffer containing 10 mM Tris, pH 7.4, 50 mM NaCl, and 100 mM EDTA. The sample was concentrated and the buffer exchanged to 10 mM Tris, pH 7.5, 50 mM NaCl using a Centriprep 30 (Amicon, Beverly, MA). At all stages, TSHR-261 recovery was monitored by bioassay (TBI neutralization; see above). The N-terminal amino acid sequence of the deglycosylated TSHR-261, cut out from a PVDF membrane, was determined by the Protein Structure Laboratory, University of California at Davis. Secretion of truncated TSHR ectodomain variants: CHO-DG44 cells
were stably transfected with plasmids coding for TSHR ectodomain variants truncated at amino acid residues 261, 289 and 309 (Fig. 17). Individual clones were obtained by limiting dilution and transgenome amplification was performed by progressive adaptation to growth in methotrexate (final concentration 10 mM). One clone of each TSHR ectodomain variant, selected for high level of TSHR expression, was expanded and used for further studies.
The ectodomain variant with the greatest degree of C-terminal truncation (TSHR-261) was entirely secreted into the medium, as detected by immunoprecipitation after an overnight chase, with no receptor remaining in the cells (Fig. 18). TSHR-289, truncate'd to a lesser extent was secreted to an intermediate degree. The receptor remaining within the cells was present in multiple forms, the dominant band having a molecular weight lower than the secreted form. Finally, for TSHR-309, the least truncated ectodomain, secretion into the medium was relatively inefficient. Thus, proportionately less receptor
was secreted than remained within the cells, the latter primarily in lower molecular weight form. Expression of the 6 His residues at the carboxyl- termini of the ectodomain variants was confirmed by nickel-NTA resin purification of precursor-labeled material secreted into the culture medium (Fig. 18). In contrast, the TSHR variants could not be clearly identified within
the cell because the nickel-NTA resin bound to a large number of labeled intracellular proteins (data not shown).
Interaction of TSHR with autoantibodies in the serum of Graves' patients: Because our main purpose in generating a secreted form of the TSHR ectodomain was to obtain material suitable for study with TSHR autoantibodies in the serum of patients with Graves' disease, it was important to test the secreted TSHR ectodomain variants for this property. We used a TSH binding inhibition (TBI) assay to test whether conditioned medium from cultured cells expressing TSHR-261, TSHR-289 and TSHR-309 could neutralize 00/05345 1 1 1 autoantibody activity in a Graves' patient's serum. Of these, TSHR-261 and TSHR-289 were clearly active in terms of reversing the inhibition by TSHR autoantibodies of 125I-TSH binding (Fig. 19).
Adsorption of TSHR ectodomain variants to lectins: Although the Ni- NTA resin was effective in purifying radiolabeled TSHR secreted by CHO cells into tissue culture medium (Fig. 18), we were unable to purify unlabeled
TSHR protein from medium using this approach. The Ni-NTA bound to many unlabeled proteins despite attempts to minimize non-specific interactions with imidazole and adsorption at lower pH (data not shown). We, therefore, attempted partial purification of TSHR ectodomain variants from conditioned medium using lectins. TSHR-261 in conditioned medium bound poorly to wheat germ agglutinin and Bandeiraea simplicifolia (Fig. 20). Almost all of this material remained in the "flow-through" and minimal amounts could be recovered by elution with specific sugar. In contrast, concanavalin A (Con A) was effective in extracting TSHR-261 from the medium.
Because the non-secreted, full-length TSHR ectodomain that did not interact with TSHR autoantibodies contained immature, high mannose carbohydrate and bound strongly to Con A (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)), we were concerned that the Con A was extracting
an inactive, high mannose component of TSHR-261, perhaps released from disintegrating cells. Fortunately, this was not the case. Thus, immunoblotting of Con A-enriched TSHR-261 showed that, like the material immunoprecipitated from conditioned medium with mAb AlO (Fig. 18), the secreted receptor was endoglycosidase H resistant and endoglycosidase F sensitive (complex carbohydrate)(Fig. 21). Indeed, this pattern was similar to the smaller amounts of TSHR-261 that could be recovered from conditioned medium using wheat germ agglutinin (Fig. 21). Most important, the Con-A enriched material was highly active in neutralizing autoantibody TBI activity in patients' sera (data not shown for these experiments; see data below on TBI activity in more extensive studies using multiple Graves' sera; Fig. 24).
In addition to TSHR-261, TSHR-289 and TSHR-309 were also extracted from culture medium using Con A. Immunoblotting indicated that TSHR-289 and TSHR-309, like TSHR-261, contained only mature, complex carbohydrate (Fig. 22). Remarkably, TSHR-261 contains - 20 kDa of N-linked glycosylation, 40% of its mass. The apparent molecular weights of the deglycosylated proteins (~ 30, 32 and 34 kDa for TSHR-261, TSHR-289 and TSHR-309, respectively) were slightly (~ 2 kDa) greater than predicted from their known amino acid sequences (including 6 H tags). A similar phenomenon was previously observed with the deglycosylated TSHR ectodomain (residues 1- 418) (Rapoport, et al, /. Clin. Endocrinol. Metab., 81:2525-2533 (1996)).
Autoantibody neutralization by partially purified TSHR-261: In the
preceding studies, the secreted TSHR variants could be detected qualitatively by immunoprecipitation, immunoblotting or by autoantibody neutralization.
However, it was important to determine quantitatively the amount of receptor that was interacting with TSHR autoantibodies in patients' sera. No TSHR
standards are available for this purpose. Indeed, the TSHR of mammalian cell origin has never been purified sufficiently for direct visualization on a polyacrylamide gel. We selected TSHR-261 for further study because, of the three ectodomain variants, it was secreted to the greatest extent (Fig. 18) and because its "bioactivity" in terms of autoantibody recognition appeared equal to that of TSHR-289 (Fig. 19).
As monitored by autoantibody neutralization, Con A chromatography provided an initial purification of - 100-fold. Subsequently, and in contrast to its use as an initial capture stem, Ni-chelate chromatography was quite effective in generating sufficient TSHR-261 for direct visualization and quantitation by Coomassie blue staining (Fig. 23, left panel). Enzymatic deglycosylation confirmed the immunoblot evidence for a -30 kDa polypeptide backbone with -20 kDa of complex carbohydrate (Fig. 23, right panel) and also provided the best means to quantitate the amount of receptor recovered. In 3 separate preparations from 2 liters of conditioned medium, recovery of TSHR-261 (corrected for a 40% glycan component) was 0.3 - 0.4
mg/ liter. Amino acid sequencing of the 30 kDa deglycosylated band confirmed the amino terminus of the TSHR (Met, Gly, X, Ser, Ser, Pro, Pro; X represents a Cys residue). Further purification of TSHR-261 (Sephacryl S-200) was associated with a major loss in activity (data not shown). However, semi-
purified TSHR-261 (20-40% estimated purity)(Fig. 23) was quite stable at -80°C. Partially-purified TSHR-261 was highly potent in neutralizing TSHR
autoantibody TBI activity in patients' sera. In a preliminary study on a serum from a Graves' patient with moderate TSH binding inhibitory (TBI) activity, 30 ng of TSHR-261 per tube (0.15 mg/ml) completely neutralized autoantibody activity (Fig. 24). Therefore, in studies on further sera, we used 50 ng of TSHR-261 per tube (0.25 mg/ml). This concentration of TSHR-261 neutralized all or most TSH binding inhibitory activity in the 18 Graves' sera examined (Fig. 25). In a study of our most potent Graves' serum, based on IgG (150 kDa) being bivalent and assuming that 100% of the TSHR-261 molecules added to the assay were capable of autoantibody neutralization, we estimate that the maximum TSHR autoantibody concentration in this particular serum is - 7 mg IgG/ml. From TBI and flow cytometry data (Jaume, et al, /. Clin. Endocrinol. Metab., 82:500-507 (1997)), most Graves' sera have autoantibody levels 10-50 fold lower than this potent serum. We, therefore, estimate that TSHR autoantibody concentrations are typically between 0.1 and 1 mg IgG/ml. These values are likely to be overestimates because 100% antigen binding is unlikely to be attained in the assay and because of moderate TSHR-261 lability at room temperature, the temperature of the TBI assay. Finally, although TSHR-261 was clearly recognized by TSHR
autoantibodies, it did not bind 125I-TSH when substituted for the porcine holoreceptor in the TBI kit (data not shown).
EXAMPLE 5: THYROTROPIN RECEPTOR AUTOANTIBODIES IN SERUM ARE PRESENT AT MUCH LOWER LEVELS
THAN THYROID PEROXIDASE AUTOANTIBODIES: ANALYSIS BY FLOW CYTOMETRY
In the present invention, we have used a new TSHR-expressing mammalian cell line that overcomes two handicaps associated with the prior art, namely TSHR concentration and structural integrity. TSHR-10,000 Chinese hamster ovary (CHO) cells express high numbers of mature TSHR on their surface in vivo (described in Example 3). Using these cells, we now report the ability to detect directly, by flow cytometry, binding of autoantibodies in a few patients' sera to the native TSHR However, flow cytometric analysis of thyroid peroxidase (TPO) autoantibodies in the same sera indicate that TSHR
autoantibodies are present at much lower levels than are TPO autoantibodies. This finding has important implications for the diagnostic detection of TSHR autoantibodies and for understanding the pathogenesis of Graves' disease.
Sera used for flow cytometry: Serum BB1, kindly provided by Dr. Stephanie Lee, New England Medical Center Hospitals, Boston, was from a patient with Graves' disease who subsequently became hypothyroid with the development of blocking antibodies. Thirty sera were generously provided to us by Mr. Juan Tercero, Corning-Nichols Institute, San Juan Capistrano, California. These sera were submitted without clinical information for the assay of autoantibodies to the TSHR (see below), presumably for suspicion of Graves' disease. Ten of the 30 sera were selected for the absence of TSHR autoantibodies, 10 for the presence of moderate TSH binding inhibitory (TBI) activity and a further 10 for their high (>50%) TBI activities. Four laboratory personnel were the source of sera from individuals clearly without autoimmune thyroid disease and four sera were from patients with systemic lupus erythematosus with anti-DNA and/or anti-cardiolipin antibodies.
All sera were tested in our laboratory for TBI activity using a commercially available diagnostic kit (Kronus, San Clemente, CA). The 30
sera obtained from Corning-Nichols had been tested previously using the same assay with very similar results. TSHR autoantibody titers of selected sera were determined by dilution of these sera in a serum from a normal individual without a history of autoimmune thyroid disease and with undetectable TSHR autoantibody activity. Sera were also tested for TPO autoantibodies using 125I-TPO (recombinant) as described previously (Portolano, et al, /. Clin. Invest., 90:720-726 (1992) ).
Cells expressing TPO and TSHR: Construction of plasmids and Chinese hamster ovary (CHO) stable transfections for overexpression of the human TSHR and TPO have been described elsewhere (Example 3; Kaufman et al, Molec. Cell. Endocrinol, 78:107-114 (1991)). These cells, as well as untransfected CHO cells (DG44; kindly provided by Dr. Robert Schimke, Stanford University, Palo Alto, CA) were propagated in Ham's F-12 medium supplemented with 10% fetal calf serum, penicillin (100 U/ml), gentamicin (50 μg/ml) and amphotericin B (2.5 μg/ml).
Flow cytometric analysis (FACS): For analysis of patients' sera, cells were processed as described previously for TPO expression on CHO cells using patients' sera and human monoclonal autoantibodies (Kaufman, et al, /. Clin. Invest., 84:394-403 (1989); Nishikawa, et al, /. Clin. Endocrinol. Metab., 79:1648-1654 (1994)), with modifications. In brief, after detachment by mild
trypsinization, cells were pelleted and rinsed (5 min at 100 x g) in Ham's F-12 medium supplemented with 10% dialyzed fetal calf serum and antibiotics as
above. For preadsorption, untransfected CHO cells were resuspended in 0.18 ml of buffer A (phosphate-buffered saline, 10 mM Hepes, pH 7.4, 0.05% Na azide and 2% fetal calf serum heat-inactivated at 56°C for 30 min). Sera (20 μl)
were added (final concentration of 1:10, or as specified in the text) and gently mixed for 60 min at 4°C. After removal of the cells by centrifugation, the sera were divided in two 0.1 ml aliquots. One aliquot was added to CHO cells expressing either the TSHR or TPO, the other aliquot to untransfected CHO
cells. After incubation for 60 min at 4°C, the cells were rinsed three times in buffer A and resuspended in 0.1 ml of same buffer. Affinity-purified goat anti-human IgG (1.5μl)(Fc specific, fluorescein isothiocyanate-conjugated;
Caltag, South San Francisco, CA) was added to the cells for 45 min at 4°C After three washes in buffer A, the cells were analyzed using the Becton Dickinson FACScan-CELLQuest system. Three parameters (forward scatter, FSC, 90° side scatter, SSC, and FL1 detector) were use for the analysis. All assays included cells treated with second antibody alone and serum from normal individuals. All sera were analyzed by flow cytometry at least twice.
Detection of TSHR on TSHR-10,000 cells using mouse monoclonal antibodies (A9 and A10)(l:100 final concentration)(Nicholson, et al, /. Mol. Endocrinol, 16:159-170 (1996)) and rabbit antiserum (1:60 final concentration) (R8) (Vlase, et al, Endocrinology, 136:4415-4423 (1995)) to the TSHR (all kindly provided by Dr. Paul Banga, London, England) was according to the protocol described for the human sera, except for the use of the use of the following
second antibodies: (i) affinity-purified goat anti-mouse IgG (0.8 μl) (fluorescein isothiocyanate-conjugated) and (ii) affinity-purified goat anti-rabbit IgG (0.5 μl)
(fluorescein isothiocyanate-conjugated), both from Caltag, South San Francisco, CA.
Flow cytometric analysis of CHO cells expressing the TSHR: We have previously been unable to detect the TSHR stably expressed on the surface of CHO cells using Graves' sera. Recently, however, two reagents became available to us; CHO cells expressing very high numbers of TSHR (nearly 2 x 106) on their surface (Example 3), and a Graves' serum (BB1) particularly potent in the indirect TSH binding inhibition (TBI) assay. Using this serum, a
very small specific signal (relative to control untransfected cells) was detected with our original line (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184-1190 (1989)) expressing - 16,000 TSHR per cell (Fig. 26A). With the same serum, a stronger signal was observed with a line expressing - 150,000
TSHR per cell (TSHR-0; previously termed 5'3'TR-ECE) (Kakinuma, et al, Endocrinology, 137:2664-2669 (1996))(Fig. 26B). Progressively greater specific fluorescence was evident with TSHR-800 and TSHR-10,000 cells expressing - 106 and 1.9 x 106 receptors per cell, respectively (Example 3) (Fig. 26C and 26D). Expression of TSHR antigen on the surface of the transfected CHO cells, previously determined by radiolabeled TSH binding and TSH-mediated signal transduction (Example 3; Nagayama, et al, Biochem. Biophys. Res. Comm.,
165:1184-1190 (1989); Kakinuma, et al, Endocrinology, 137:2664-2669 (1996)), was confirmed using a rabbit polyclonal antiserum (R8) to the TSHR (Fig. 27C).
Murine monoclonal antibodies (A9 and A10)(Nicholson, et al, /. Mol. Endocrinol, 16:159-170 (1996)) were less effective in recognizing the native TSHR on the cell surface (Fig. 27A, 27B). The TSHR-10,000 cells were,
therefore, used in subsequent attempts to detect TSHR autoantibodies in the sera of other patients by direct binding to the native antigen.
Use of TSHR-10,000 cells to detect TSHR autoantibodies in different sera: In preliminary studies, we observed that some sera, regardless of whether or not they contained TSHR autoantibodies, elicited high fluorescence on flow cytometry with TSHR-10,000 cells. We observed similar high fluorescence when these sera were incubated with untransfected CHO cells not expressing the TSHR (data not shown). Therefore, some sera contained antibodies against unknown antigens on the surface of CHO cells. For this reason, we instituted a preadsorption step, in which sera were preincubated with untransfected CHO cells prior to addition to the TSHR-10,000 cells. Preadsorption was effective in eliminating, or greatly reducing, this non¬
specific background. For example, without preadsorption, a serum (7H) with a high TBI value (81.7%) induced a strong signal on TSHR-10,000 cells relative to that of a serum without TSHR autoantibodies (Fig. 28A). However, after preadsorption, the activity in this apparently positive serum was clearly nonspecific (Fig. 28B). In contrast, with sera like BBl (see above), preadsorption actually enhanced the specificity of the signal (Fig. 28C and 28D). We have studied the interaction with the TSHR-10,000 cells and untransfected CHO cells of 39 sera after preadsorption on untransfected CHO cells (Table 1). In addition to serum BBl, this panel included 10 sera (IL - 10L) without TBI activity (1 - 4.2% inhibition); 10 sera (IM - 10M) with moderately high TBI values (17.3 - 39.4% inhibition); 10 sera (1H - 10H) with high TBI levels (52 - 95.1% inhibition); four normal individuals without autoimmune thyroid disease and four patients with systemic lupus erythematosus with anti-DNA and/or anti-cardiolipin antibodies. None of the sera from normal individuals, individuals with negative TBI values or patients with systemic autoimmunity generated a positive signal on flow cytometry. Remarkably, including BBl (selected for its very high TBI activity) only four of the 21 sera positive for TBI (10M, 3H and 10H) unequivocally recognized the TSHR on flow cytometry using cells expressing large numbers of receptors (Table 1).
Specificity of the FACS signals on TSHR-10,000 cells observed with sera BBl, 10M, 3H and 10H was evident by the return to background of the signals following pre-adsorption on TSHR-10,000 cells, rather than on untransfected
cells (Fig. 29).
The TSHR autoantibody titers in the four sera positive for the TSHR on flow cytometry were determined in the TBI assay (Table 2). Dilution of these sera indicated that BBl and 10H had similar, high TSHR autoantibody titers, consistent with their strong fluorescence signals on flow cytometry. The lower TBI titer of serum 3H was also consistent with its relatively low fluorescence signal. Surprisingly, serum 10M, with the lowest TSHR autoantibody titer, generated a strong signal on flow cytometry, raising the possibility of the presence in this serum of "neutral" autoantibodies to the TSHR that do not inhibit TSH binding.
TPO autoantibodies detected by flow cytometry: In view of the small number of sera that could unequivocally recognize the TSHR by flow cytometry, we studied TPO autoantibodies in the same sera by the same approach using CHO cells overexpressing TPO on their surface (Kaufman, et al, Molec. Cell. Endocrinol, 1991; 78:107-114 (1991)). TPO autoantibodies commonly coexist with TSHR autoantibodies. Indeed, of the 20 TBI positive sera (1-lOM and 1-lOH), 19 bound > 13% 125I-TPO, well above the upper limit detected in the sera of normal individuals (2.6% binding)(Table 1). In addition, two of the TBI-negative sera (7L and 10L) were also TPO autoantibody positive by this method. Strikingly, all 20 sera with detectable TPO autoantibodies were clearly positive on flow cytometry with CHO-TPO cells. Not only were more sera positive for TPO than for the TSHR by flow cytometry, but the net fluorescence (after subtraction of fluorescence with non- transfected cells) was far higher with TPO-expressing cells than with TSHR- expressing cells (Table 1). Like the TSHR-10,000 cells, the cells overexpressing TPO (TPO-10,000) have - 2 x 106 TPO molecules on their surface (unpublished data).
We studied the serum (BBl) with the highest TSHR autoantibody level by flow cytometry to determine the extent to which the serum could be diluted before loss of a fluorescence signal (Fig. 29). Serum from a normal individual was diluted in a similar manner (open histograms). Both sera, at all dilutions tested, were preadsorbed on untransfected CHO cells prior to incubation with TSHR-10,000 cells. The fluorescence signal with BBl (Fig. 30: left panels, shaded histograms) progressively diminished upon dilution. At 1:10 the net signal (BBl - the normal serum) was 276.3 fluorescence units. At
1:1000, BBl elicited only a very small signal (net fluorescence of 7.3 units). When the same adsorbed serum was incubated with TPO-10,000 cells, the net fluorescence diminished from 1240.9 to 243.6 fluorescence units (Fig. 30; right
panels, shaded histograms). Similar fluorescence (243.6 and 276.3 units) was evident for TPO autoantibodies and TSHR autoantibodies at dilutions of 1:1000 and 1:10, respectively. Thus, by flow cytometry, the titer of TPO autoantibodies in the BBl serum is - 100-fold higher than that for TSHR autoantibodies in the same serum.
It should be noted that with a number of sera, fluorescence was lower with TSHR-10,000 or (less commonly) TPO-10,000 cells than with
untransfected control cells, resulting in a negative "net" fluorescence value
(Table 1). This greater fluorescence elicited by some sera with control cells could not be eliminated by more stringent adsorption (data not shown).
EXAMPLE 6: IMPLICATION OF N-LINKED GLYCOSYLATION IN THE EVOLUTIONARY DIVERGENCE OF RECEPTOR
SUBUNIT STRUCTURE
Recent evidence raised the surprising possibility that cleavage of the
TSHR into A and B subunits does not occur at a single site as previously suspected, but at two sites (described in Example 2), a feature unique to currently known members of the family of G protein-coupled receptors with
seven membrane-spanning segments. In the present study, we sought to identify the amino acid residues related to each putative cleavage site, using a strategy involving mutagenesis of selected chimeric TSH-LH/CG receptors. The basis for this approach was that cleavage into A and B subunits does not occur in a chimeric receptor (TSH-LHR-6) in which the carboxyl terminal portion of the TSHR ectodomain (amino acid residues 261-418; arbitrary
domains "D and E") is replaced with the corresponding region of the LH/CG receptor (Nagayama, et al, Proc. Natl. Acad. Sci. USA, 88:902 (1991); Russo, et al, Endocrinology, 130:2135 (1992))(Fig. 31). On the other hand, cleavage still occurs when either domain D or domain E (residues 261-360 and 363-418; chimeric receptors TSH-LHR-4 and TSH-LHR-5, respectively) are substituted on an individual basis. These data, together with other information in Example 2, suggested that cleavage sites 1 and 2 were in TSHR domains D and E, respectively.
5 Because elimination by mutagenesis of only one cleavage site would not be sufficient to abrogate receptor cleavage, we mutated regions in the vicinity
of putative site 1 on a background of TSH-LHR-5 (In order to increase the level of receptor expression, we deleted the 5' and 3' untranslated regions of
chimeric receptor TSH-LHR-5 (Nagayama, et al, Proc. Natl. Aωd. Sci. USA,
10 88:902 (1991)) by transposing its Afl II - Spe I fragment (domains D and E)(Fig. 31) with the corresponding fragment in TSHR-5'3'TR-NEO-ECE (Kakinuma, et al, Endocrinology, 137:2664 (1996)). Mutations in domain D of chimeric receptor TSH-LHR-5 were generated by PCR using overlapping primers and Pfu DNA polymerase (Stratagene, San Diego, CA). The nucleotide sequences
15 of the PCR fragments were confirmed by the dideoxy nucleotide termination method (Sanger, et al, Proc. Natl Aωd. Sci. USA, 74:5463 (1977)). Plasmids were stably transfected with Lipofectin (Gibco-BRL, Gaithersburg, MD) into Chinese hamster ovary (CHO) cells cultured in Ham's F-12 medium supplemented with 10% fetal calf serum (FCS) and standard antibiotics.
20 Selection was with with 400 μg/ml G418 (GIBCO). Surviving clones (> 100 per 100 mm diameter culture dish) were pooled and propagated for further study.). Conversely, we mutated regions in the vicinity of putative site 2 on a
background of TSH-LHR-4 (For our initial series of mutations in domain E of chimeric receptor TSH-LHR-4, we used the El, E2 and E3 mutations (Fig. 33 A) previously constructed in the wild-type TSHR (Nagayama, et aϊ, Endocrinology, 131:548 (1992)). These mutations were transposed into the cDNA for TSH- LHR-4 (Eco RV - Xba I fragment). Subsequent finer mutations in the E domain of TSH-LHR-4 were made by PCR using overlapping primers, with replacement of the Afl II - Spe I fragment. The nucleotide sequences of all PCR products were confirmed and stably-transfected CHO cell lines were generated as described for the domain D mutations.). By this means, we were able to determine the structural significance of each mutation on receptor cleavage into subunits, as determined by 125I-TSH crosslinking to monolayers of intact, stably-transfected cells (Covalent crosslinking of bovine 125I-TSH to monolayers of intact cells was performed with disuccinimidyl suberate (DSS; 1
mM; Sigma), as described previously (Chazenbalk, et al, Endocrinology, 137:4586 (1996)). Membrane preparations from the cells were subjected SDS- PAGE and autoradiography.). As a general principle for mutagenesis, we replaced TSHR residues with the homologous residues of the non-cleaving LH/CG receptor. Residues common to both receptors were unaltered. In the
case of a 50 amino acid region that is unique to the TSHR and lacking in the LH/CG receptor (Nagayama, et al, Biochem. Biophys. Res. Comm., 165:1184 (1989))(Fig. 31), homologous substitutions could not be performed so we introduced alanine residues in most instances. It is noteworthy that this 50 amino acid segment (estimated to be between residues 317-366) is very
hydrophilic and can be deleted from the wild-type TSHR without loss of ligand binding and function (Wadsworth, et al, Science, 249:1423 (1990)) and without preventing cleavage into A and B subunits (Russo, et al, Mol. Endocrinol, 5:1607 (1991)).
The deglycosylated TSHR A subunit is - 35 kDa in size (Example 4; Misrahi, et al, Eur. f. Biochem., 222:711 (1994)), which would place cleavage site 1 at approximately amino acid residue 335 (numbering includes a 21 residue signal peptide). On this basis, we initially targeted residues 330-338 for alanine scanning mutagenesis (Fig. 32A). None of these individual substitutions prevented cleavage of chimeric receptor TSH-LHR-5, as determined by release of the TSH-linked A subunit on disulfide bond reduction (Fig. 32B). Note that, consistent with previous TSH cross-linking studies to intact cells (Furmaniak, et al, FEBS Letters, 215:316 (1987); Russo, et al, Mol. Endocrinol, 5:1607 (1991); Example 4; Chazenbalk, et al, /. Biol. Chem., 269:32209 (1994)), only a portion of the TSHR on the cell surface cleave into two subunits, with TSH also binding to single polypeptide chain TSHR. Because of the possibility that a single amino acid residue may be insufficient to disrupt a cleavage site, we next performed multiple substitutions over a wider area between residues 324 and 352, also without abolishing cleavage.
Finally, we mutagenized TSH-LHR-5 even further afield (residues 317-323), well upstream of the calculated cleavage site and up to the carboxyl-terminus
of the D domain (residues 353-362), also without effect (Fig. 32B).
Mutagenesis of TSH-LHR-4 in the vicinity predicted to harbor putative cleavage site 2 (Fig. 33A) identified residues 367-375 (El subdomain) as being related to TSHR subunit formation (Fig. 33B). Subdivision of the El region into two segments next identified residues 367-371 (Ela segment) to be associated with ectodomain cleavage. The subsequent substitution of individual alanines at residues 367, 368, 369 and 371 (residue 370 being conserved) did not abrogate cleavage, suggesting that multiple amino acids
contributed to this event. Therefore, to refine further the cleavage-related
residues, we created two overlapping mutants within the Ela segment, Elal(GQE367.369NET) and Ela2 (ELK369.371T-Y)(Fig. 33A). Abrogation of
cleavage in the former identified residues 367-369 to be involved in cleavage at putative site 2 (Fig. 33B).
The inability of single amino acid substitutions to prevent cleavage at putative site 2, as well the involvement of multiple amino acids in this
cleavage site, was instructive in view of our inability to localize putative cleavage site 1 despite the generation of twenty one new receptors mutagenized in the anticipated region. Given the vast number of additional permutations that might be required to characterize site 1, further mutagenesis was daunting. Moreover, a number of possibilities existed: (i) Cleavage site 1 could be upstream of amino acid residue 317. However, in this case the deglycosylated A subunit would be 33 kDa or less, smaller than observed by multiple investigators (Graves, et al, Endocrinology, 137:3915 (1996); Example 4; Misrahi, et al, Eur. J. Biochem., 222:711 (1994)); (ii) The specificity of cleavage at site 1 was "relaxed" and, (iii) our hypothesis for two cleavage sites was wrong, despite the strong supporting evidence that we had obtained previously (Example 2).
In order to exclude the possibility of only a single cleavage site, we introduced the Elal mutation (GQE^.^ ET), known to prevent cleavage of TSH-LHR-4, into the wild-type TSHR. Thus, if this segment was the sole site related to TSHR cleavage, its introduction into the wild-type TSHR should prevent cleavage. Conversely, if cleavage still occurred in the wild-type TSHR harboring the GQE367.369 NET mutation, there must be two cleavage sites in the TSHR ectodomain. Cross-linking of 125I-TSH to this new construct clearly indicated cleavage (Fig. 34), proving the existence of site 1. Taken together, the data suggest relaxed specificity in the amino acid motif for the upstream cleavage site (site 1).
Remarkably, the mutation
Figure imgf000129_0001
that abrogates cleavage at site 2 introduces a consensus sequence for an N-linked glycosylation site. A carbohydrate side-chain in this vicinity could, therefore, prevent ectodomain cleavage, for example by steric hindrance of a proteolytic enzyme. As mentioned above, the mutagenesis strategy used to investigate cleavage site 2 in the TSHR involved substitution into the TSHR of the corresponding segments of the non-cleaving LH/CG receptor. The GQE^.^NET substitution in the TSHR transposes NET^,.^ from the LH/CG receptor, a motif that is glycosylated in the latter receptor (Davis, et al, Mol. Endocrinol, 11:550 (1997)). In order to determine the functional significance of the GQE^.^NET
substitution in TSH-LHR-4, we introduced into this chimeric receptor a motif (AAA) that would not be a potential glycosylation site (Fig. 33A). In contrast
to the non-cleaving receptor, TSH-LHR^-GQEa^.^AAA did cleave (Fig. 33B). EXAMPLE 7: DIRECT RECEPTOR ASSAY FOR TSHR
AUTOANTIBODIES IN HUMAN SERUM
This example describes what is believed by the inventors in be the first report of a practical direct TSH receptor assay for the detection and/or quantitation of autoantibodies against TSHR in a biological fluid. Serum samples from normal and Graves' patients were assayed directly for autoantibodies against human TSHR. Of the representative ectodomain variants TSHR-261, TSHR-289 and TSHR-309, TSHR-261 was secreted to the greatest extent(Fig.l8), and its "bioactivity" in terms of autoantibody recognition appeared equal to that of TSHR-289 (Fig.19). However, TSHR-289 was selected by the inventors for use in this example because, while less efficiently secreted than TSHR-261, it appeared to exhibit more stability than TSHR-261. As such, it is presently preferred for this purpose. The TSHR-289 included a 6 histidine tail as described herein (TSHR-289-6His). TSHR-2896His antigen was produced in tissue culture medium harvested from CHO cells secreting TSHR- 289-6His, as described herein. Sepharose-Protein A beads were obtained from Sigma, and other reagents were obtained from Sigma or similar suppliers. Assay buffer was lOmM Tris, pH 7.5, 0.1 M NaCl, 0.1 % Tween, 0.5% bovine serum albumin, and 0.025% Na azide. Anti- histidine mouse monoclonal antibody labeled with Na 125I was obtained from QIAGEN, Inc., Chatsworth, California. Human serum samples were obtained from normal volunteers and from two confirmed clinically active Graves' patients. Assay Procedure
0.1 ml of human serum (normal or Graves') was diluted with 1.9 ml assay buffer (1:20 dilution) in a 12x75 mm polypropylene tube. 0.1 ml Sepharose-Protein A beads was added, and the tube was rotated overnight at 4°C. The tube was then centrifuged (2 min., 2000 rpm, 4°C), and the assay buffer was aspirated. The pelleted beads were washed by resuspending in 3 ml of assay buffer, followed by centrifugation (2 min., 2000 rpm, 4°C).
The beads were resuspended in 0.7 ml of normal human serum and 1.3 ml of buffer, and rotated for 1 hour at 4°C. Following centrifugation (2 min., 2000 rpm, 4°C), the beads were washed once by resuspension in assay buffer and centrifugation (2 min., 2000 rpm, 4°C).
The beads were then resuspended in 3 ml of TSHR-289-6His conditioned medium and rotated for 6 hours at 4°C. Following this incubation, the beads were centrifuged (2 min.,
2000 rpm, 4°C) and washed twice by resuspension in assay buffer and centrifugation as above. The beads were then resuspended in 2.5 ml assay buffer, to which was added approximately 70,000 cpm I25I-anti-histidine mouse monoclonal antibody, and rotated overnight at 4°C. The beads were then centrifuged (2 min., 2000 rpm, 4°C), and washed twice by resuspension in assay buffer and centrifugation as above. Radioactivity in the beads was measured using a gamma counter. Results
Human serum autoantibodies against human TSHR were markedly elevated in patients with confirmed clinical Graves' disease as compared to normal human serum (Table 3). Assay results of closely agreeing duplicate determinations shown in Table 3 are representative of two other experiments.
Table 3: Direct TSHR Autoantibody Assay in Normal and Graves' Serum
Figure imgf000131_0001
Mean TSHR autoantibody levels in the two Graves' disease patients, as reflected in counts per minute (cpm) of 125I activity, exceeded mean normal serum levels by over 600% (Table 3). Such elevated autoantibody levels as measure according to the direct assay methods of the present invention are consistent with TSHR activation, known to result in thyroid overactivity and thyrotoxicosis in Graves 'patients (Rees Smith, et al, Endocr. Rev.,
9:106-121 (1988)).
All publications mentioned herein are incorporated in full by reference, to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. It will be understood that the invention is capable of further modifications and this application is intended to cover any variations, uses, adaptation or adoptions of the invention including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains, and that the invention is intended to be limited only by the appended claims.

Claims

What is claimed is:
1. A recombinant nucleic acid sequence encoding a secreted, soluble, complex carbohydrate-containing form of the TSHR ectodomain, in a replicatable vector.
2. A recombinant nucleic acid sequence according to claim 1, wherein said sequence encodes a TSHR ectodomain which is C-
terminal truncated.
3. A recombinant nucleic acid sequence according to claim 2, wherein said C-terminal truncation occurs at an amino acid residue selected from the group consisting of TSHR-261 through TSHR-309.
4. A recombinant nucleic acid sequence according to claim 3, wherein said C-terminal truncation occurs at amino acid residue TSHR- 261.
5. A recombinant nucleic acid sequence according to claim 3, wherein said C-terminal truncation occurs at amino acid residue TSHR- 289.
6. A recombinant nucleic acid sequence according to claim 3, wherein said C-terminal truncation occurs at amino acid residue TSHR- 309.
7. A recombinant nucleic acid sequence according to claim 3, wherein the replicatable vector is an expression vector.
8. A host cell comprising the recombinant nucleic acid sequence according to any of claims 1, 2, 3, 4, 5, 6 or 7.
9. A host cell according to claim 8 which is a mammalian cell.
10. A host cell according to claim 9 which is a Chinese Hamster Ovary cell.
11. A host cell according to any of claims 9 or 10 which is stably transfected.
12. A polypeptide comprising a secreted, truncated, soluble, complex carbohydrate-containing form of the TSHR ectodomain.
13. A polypeptide according to claim 12, wherein the TSHR ectodomain is C-terminal truncated.
14. A polypeptide according to claim 13, wherein said C-terminal truncation occurs at an amino acid residue selected from the group consisting of TSHR-261 through TSHR-309.
15. A polypeptide according to claim 14, wherein said C-terminal truncation occurs at amino acid residue TSHR-261.
16. A polypeptide according to claim 14, wherein said C-terminal truncation occurs at amino acid residue TSHR-289.
17. A polypeptide according to claim 14, wherein said C-terminal truncation occurs at amino acid residue TSHR-309.
18. A polypeptide according to any of claims 12, 13, 14, 15, 16 or 17, which additionally comprises histidine residues at its carboxyl terminus.
19. A polypeptide according to claim 18 having six histidine residues at its carboxyl terminus.
20. A method of producing a secreted, soluble, complex carbohydrate-containing form of the TSHR ectodomain, comprising culturing the host cell of claims 8, 9, 10, or 11 under conditions allowing expression, and recovering secreted, soluble, complex carbohydrate- containing form of the TSHR ectodomain.
21. An antibody against the polypeptide of any of claims 12, 13, 14, 15, 16, 17, 18 or 19.
22. The antibody of claim 21, wherein said antibody is selected from the group consisting of a monoclonal antibody, polyclonal antibody, an
anti-idiotypic antibody or and anti anti-idiotypic antibody.
23. In a TSH binding inhibition assay using intact cells, the
improvement comprising using as intact cells the host cell of any of claims 8, 9, 10 or 11.
24. In a TSH binding inhibition assay using intact cells, the improvement comprising using as intact cells a Chinese Hamster Ovary cell line which over-expresses the TSHR holoreceptor.
25. The assay of claim 24, where said Chinese Hamster Ovary cell line which over-expresses the TSHR holoreceptor expresses about 106 receptors per cell.
26. The assay of claim 24, where said Chinese Hamster Ovary cell line which over-expresses the TSHR holoreceptor expresses about 1.9 x
106 receptors per cell.
27. In a TSH binding inhibition assay using solubilized TSHR, the
improvement comprising using the polypeptide of any of claims 12, 13, 14, 15, 16, 17 or 18.
28. A method of detecting directly, by flow cytometry, binding of
autoantibodies in a patient's serum to native TSHR, comprising use in a flow cytometric assay of a Chinese Hamster Ovary cell line which over- expresses the TSHR holoreceptor.
29. The method of claim 28 which additionally comprises a preadsorption step, comprising preincubating the patient's serum with untransfected Chinese Hamster Ovary cells prior to addition to the Chinese Hamster Ovary cell line which over-expresses the TSHR holoreceptor.
30. The method of any of claims 28 or 29, where said Chinese Hamster Ovary cell line which over-expresses the TSHR holoreceptor expresses about 106 receptors per cell.
31. The method of any of claims 28 or 29, where said Chinese Hamster Ovary cell line vyhich over-expresses the TSHR holoreceptor expresses about 1.9 x 106 receptors per cell.
32. A method of directly detecting human autoantibodies against human TSHR in a biological fluid sample comprising incubating a biological fluid sample suspected of containing autoantibodies against human TSHR in the presence of a solid support comprising a capture ligand capable of binding said autoantibodies, washing said solid support to remove unbound material, incubating said solid support comprising said autoantibodies bound thereto in the presence of a secreted, soluble, complex carbohydrate-containing form of the TSHR ectodomain, washing said sohd support to remove unbound material, and detecting said secreted, soluble, complex carbohydrate-containing form of the TSHR ectodomain bound to said autoantibodies bound to said solid support, thereby directly detecting human autoantibodies against human TSHR in said biological fluid sample.
33. The method of claim 32, wherein said biological fluid is serum, said solid support comprising a capture ligand comprises Sepharose-Protein A beads, said secreted, soluble, complex carbohydrate -containing from of the TSHR ectodomain is TSHR-289-6His, and wherein said TSHR-289-6His is detected by means of a detectably labeled anti-histidine antibody.
PCT/US1999/016636 1998-07-21 1999-07-21 Human thyrotropin receptor compositions and use thereof WO2000005345A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU51245/99A AU5124599A (en) 1998-07-21 1999-07-21 Human thyrotropin receptor compositions and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9353398P 1998-07-21 1998-07-21
US60/093,533 1998-07-21

Publications (1)

Publication Number Publication Date
WO2000005345A1 true WO2000005345A1 (en) 2000-02-03

Family

ID=22239455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/016636 WO2000005345A1 (en) 1998-07-21 1999-07-21 Human thyrotropin receptor compositions and use thereof

Country Status (2)

Country Link
AU (1) AU5124599A (en)
WO (1) WO2000005345A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018632A3 (en) * 2001-08-23 2004-06-17 Rsr Ltd Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto
WO2006016121A1 (en) 2004-08-13 2006-02-16 Rsr Limited Thyrotropin receptor preparations, binding regions thereof, antibody and hormone interactions therewith, and uses thereof
WO2020022776A1 (en) * 2018-07-25 2020-01-30 Yuhan Corporation Fusion protein comprising thyrotropin receptor variants and use thereof
KR102676582B1 (en) 2018-07-25 2024-06-20 주식회사유한양행 Fusion Protein Comprising Thyrotropin Receptor Variants And Use Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614363A (en) * 1990-01-25 1997-03-25 New England Medical Center Hospitals, Inc. TSH receptor
US5744348A (en) * 1989-09-08 1998-04-28 New England Medical Center Hospitals, Inc. TSH receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744348A (en) * 1989-09-08 1998-04-28 New England Medical Center Hospitals, Inc. TSH receptor
US5614363A (en) * 1990-01-25 1997-03-25 New England Medical Center Hospitals, Inc. TSH receptor

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309693B2 (en) 2001-08-23 2012-11-13 Rsr Limited Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
CN1622958B (en) * 2001-08-23 2013-04-03 Rsr有限公司 Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
CN103224562B (en) * 2001-08-23 2017-09-08 Rsr有限公司 The epitope regions of thyrotropin receptor and the antibody for the region
EP2383290A3 (en) * 2001-08-23 2012-10-10 Rsr Limited Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
US8298771B2 (en) 2001-08-23 2012-10-30 Rsr Limited Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
US8298769B2 (en) 2001-08-23 2012-10-30 Rsr Limited Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
US9751940B2 (en) 2001-08-23 2017-09-05 Rsr Limited Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
EP2383291A3 (en) * 2001-08-23 2013-02-13 Rsr Limited Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
WO2003018632A3 (en) * 2001-08-23 2004-06-17 Rsr Ltd Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto
US9046519B2 (en) 2004-08-13 2015-06-02 Rsr Limited Mutated thyrotropin receptor
WO2006016121A1 (en) 2004-08-13 2006-02-16 Rsr Limited Thyrotropin receptor preparations, binding regions thereof, antibody and hormone interactions therewith, and uses thereof
JP2008515387A (en) * 2004-08-13 2008-05-15 アールエスアール リミテッド Thyroid-stimulating hormone receptor sample, binding site of the thyroid-stimulating hormone receptor, antibody and hormone interaction with the binding site, and use thereof
WO2020022776A1 (en) * 2018-07-25 2020-01-30 Yuhan Corporation Fusion protein comprising thyrotropin receptor variants and use thereof
US11479596B2 (en) 2018-07-25 2022-10-25 Yuhan Corporation Fusion protein comprising thyrotropin receptor variants and use thereof
KR102676582B1 (en) 2018-07-25 2024-06-20 주식회사유한양행 Fusion Protein Comprising Thyrotropin Receptor Variants And Use Thereof

Also Published As

Publication number Publication date
AU5124599A (en) 2000-02-14

Similar Documents

Publication Publication Date Title
EP0959896B1 (en) Method of producing secreted truncated variants of human thyrotropin receptor
WO1997046206A9 (en) Human thyrotropin receptor compositions and use thereof
JP5873034B2 (en) Estrogen receptor and method of use
US8753637B2 (en) Binding partners for the thyrotropin receptor and uses thereof
Chazenbalk et al. Evidence for negative cooperativity among human thyrotropin receptors overexpressed in mammalian cells
US20040086966A1 (en) Compositions and methods comprising a ligand of ChemerinR
WO2000000590A1 (en) Human thyrotropin receptor compositions and use thereof
WO2000005345A1 (en) Human thyrotropin receptor compositions and use thereof
US6020158A (en) Isolated polynucleotide for novel G-protein coupled receptor
US20050026224A1 (en) Methods and compositions for modulating G-protein coupled receptor 54
WO1995024426A1 (en) A novel expression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target proteins
Traish et al. Identification of structurally altered estrogen receptors in human breast cancer by site-directed monoclonal antibodies
US6391584B1 (en) Expression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target proteins
KR20040010644A (en) EPF receptor assays, compounds and therapeutic compositions
US7265202B1 (en) PIAS molecules that recognize and bind STAT proteins and uses thereof
WO1999028465A2 (en) Pias molecules that recognize and bind stat proteins and uses thereof
US20030158100A1 (en) Isolated cytokine receptor LICR-2
Baum et al. Anti‐peptide Sera Against Cell‐CAM 105 Determine High Molecular‐mass Variants of the Long Isoform in Rat Hepatocytes
WO2005017484A2 (en) Methods for identifying compounds for regulating muscle mass or function using dopamine receptors
ES2371244T3 (en) ANTIBODY FOR THE RECEIVER OF TIROTROPINA AND USES OF THE SAME.
US20040248245A1 (en) Zinc activated ion channel
JPH06189786A (en) Anti-oxytocin receptor antibody and its production
Simon et al. Studies on µ-Opioid-Binding Sites With Peptide Antibodies
JP2005522992A (en) Human vanilloid receptor protein and polynucleotide sequence encoding said protein
JP2002542760A (en) DNA molecule encoding rhesus monkey melanocortin 3 receptor protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase